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Ao Zhou 
CHARACTERIZING ALTERNATIVE SPLICING  
AND LONG NON-CODING RNA  
WITH HIGH-THROUGHPUT SEQUENCING TECHNOLOGY 
Several experimental methods has been developed for the study of the central 
dogma since late 20th century. Protein mass spectrometry and next generation sequencing 
(including DNA-Seq and RNA-Seq) forms a triangle of experimental methods, 
corresponding to the three vertices of the central dogma, i.e., DNA, RNA and protein. 
Numerous RNA sequencing and protein mass spectrometry experiments has been carried 
out in attempt to understand how the expression change of known genes affect biological 
functions in various of organisms, however, it has been once overlooked that the result 
data of these experiments are in fact holograms which also reveals other delicate 
biological mechanisms, such as RNA splicing and the expression of long non-coding 
RNAs. In this dissertation, we carried out five studies based on high-throughput 
sequencing data, in an attempt to understand how RNA splicing and differential 
expression of long non-coding RNAs is associated biological functions. 
In the first two studies, we identified and characterized 197 stimulant induced and 
477 developmentally regulated alternative splicing events from RNA sequencing data. In 
the third study, we introduced a method for identifying novel alternative splicing events 
that were never documented. In the fourth study, we introduced a method for identifying 
known and novel RNA splicing junctions from protein mass spectrometry data. In the 
fifth study, we introduced a method for identifying long non-coding RNAs from poly-A 
selected RNA sequencing data. Taking advantage of these methods, we turned RNA 
sequencing and protein mass spectrometry data into an information gold mine of splicing 
and long non-coding RNA activities. 
Huanmei Wu, Ph.D., Chair 
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Chapter 1. Introduction to Sequencing and Data Analysis Methods 
The central dogma consists of three major levels, genome, transcriptome and 
proteome. The advance of high-throughput sequencing technologies for nucleic acid and 
proteins has provided affordable measures for investigating biological processes, 
mechanisms and functions at all three major levels of the central dogma. In Chapter 1, we 
review the current nucleic acid and protein sequencing technologies, as well as the 
biological background and current data analysis methods of the two major topics we 
investigated in this dissertation, alternative splicing and long non-coding RNA. 
1.1 Next Generation Nucleic Acid Sequencing Technology 
1.1.1 Brief History of Nucleic Acid Discovery 
Chromosome was the first observed before human realize DNA was its main 
component. The word chromosome originates from the Greek roots chroma, meaning color, 
and soma, meaning body. In the 19th century, Schleiden [1], Virchow [2] and Bütschli [3] 
recognized the structures now known as chromosome. Walther Flemming named this 
structure “chromatin” [4]. In 1878, he published his discovery on how “chromatin” 
separate during cell division, also known as mitosis. In 1888, von Waldeyer-Hartz coined 
the name “chromosome”, describing their strong staining by particular dyes [5]. Aided by 
Mendel’s earlier work rediscovered in the early 1900s, Boveri pointed out the association 
between heredity and behavior of chromosomes [6]. The number of human chromosomes, 
46, was determined by Joe Hin Tjio in 1956 [7]. 
In 1869, almost the same time when chromosome was recognized, Friedrich 
Miescher discovered a microscopic substance he named “nuclein”, which is now known as 
DNA [8]. In 1878, Albrecht Kossel isolated the pure form of “nuclein”, nucleic acid, and 
later isolated its five primary nucleobases [9]. In 1919, Phobus Levene identified the base, 
sugar and phosphate nucleotide units [10]. In 1927, Nikolai Koltssov proposed that the 
inheritance of traits could be carried via a “giant hereditary molecule” made up with “two 
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mirror strands that replicate in a semi-conservative fashion using each strand as a template” 
[11]. In 1953, Watson and Crick suggested the now accepted double-helix model of DNA 
structure based on X-ray diffraction images [12]. 
When first studied in the early 1900s, the biological differences between RNA and 
DNA were not well understood. The role of RNA in protein synthesis was suspected as late 
as 1939 [13]. The concept of messenger RNA emerged during the late 1950s, and was 
associated with Crick’s description of his “Central Dogma of Molecular Biology”, which 
asserted that genetic information flows from DNA to RNA, and thus led to the synthesis of 
proteins [14]. During the 1970s, retroviruses and reverse transcriptase were discovered, 
which later enables RNAs to be sequenced by DNA sequencing technology [15, 16]. In 
1977, introns and RNA splicing were discovered by Philip Sharp and Richard Roberts.[17, 
18] 
1.1.1 Basic DNA Sequencing Methods 
Two DNA sequencing technologies were developed around 1977, one is 
Maxam-Gilbert sequencing, developed by Allan Maxam and Walter Gilbert [19], the other 
is Sanger sequencing, developed by Frederick Sanger [20, 21]. 
Maxam-Gilbert sequencing requires radioactive 32P labelling of the 5’ end of the 
purified DNA sequence. Four different chemical treatments are applied to DNA to create 
breakages on DNA molecules at one or two specific bases (G, A+G, C, C+T). The 
concentration of chemicals are controlled to induce on average one breakage per DNA 
molecule. The DNA fragments are then electrophoresed and the resulting gel is exposed to 
X-ray film for autoradiography. Then the DNA sequence is inferred from presence and 
absence of certain DNA fragments. 
Maxam-Gilbert sequencing was once widely used right after its invention because 
of certain advantages: 1) PCR amplification on DNA is not required, 2) high accuracy in 
inferring homopolimetric DNA sequences, and 3) can be used to analyze DNA-protein 
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interactions and epigenetic modifications. However, it is no longer commonly used today 
because of certain disadvantages: 1) extensive usage of hazardous chemicals, 2) the 
complexity in the experiment set-up, and 3) not being capable to analyze sequences with 
more than 500 base pairs. 
Sanger sequencing, or the chain-termination method, involves DNA 
polymerization with for standard deoxynucleotides (dATP, dGTP, dCTP and dTTP) and 
four radioactively or fluorescently labelled dideoxynucleotides (ddATP, ddGTP, ddCTP 
and ddTTP). The existence of dideoxynucleotides stops the polymerization of the DNA 
templates at a random loci, thus creating a library of DNA sequences of different lengths. If 
the experiment is designed properly, the library should cover each base on the DNA 
template to be sequenced. The concentration of dideoxynucleotides is low enough to make 
sure some polymerized DNA fragments covers the whole length of the DNA template to be 
sequenced. Then the DNA library is electrophoresed and the nucleotide on each loci can be 
inferred from the bands of the electrophoresis. 
Sanger sequencing and Maxam-Gilbert sequencing share similar ideas in their 
design. Both methods process the DNA molecule and derive shortened fragments of all 
possible lengths at chosen nucleic acids, then infer the original DNA sequence with 
electrophoresis. Sanger sequencing was first automated and commercialized by Applied 
Biosystems. It was widely accepted and prevailed from the 1980s to mid-2000s for its 
advantages, including its relative ease and reliability, and longer read length (800bp). The 
Sanger sequencing technology led to the first human genome in 2001. From the late 2000s, 
high-throughput DNA sequencing methods reached the market and brought the cost per 
genome from $100 million in 2001 to $100 in 2017. 
1.1.2 High-throughput DNA Sequencing Methods 
Several high-throughput DNA sequencing methods has been developed in the 21st 
century. Among these methods, 454 pyrosequencing, Illumina (Solexa) sequencing, ion 
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torrent semiconductor sequencing and SOLiD sequencing have been widely used in 
academic and industrial scenarios. The sequencing data analyzed in this dissertation is 
derived with either the Illumina or the SOLiD technology, which are the most popular 
sequencing technologies in the late 2000’s and early 2010’s. 
Owned by 454 Life Sciences and later by Roche, the 454 technology is the first 
widely used high-throughput sequencing technology and was once popular in the 2000s. It 
was known for its long read length (400-500 bases), but its sequencing depth is lower 
(400-600M reads per run) than SOLiD and Illumina technologies. The production of 454 
sequencers has been shut down by Roche in 2013. The 454 technology separates DNA 
templates to be sequenced in detached droplets, and adds solutions of A, T, C and G 
sequentially for synthesis. When the nucleic acid matches the template and the synthesis 
happens, a pyrophosphate (PPi) will be released. Then the PPi molecules go through a 
series reaction and finally reacts with the luciferin in the solution and generates visible 
light in amounts that are proportional to the amount of PPi. After the light signal is 
captured, the nucleotides and other byproducts are washed away and the reaction restarts 
with another nucleotide. The DNA sequences can be interpreted from a stack of images 
captured in each reaction. Similar to Sanger sequencing, the 454 technology also involved 
DNA synthesis, however, the 454 design allows it to sequence many sequences at once, 
and the avoidance of electrophoresis potentiates a much faster sequencing speed. 
By the year of 2017, the Illumina sequencing technology is the most popular large 
scale sequencing method among the academia and industry. Currently the Illumina 
sequencing technology can achieve up to 8-10B reads per run (NovaSeq 6000) with 2x150 
bases paired-end reads. Illumina also provides a lightweight benchtop sequencing solution 
MiSeq, which is capable of achieving 25M reads per run with 2x300 bases each read. In 
this method, the DNA molecules are first attached to a glass slide (flowcell) and amplified 
to form clusters. To identify the DNA sequence, four types of reversible terminator bases 
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(RT-bases) are added once a time. An RT-base is an engineered nucleic acid molecule that 
can be synthesized to a DNA molecule, but inhibits subsequent synthesis. The RT-base also 
carries a fluorescent unit that allows detection of synthesis activity by camera. After the 
camera has recorded the location of clusters with the synthesis activity, the fluorescent unit 
is chemically removed and a new base is added to the flowcell. After all four bases are 
added to the flowcell, the synthesis inhibition unit is removed to allow a new cycle of 
synthesis. The design of RT-base granted two advantages to the Illumina sequencing 
technology comparing to the 454 technology, 1) the DNA chain is extended one base at a 
time, which achieves higher accuracy on repetitive DNA sequences; 2) the light signal unit 
is attached to the DNA instead of released in the solution, which eliminated the need of 
droplets and simplified the experiment design. 
Owned by the Thermo Fisher Scientific, Ion Torrent is another popular lightweight 
sequencing solution that is comparable to MiSeq in throughput in 2017. It is capable to 
sequence 9-12M reads with 600 bases per run. Ion Torrent is also a sequencing by synthesis 
method. The DNA sequence and DNA polymerase are flooded by A, T, C and G dNTP 
sequentially. When the dNTP matches the DNA sequence, DNA synthesis takes place and a 
hydrogen ion is released. The hydrogen ion is then detected by a semiconductor sensor and 
the DNA sequence can be interpreted from the synthesis signals. The Ion Torrent 
technology suffers from a limitation. If the DNA sequence contains a long repetition of a 
certain base, then multiple hydrogen ions would be released in the corresponding cycle. 
Theoretically this would result in a proportionally higher electronic signal, however, the 
strength difference between two repetitions with different lengths are not easy to determine 
in practice. Similar to the 454 pyrosequencing technology, this characteristic has limited 
the accuracy of Ion Torrent technology on repetitive sequences. 
Owned by Life Technologies, SOLiD was a popular sequencing technology in the 
late 2000’s. It used to be the only sequencing method on the market that was comparable 
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against the Illumina technology. However, due to concerns in its cost and accuracy, SOLiD 
was discontinued from January 2013. Life Technologies was then acquired by Thermo 
Fisher in January 2014. Different from 454, Illumina and Ion Torrent technologies, SOLiD 
sequencing is based on DNA ligation instead of synthesis. SOLiD sequencing first ligates 
adapters with known sequences to the DNA molecules to be sequenced. Then it attaches 
these DNA molecules to magnetic beads and a PCR process makes clones of only one DNA 
sequence occupy the surface of each bead. The beads are then covalently bound to a glass 
slide. The SOLiD method involves 16 di-base probes, which consists of two bases for 
mapping the DNA molecule to be sequenced, three universal bases for enhanced affinity, 
and three universal bases with fluorescent dye. The 16 di-base probes are divided in four 
groups, each group includes 4 probes labeled with a distinct color. Four groups of di-base 
probes are added to the flowcell in sequence for ligation reactions. Due to the design of the 
three universal bases in the di-base probes, a series of continuous ligation reactions can 
only cover two in every five bases. To cover all bases in the DNA molecule, five series of 
ligation reactions with 1 base offset in each series are implemented. The first base of each 
series of reactions is known because the reaction initiates on the primer. The whole DNA 
sequence can be interpreted from the first base and the colored light signals captured 
during the ligation reactions. 
Other nucleic acid sequencing technologies also present in the same era, such as the 
SMRT sequencing by Pacific Biosciences [22], the Nanoball sequencing by Complete 
Genomics [23], the HeliScope single molecule sequencing by Helicos [24] and the 
Nanopore DNA sequencing by Oxford Nanopore [25]. However these technologies are not 
as widely applied as previous four because of disadvantages in cost, accuracy or 
technology maturity. The RNA sequencing (RNA-seq) data analyzed in this dissertation 
are derived from either the SOLiD or the Illumina sequencing technology, which are two of 
the most accurate and cost efficient technologies around 2010. 
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1.1.3 Sequencing Reads Alignment 
The sequences of the cDNA fragments detected in the sequencing experiment are 
called reads. The sequencer only produces read sequences in its output files, however the 
genomic locations of these reads need to be find out through a computational process 
called alignment. In the alignment step, the reads are usually compared against the 
corresponding UCSC genome [26]. 
Suppose the length of the genome is n, then we actually face such a problem in 
short read alignment: to implement a substring search and tolerate mismatches to a certain 
level in approximately O(1) time and O(n) memory space. Several short read aligners have 
been developed to address this problem, including BFAST [27], Bowtie [28] and BWA [29]. 
All these tools employed the Smith-Waterman algorithm for final alignment and scoring. 
Bowtie and BWA employed a suffix tree based on the Burrows-Wheeler transform (or 
FM-index) to speed up the substring match. BFAST also employed a suffix array for 
genome indexing but as genome positions sorted by suffix sequence. 
Short read aligners are only able to implement non-spliced alignment, which means 
the RNA-seq reads crossing splicing junctions between exons will get a low mapping score 
because of the huge gap in the intron and will not be considered as a match if aligned 
directly by BFAST, Bowtie or BWA. To take RNA splicing in consideration, RNA aligner 
tools need to be used for RNA-seq alignment. Such tools includes Tophat [30] and STAR 
[31]. 
1.1.4 Gene Expression Analysis Methods 
After the RNA-seq reads are mapped to the genome, the expression intensity of 
each gene can be inferred from the number of reads mapped. There are two primary factors 
affecting this number, the length of the gene and the overall sequencing depth of this 
sample. To normalize these factors, the unit reads per kilo-base per million mapped reads 
(RPKM) is used to evaluate gene expression intensity. The “per kilo-base” factor 
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normalizes the length of the gene, it could be either the total length of the gene or the 
exonic length. The “per million mapped reads” factor normalizes the overall sequencing 
depth of the sample. 
To test whether a gene is differentially expressed across two biological conditions, 
analysis of variance (ANOVA) or Friedman-test can be used to test RPKM. For these tests, 
one factor is the grouping based on the biological conditions. Another factor, if applicable, 
can be batch effect. Batch effect is the random effects during a sequencing experiment, 
such as time, light, or temperature that may affect the RPKM values. If the same sample is 
processed twice in two experiments, its RPKM may differ because of batch effects. Batch 
effects can be removed by adding a batch factor when implementing ANOVA or 
Friedman-test. ANOVA uses the actual RPKM values for testing, while Friedman-test uses 
the rank of the RPKM values for testing. 
Another model for gene expression analysis is edgeR [32]. Different from ANOVA 
and Friedman-test, which assumes the gene expression level follows normal distribution or 
chi-square distribution, edgeR models it with negative binomial distribution. In ideal 
condition, the natural distribution of the counts of reads falling on a gene should follow a 
Poisson distribution. However, more variation is observed in practice, which is known as 
overdispersion, which is induced by measurement errors. Therefore edgeR utilized the 
negative binomial distribution to model overdispersion. When the overdispersion is 0, the 
negative binomial distribution will become Poisson distribution. Instead of calculating the 
RPKM first, edgeR implements gene expression tests with counts of reads directly. 
1.2 Protein Mass Spectrometry Technology 
1.2.1 Brief History of Protein Science 
In 1838, the Dutch chemist Gerardus Johannes Mulder carried out elemental 
analysis on common proteins and erroneously concluded that proteins might be composed 
by a single type of large molecule [33]. Mulder’s collaborator, the Swedish chemist Jöns 
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Jacob Berzelius coined the term “protein”, which is derived from the Greek proteios, which 
means “primary”, and the suffix -in [34]. Mulder identified the first known amino acid 
leucine. For a long time, the exact composition of protein is not well known, until the 20th 
amino acid, threonine, was discovered in 1936. In 1949, the first protein sequencing was 
successfully implemented on insulin by Frederik Sanger, thus demonstrating that proteins 
are linear polymers of amino acids [35]. Linus Pauling suggested two main types of protein 
secondary structure, the α-helix and the β-strand (or β-sheet) in 1951 [36]. In the 1980s, 
mass spectrometry (MS) was widely applied in high-throughput sequencing and 
identification of proteins. In November 2017, the UniProt database has collected 556,196 
protein entries. At the same time, the protein data bank (PDB) [37] has collected 135,359 
protein tertiary structures, including 121,176 derived from X-ray crystallography, 12,032 
derived from NMR, and 1,817 derived from electron microscopy. 
1.2.2 Protein Mass Spectrometry 
A typical mass spectrometry experiment for protein identification involves the 
following stages: protein sorting, digestion, ionization, and tandem mass spectrometry 
(MS/MS). Protein sorting can be done by 2 dimensional electrophoresis, in which the first 
dimension separates proteins by their isoelectric points, and the second dimension 
separates proteins by their molecular weights. The protein molecules in each band have 
similar isoelectric points and molecular weights. Then these protein molecules are 
extracted and digested by a protease such as trypsin. The digested peptides are then ionized 
by either matrix-assisted laser desorption/ionization (MALDI) or electrospray ionization 
(ESI). The first stage of MS/MS sorts the peptide ions by their mass-to-charge ratio, and 
these peptide ions are further fragmented by collision-induced dissociation, 
photo-dissociation or other processes. The fragment ions then enter the second stage and 
the final mass spectrum was derived. The mass spectrum was then compared against 
known protein databases to identify the protein molecules in the sample. Before 2011, the 
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international protein index (IPI) database was widely used for such purpose, and later the 
UniProtKB database took its place after IPI’s retirement. The mass spectrometry analyses 
in this dissertation were finished in 2009 and were based on MS/MS and IPI. 
1.3 Alternative Splicing 
1.3.1 Discovery of Alternative Splicing 
During messenger RNA transcription, the RNA polymerase II travels through the 
gene region of the antisense strand of DNA and produces pre-mRNA, which is an identical 
copy of the sense strand of DNA. Then the spliceosome cuts out the intron regions on the 
pre-RNA and splices exons together, this process is called RNA splicing. In 1977, Phillip 
Sharp, Richard Roberts and Louise T. Chow demonstrated the existence of RNA splicing 
by visualizing the loops of introns under electron microscope when hybriding a cDNA 
sequence to its mRNA. The GT-AG sequence pattern on intron boundaries was discovered 
in 1978 by Breathnach [38]. When investigating the biological mechanism that enables 
RNA splicing, researchers soon realized that splicing can take place with “alternative 
splicing pathways” [39]. 
There are four basic modes of alternative splicing (AS). 1) Skipped exon (SE), or 
exon skipping, or cassette exon, where an exon may be left out during splicing. This is the 
most common type of AS in mammals. 2) Alternative 5’ splice site (A5SS), where an 
alternative 3’ end of the upstream exon (also the 5’ donor site) was used. 3) Alternative 3’ 
splice site (A3SS), where an alternative 5’ end of the downstream exon (also the 3’ acceptor 
site) was used. 4) Retained intron (RI) or intron retention, where the whole intron is 
retained in the final mRNA transcript. (Figure 1.1). 
1.3.2 Alternative Splicing Identification Methods 
Once the FASTQ or color spaced data are derived from sequencers, sequencing 
alignment will be implemented with RNA aligners, including Tophat and STAR. The 
intron regions appear as long deletions on the RNA-seq reads crossing two exons (or splice 
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junction reads), and such reads will get discarded by DNA aligners because of low scoring. 
RNA aligners are able to process these splice junction reads and achieve correct alignment. 
The alignments and scores of the RNA-seq reads are saved in BAM files. 
Based on BAM files, two approaches may be used to investigate AS. The first 
approach is whole mRNA transcript reconstruction. Software tools following this approach 
include Cufflinks [40] and Scripture [41]. Both of these tools construct transcripts with 
graph-based methods. Cufflinks builds a connectivity graph with each paired-end read as a 
node, and then attempts to search a minimal set of paths that covers all reads. Then these 
paths are scored and prioritized based on the abundance of reads they cover. On the other 
hand, Scripture first ignores the paired-end information and constructs the exons just based 
on overlapping sequence, then builds the connectivity graph based on exons and junction 
reads. These graphs are scored and filtered by read coverage, and then joined with 
paired-end data. In practice, Cufflinks has better specificity and Scripture has better 
sensitivity. 
 
Figure 1.1 Four types of alternative splicing events 
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Both Cufflinks and Scripture refines their connectivity paths based on 
mathematical assumptions, which may not be real in biology. Therefore the mRNA 
transcripts reconstructed from the RNA-seq data may not reveal the real composition of the 
transcriptome. This is a limitation of the short read RNA-seq and the best solution would 
be shifting to a long read RNA-seq method, such as the SMRT technology by Pacific 
Biosciences [22]. However, those sequencing methods were either expensive or not 
available in the first decade of 21th century. As a workaround, the approach for AS 
investigation was developed. Instead of attempting to reconstruct the transcriptome, this 
approach focuses on quantifying the ratio of mRNA transcripts supporting the inclusive 
and exclusive isoform of a single AS event. Such tools include MISO [42] and rMATS [43]. 
In this approach, an AS event is modeled as a pair of isoform transcripts, the one with 
flanking exons and the alternative region is defined as the inclusive isoform, and the one 
with flanking exons only is defined as the exclusive isoform. Figure 1.1 shows four types 
of AS events, including SE, A5SS, A3SS and RI. The boxes denotes regions that may be 
transcribed in the mRNA. White boxes denote constitutive regions that will present in all 
transcripts. Gray boxes denote alternative regions that only present in some transcripts. 
The straight line in the middle denotes introns, the curve on the top denotes exon junctions 
in the exclusive isoform, and the curves at the bottom denote junctions in the inclusive 
isoform. Both MISO and MATS calculates a percentage spliced-in (PSI or Ψ) value to 
quantify AS events. The Ψ denotes the percentage of the transcripts including the 
alternative region (cassette exon, retained intron, etc). Both MISO and MATS are capable 
to implement sample-wise or group-wise comparison for AS changes. 
1.3.3 Algorithms of MISO 
MISO [42] is one of the most frequently used AS quantification software tools in 
this dissertation. Here we introduce MISO’s algorithm in Ψ calculation and sample-wise 
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comparison. The following equation describes the most straightforward way of estimating 
Ψ: 
 ?̂? =
𝐷𝐼
𝐷𝐼 + 𝐷𝐸
 [1.1] 
 
DI is the density of inclusive reads, DE is the density of exclusive reads. DI and DE can be 
derived by the following equations: 
 𝐷𝐼 =
𝑁𝐼𝑛𝑐
𝑎 − 𝑟 + 1 + 2(𝑟 + 1 − 2𝑜)
 [1.2] 
 𝐷𝐸 =
𝑁𝐸𝑥𝑐
𝑟 + 1 − 2𝑜
 [1.3] 
NInc and NExc are the number of reads supporting inclusion and exclusion isoforms, 
respectively. Let a be the length of the alternative region, r be the length of the RNA-seq 
reads, and o the overhang constraint placed on splice junctions. These two equations 
normalizes the number of reads mapped to RNA isoforms (the numerator) with the 
number of the possible positions on each isoform (the denominator). 
However this is not the real approach that MISO used to deduce the Ψ value. 
Beside the inclusive and exclusive reads (or informative reads), MISO also utilized the 
constitutive reads to improve and stabilize Ψ estimates. The idea is to formulate the 
probability distribution of Ψ (a posteriori) values given the reads detected from 
mRNA-seq (a priori). It can be described by the following equation: 
 𝑃(𝑅1:𝑁|𝛹) =∏[𝑃(𝑅𝑛|𝐼𝑛𝑐)𝛹 + P(𝑅𝑛|𝐸𝑥𝑐)(1 − 𝛹)]
𝑁
𝑛=1
 [1.4] 
In this equation, 𝑃(𝑅𝑛|𝐼𝑛𝑐) and 𝑃(𝑅𝑛|𝐸𝑥𝑐) denote the probability of read n supporting 
the inclusive and exclusive transcript, respectively. Their values are determined by two 
factors, the possible positions of a read can be mapped to a transcript, which is denoted 
by p here, and whether a read is mapped to a transcript, which is denoted by R. Therefore 
we have the following equations: 
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𝑃(𝑅𝑛|𝐼𝑛𝑐) = 𝑝𝐼𝑛𝑐𝑅𝑛
𝐼𝑛𝑐 
=
𝑅𝑛
𝐼𝑛𝑐
𝑎 − 𝑟 + 1 + 2(𝑟 + 1 − 2𝑜)
 
 
[1.5] 
 
𝑃(𝑅𝑛|𝐸𝑥𝑐) = 𝑝𝐸𝑥𝑐𝑅𝑛
𝐸𝑥𝑐 
=
𝑅𝑛
𝐸𝑥𝑐
𝑟 + 1 − 2𝑜
 
[1.6] 
For one AS event, both pInc and pExc are constants, we may simply use this notation for 
readability. 𝑅𝑛
𝐼𝑛𝑐 and 𝑅𝑛
𝐸𝑥𝑐 denote whether the read n is mapped to the corresponding 
transcript isoform. If the read is uniquely mapped then the value is 1, if not then 0. If the 
read is mapped to the constitutive region then both 𝑅𝑛
𝐼𝑛𝑐 and 𝑅𝑛
𝐸𝑥𝑐 equal to 0.5. Thus 
we have the updated expression of the probability of the given set of reads and Ψ: 
 𝑃(𝑅1:𝑁|𝛹) =∏[𝑝𝐼𝑛𝑐𝑅𝑛
𝐼𝑛𝑐𝛹 + 𝑝𝐸𝑥𝑐𝑅𝑛
𝐸𝑥𝑐(1 − 𝛹)]
𝑁
𝑛=1
 [1.7] 
This equation describes the probability distribution of Ψ with a given set of reads. The 
mapping probability (p) and the mapping result (R) are both fixed, the Ψ value that 
achieves the maximum 𝑃(𝑅1:𝑁|Ψ)  will become the most likely Ψ. Here is the 
expression after taking the log: 
 ?̂? = argmax
Ψ
∑log[𝑝𝐼𝑛𝑐𝑅𝑛
𝐼𝑛𝑐𝛹 + 𝑝𝐸𝑥𝑐𝑅𝑛
𝐸𝑥𝑐(1 − 𝛹)]
𝑁
𝑛=1
 [1.8] 
After taking the derivative, we have the final equation for getting most likely Ψ: 
 
𝑑
𝑑𝛹
∑ log[𝑝𝐼𝑛𝑐𝑅𝑛
𝐼𝑛𝑐𝛹 + 𝑝𝐸𝑥𝑐𝑅𝑛
𝐸𝑥𝑐(1 − 𝛹)]
𝑁
𝑛=1
= 0 
∑
𝑝𝐼𝑛𝑐𝑅𝑛
𝐼𝑛𝑐 − 𝑝𝐸𝑥𝑐𝑅𝑛
𝐸𝑥𝑐
𝑝𝐼𝑛𝑐𝑅𝑛
𝐼𝑛𝑐𝛹 + 𝑝𝐸𝑥𝑐𝑅𝑛
𝐸𝑥𝑐(1 − 𝛹)
𝑁
𝑛=1
= 0 
[1.9] 
Assuming the estimated Ψ value has been evaluated for biological condition A 
and B, now it is important to compare whether ΨA is significantly different from ΨB. 
MISO calculates a Bayes factor (BF) to evaluate the likelihood of differential splicing. 
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Let δ be the difference between ΨA and ΨB, then the null hypothesis (H0) is δ=0, and the 
alternative hypothesis is δ≠0. The BF is defined as the weight of the evidence in the data 
D in support of H1 over H0: 
 𝐵𝐹 =
𝑃(𝐷,𝐻1)
𝑃(𝐷,𝐻0)
=
𝑃(𝐷|𝐻1)𝑃(𝐻1)
𝑃(𝐷|𝐻0)𝑃(𝐻0)
 [1.10] 
The authors of MISO uses Savage-Dickey density ratio [44] to approximately estimate 
BF: 
 𝐵𝐹 ≈
𝑃(δ = 0|𝐻1)
𝑃(δ = 0|𝐷,𝐻1)
 [1.11] 
When H1 stands, the probability of δ=0 is 1, so the equation can be simplified as: 
 𝐵𝐹 ≈
1
𝑃(δ = 0|𝐷,𝐻1)
 [1.12] 
Associating to the equation of Ψ before, the denominator of the equation above can be 
stated as: 
 𝑃(δ = 0|𝐷,𝐻1) = ∫ 𝑃𝐴(𝑅1:𝑀|𝛹)𝑃𝐵(𝑅1:𝑁|𝛹)
1
0
 [1.13] 
MISO’s BF approach for differential AS testing requires merging the BAM files 
of each group. This procedure has ignored the within-group variation and the result may 
be skewed by outliers. 
1.3.4 Algorithms of rMATS 
To put the within-group variation in consideration, the rMATS [43] package has 
been developed in 2014. Its algorithm for Ψ value estimation uses only reads that can be 
uniquely mapped to inclusive or exclusive isoforms. The equation for calculating Ψ in 
rMATS is the same as equation [1.1]. 
In the rMATS model, the observed Ψ of a given AS event is affected by two types 
of variations, including 1) the biological variation of the replicate Ψ within the sample 
group, which is modeled by a normal distribution, and 2) the variation of observed reads 
given a Ψ value, which is modeled by a binomial distribution. The first variation is 
represented in the following model: 
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log𝛹𝑔𝑘 ~Normal(𝜇 = log𝛹𝑔 , 𝜎
2 = 𝜎𝑔
2) [1.14] 
In model [1.14], g represents group number, and k represents the sample number within 
the corresponding group. The second variation is represented in model [1.15]: 
𝐼𝑔𝑘|𝛹𝑔𝑘~Binomial(𝑛𝑔𝑘 = 𝑁𝐼𝑛𝑐,𝑘 + 𝑁𝐸𝑥𝑐,𝑘, 𝑝𝑔𝑘 =
𝑙𝐼𝑛𝑐𝛹𝑔
𝑙𝐼𝑛𝑐𝛹𝑔 + 𝑙𝐸𝑥𝑐(1 − 𝛹𝑔)
) [1.15]  
In this model, NInc,k and NExc,k represent the numbers of reads mapped to the inclusive 
and exclusive isoform, respectively. The effective lengths of the inclusive and exclusive 
isoform are represented with lInc and lExc. 
Based on the variation models above, it is possible to estimate the likelihood of 
getting the observed read counts from sample group A and B bases on a given ΨA and ΨB: 
𝐿 = 𝐿1𝐿2 
𝐿1 =∏𝑃(𝐼𝐴𝑘|𝛹𝐴𝑘 , 𝑛𝐴𝑘)
𝑀𝐴
𝑘=1
∏𝑃(𝐼𝐵𝑘|𝛹𝐵𝑘 , 𝑛𝐵𝑘)
𝑀𝐵
𝑘=1
 
𝐿2 =∏𝑃(𝛹𝐴𝑘|𝛹𝐴, 𝜎𝐴)
𝑀𝐴
𝑘=1
∏𝑃(𝛹𝐵𝑘|𝛹𝐵, 𝜎𝐵)
𝑀𝐵
𝑘=1
 
[1.16] 
𝑃(𝐼𝑔𝑘|𝛹𝑔𝑘, 𝑛𝑔𝑘) can be derived from the binomial distribution: 
∏𝑃(𝐼𝑔𝑘|𝛹𝑔𝑘, 𝑛𝑔𝑘)
𝑀𝑔
𝑘=1
=∏(
𝑁𝐼𝑛𝑐 + 𝑁𝐸𝑥𝑐
𝑁𝐼𝑛𝑐
)
𝑀𝑔
𝑘=1
 
× exp⁡(∑𝑁𝑔𝑘,𝐼𝑛𝑐 log
𝑙𝐼𝑛𝑐𝛹𝑔𝑘
𝑙𝐼𝑛𝑐𝛹𝑔𝑘 + 𝑙𝐸𝑥𝑐(1 − 𝛹𝑔𝑘)
𝑀𝑔
𝑘=1
+ 𝑁𝑔𝑘,𝐸𝑥𝑐 log
𝑙𝐸𝑥𝑐(1 − 𝛹𝑔𝑘)
𝑙𝐼𝑛𝑐𝛹𝑔𝑘 + 𝑙𝐸𝑥𝑐(1 − 𝛹𝑔𝑘)
) 
[1.17] 
𝑃(𝛹𝑔𝑘|𝛹𝑔, 𝜎𝑔) can be derived from the normal distribution: 
∏𝑃(𝛹𝑔𝑘|𝛹𝑔, 𝜎𝑔)
𝑀𝑔
𝑘=1
= [1.18] 
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exp(∑
− log 2𝜋
2
− log 𝜎𝑔 −
(log𝛹𝑔𝑘 − log𝛹𝑔)
2
2𝜎𝑔2
+ log(𝛹𝑔𝑘(1 − 𝛹𝑔𝑘))
𝑀𝑔
𝑘=1
) 
Since the goal is to test the difference of mean inclusion level between two sample groups 
(i.e., Ψ1-Ψ2), the Ψ value of each sample Ψ1k and Ψ2k can be treated as latent variables, 
and the marginal distribution can be transformed with integral of Ψ1k and Ψ2k: 
𝑓(𝛹1, 𝜎1, 𝛹2, 𝜎2)
= 𝑐 (∏∫𝑓(𝛹1, 𝜎1, 𝛹1𝑘)𝑑𝛹1𝑘
𝑀1
𝑘=1
∏∫𝑓(𝛹2, 𝜎2, 𝛹2𝑘)𝑑𝛹2𝑘
𝑀2
𝑘=1
) 
[1.19] 
In equation [1.19], c is a constant, and f(Ψ1, σ1, Ψ1k) can be defined by the following 
equation: 
𝑓(𝛹𝑔, 𝜎𝑔, 𝛹𝑔𝑘) = exp(− log 𝜎𝑔 −
(log𝛹𝑔𝑘 − log𝛹𝑔)
2
2𝜎𝑔2
 
+ log (𝛹𝑔𝑘(1 − 𝛹𝑔𝑘)) 
+𝑁𝑔𝑘,𝐼𝑛𝑐 log
𝑙𝐼𝑛𝑐𝛹𝑔𝑘
𝑙𝐼𝑛𝑐𝛹𝑔𝑘 + 𝑙𝐸𝑥𝑐(1 − 𝛹𝑔𝑘)
 
+𝑁𝑔𝑘,𝐸𝑥𝑐 log
𝑙𝐸𝑥𝑐(1 − 𝛹𝑔𝑘)
𝑙𝐼𝑛𝑐𝛹𝑔𝑘 + 𝑙𝐸𝑥𝑐(1 − 𝛹𝑔𝑘)
) 
[1.20] 
After Laplace approximation, we can derive the following equation: 
∫𝑓(𝛹𝑔, 𝜎𝑔, 𝛹𝑔𝑘)𝑑𝛹𝑔𝑘 ≈ √2𝜋 (|
𝜕2𝑓1(𝛹𝑔, 𝜎𝑔, ?̂?𝑔𝑘)
𝜕𝛹𝑔𝑘
2 |)
−0.5
 
× exp⁡(𝑓1(𝛹𝑔, 𝜎𝑔, ?̂?𝑔𝑘) 
𝜕2𝑓1(𝛹𝑔, 𝜎𝑔, ?̂?𝑔𝑘)
𝜕𝛹𝑔𝑘
2  
=
2?̂?𝑔𝑘 − 1
?̂?𝑔𝑘
2 (1 − ?̂?𝑔𝑘)
2 (
log𝛹𝑔 − log ?̂?𝑔𝑘 − (2?̂?𝑔𝑘 − 1)
−1
𝜎𝑔2
+ 1) 
[1.21] 
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−𝑁𝑔𝑘,𝐼𝑛𝑐𝑙𝐸𝑥𝑐
(2𝑙𝐼𝑛𝑐 + 𝑙𝐸𝑥𝑐)?̂?𝑔𝑘 + 𝑙𝐸𝑥𝑐(1 − ?̂?𝑔𝑘)
?̂?𝑔𝑘
2 (𝑙𝐼𝑛𝑐?̂?𝑔𝑘 + 𝑙𝐸𝑥𝑐(1 − ?̂?𝑔𝑘))
2  
−𝑁𝑔𝑘,𝐸𝑥𝑐𝑙𝐼𝑛𝑐
(𝑙𝐼𝑛𝑐 + 2𝑙𝐸𝑥𝑐)(1 − ?̂?𝑔𝑘) + 𝑙𝐼𝑛𝑐?̂?𝑔𝑘
(1 − ?̂?𝑔𝑘)
2
(𝑙𝐼𝑛𝑐?̂?𝑔𝑘 + 𝑙𝐸𝑥𝑐(1 − ?̂?𝑔𝑘))2
 
The Laplace’s method approximates the distribution of Ψgk by normal distribution. The 
estimated values of Ψgk can be derived in optimization procedure for 
maximum-likelihood estimation (MLE): 
?̂?𝑔𝑘 = argmax
𝛹𝑔𝑘
(
−0.5(log𝛹𝑔𝑘 − log ?̂?𝑔)
2
𝜎𝑔2
+ log𝛹𝑔𝑘 
+ log(1 − 𝛹𝑔𝑘) + 𝑁𝑔𝑘,𝐼𝑛𝑐 log (
𝑙𝐼𝑛𝑐𝛹𝑔𝑘
𝑙𝐼𝑛𝑐𝛹𝑔𝑘 + 𝑙𝐸𝑥𝑐(1 − 𝛹𝑔𝑘)
) 
+𝑁𝑔𝑘,𝐸𝑥𝑐 log (
𝑙𝐸𝑥𝑐(1 − 𝛹𝑔𝑘)
𝑙𝐼𝑛𝑐𝛹𝑔𝑘 + 𝑙𝐸𝑥𝑐(1 − 𝛹𝑔𝑘)
)) 
[1.22] 
Based on the marginal distribution described above, P value of the splicing difference 
across two groups of samples can be calculated. For each AS event, the null hypothesis is 
the difference of Ψ across two groups is smaller than or equal to a user defined cutoff, 
and the alternative hypothesis is the difference of Ψ is larger than the cutoff. 
1.4 Long Non-coding RNA 
A major portion of eukaryotic genome is covered by DNA sequences that do not 
code for proteins, however, it is observed that many of these regions are transcribed and 
produces a huge species of non-coding RNAs (ncRNAs) [45, 46]. Some of ncRNAs are 
constructively expressed in all cells, such as ribosomal RNA, transfer RNA, and small 
nuclear and nucleolar RNA, and are known as housekeeping ncRNAs. Besides 
housekeeping ncRNAs, other ncRNAs can be categorized into small non-coding RNAs, 
which are 100 nucleotides and shorter, and long non-coding RNAs, which are longer than 
200 nucleotides. 
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Small non-coding RNAs can be subdivided into subgroups (miRNA, siRNA, 
piRNA, etc.) based on their size, biogenesis and mode of action. It is known that small 
ncRNAs regulate gene expression by guiding repressive chromatin complexes and 
RNA-dependent RNA polymerase complexes, which regulates transcription silencing and 
starting respectively at the transcriptional level, and by guiding RNA-induced silencing 
complexes (RISCs) to cleave the target mRNA at the post-transcriptional level [47-51]. 
Comparing with small ncRNAs, long non-coding RNAs (lncRNAs) are less 
characterized, and their biological functions are poorly investigated. Most of lncRNAs are 
transcribed by RNA Polymerase II (RNA pol II), and possess a 5’ methyl cap and polyA tail, 
which is the same as messenger RNAs (mRNA). LncRNAs may be transcribed from four 
possible locations: 1) introns of another gene, 2) intergenic regions, 3) sense strand of a 
gene or 4) antisense strand of a gene. LncRNAs are less conservative in sequence than 
protein-coding mRNAs, but still shows positive selection over neutral sequences [52]. 
LncRNAs may act as transcription silencers via transcriptional interference. A very 
well-known example is the X inactivation specific transcript (Xist), which deactivates 
whole X chromosome in female mammals by spreading across the X chromosome and 
recruiting polycomb repressive complex 2 (PRC2), which hence transfers repressive 
histone markers (H3K27me3 and H3K9me3) to the chromosome [53]. Besides whole 
chromosome repression, lncRNA also participates in individual gene repressions. In yeast 
S.cerevisiae, the transcription of a non-coding gene SRG1, which is located upstream of 
the promoter of another gene, SER3, suppresses the transcription of SER3 [54, 55]. There 
are two models that may explain lncRNA’s repressive effect on gene expression. The first 
model is the transcription activity causes the occlusion of the transcription machinery. The 
second model is the lncRNA itself may bind to the transcriptional complex and act as an 
inhibitor. In some cases, lncRNA may act as transcription activators, if its transcription 
occludes transcription inhibitors of another gene. For example, the transcription of lncRNA 
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LINoCR occludes the chromatin insulator protein CTCF, a gene expression repressor, and 
activates the chicken Lysozyme gene [56]. LncRNA may also regulate mRNA splicing. 
During epithelial to mesenchymal transition (EMT), the translation of Zeb2 mRNA is 
prevented in epithelial cells by a splicing event which removes the internal ribosome entry 
site (IRES) containing the 5’ UTR. On the other hand, in mesenchymal cells, an antisense 
lncRNA binds to the mRNA and prevents this splicing event, and hence allowing the 
translation of Zeb2 mRNA [57]. 
Currently lncRNAs can be identified at a genome-wide scale by active chromatin 
signatures associated with RNA pol II transcription. Such chromatin signatures include 
histone H3 lysine 4 trimethylation and histone H3 lysine 36 trimethylation domains 
(K4-K36 domain) [58, 59]. 
1.5 Organization of the Dissertation 
This dissertation identified and quantified AS events and novel lncRNA in several 
organisms and cell lines with help of high-throughput sequencing technologies. In Chapter 
2, we investigated stimulant induced AS with lipopolysaccharide stimulated bone 
marrow-derived mesenchymal stem cells (BMSC) [60]. In Chapter 3, we investigated 
developmentally regulated AS within human liver across three developmental stages (fetal, 
pediatric and adult). In Chapter 4, we discussed a method for identifying novel AS events 
from any mRNA-seq experiment [61]. In Chapter 5, we built a peptidomic database for 
identifying novel AS events from MS/MS data [62]. In Chapter 6, we identified and 
characterized lncRNAs associated with alcohol dependence from mRNA-seq data [63]. 
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Chapter 2. Stimulant Induced Alternative Splicing 
2.1 Background 
Alternative splicing (AS) is important for gene regulation and is a major source of 
proteome diversity in mammals [64] through altering the composition of mRNA transcripts 
by including or excluding specific exons [65]. AS can further modulate organism 
complexity not only by effectively increasing regulatory and signaling network complexity, 
but also by doing so in a temporal- and spatial-specific manner, supporting cell 
differentiation, developmental pathways, and other processes associated with multicellular 
organisms. Indeed, AS shows a strong relationship with organism complexity, as estimated 
by the organism’s number of different cell types [66]. The recent ENCODE Project 
concluded that at least 90% of human genes express multiple mRNAs through alternative 
splicing of exons or exon segments [67]. As might be expected, deregulation of this 
process is associated with numerous diseases [68-73]. 
Bone marrow-derived mesenchymal stem cells (BMSCs) are adult stem cells 
capable of self-renewal and differentiation into numerous cell lineages, including 
osteocytes, adipocytes, and chondrocytes [74]. One promising use of BMSCs is repair of 
ischemia-damaged cardiac tissue. BMSCs are easy to expand in vitro, can be genetically 
modified and exhibit significant immunotolerance properties [75-77], making BMSCs an 
attractive candidate for tissue repair/regeneration therapy. Intramyocardial injection of 
BMSCs reduces inflammation, fibrosis, infarct size, ventricular remodeling, and therefore, 
improves cardiac function following tissue insult [78-81]. 
Because the majority of BMSCs are soon lost during after injection, the observed 
therapeutic effects likely derive from paracrine effects of bioactive molecules released 
from these cells [78, 79]. Indeed, BMSC-mediated release of cytoprotective protein factors 
or transfer of intracellular components (e.g.,mRNAs, microRNAs, and proteins) via cell 
membrane exosomes, represents a novel mechanism of cell-to-cell communication [82]. 
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To date, however, clinical trials have demonstrated that while effective, delivery of BMSCs 
to ischemic myocardium results in only modest and short-lived benefits [83, 84]. Therefore, 
there is a critical need to elucidate the mechanisms by which BMSCs mediate their 
therapeutic benefits, including identification of their specific paracrine factor(s), and 
conditions under which their functions can be optimized. 
Upon injection into damaged heart tissue, BMSCs face a hypoxic, ischemic 
environment that severely limits their therapeutic efficacy. Thus, preconditioning BMSCs 
with various growth factors and endogenous or exogenous molecules has been used to 
improve BMSC therapeutic efficacy [85-87]. Indeed, it has been reported previously that 
bacterial endotoxin (lipopolysaccharide, LPS) could stimulate BMSCs to release paracrine 
factors, including angiogenic growth factors, cytokines, and chemokines that facilitate 
tissue repair [76, 77]. In addition, our previous study suggested that BMSC expression of 
the LPS receptor, toll-like receptor 4 (TLR4), regulates BMSC paracrine properties and 
intracellular STAT3 signaling cascades [88]. Moreover, preconditioning of BMSCs with 
LPS improves their therapeutic efficacy in rodent models of ischemia/reperfusion injury 
[86]. However, BMSC transcriptomic changes (in particular, alterations in mRNA 
transcript processing and splicing) that occur following LPS stimulation have been little 
studied. 
Besides use as an attractive therapeutic tool for repairing ischemic heart, BMSCs 
have been used for numerous other diseases, including graft-versus-host disease, Crohn’s 
disease, stroke, cartilage defects, diabetes and many others [89-94]. With the growing 
incidence of bacterial endotoxin LPS detected in older or immunocompromised patients 
with multiple-drug resistant bacteria, diabetes, cancer, indwelling IV catheters, and on 
complex chemotherapy regimens [95, 96], it is of great importance to study whether the 
stimulation of these implanted BMSCs by endogenous LPS would alter their therapeutic 
efficacy. Moreover, because MSCs are present in bone marrow and many other tissues, it 
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merits extensive investigation whether LPS stimulation of these endogenous MSCs would 
influence the clinical outcomes of complex therapeutic regimens. 
Despite BMSC’s strong clinical potential, the role(s) of alternative splicing in LPS 
response has not been fully explored. The recent development of high-throughput 
sequencing technology has now made transcriptome-wide profiling of splicing isoforms 
possible. In this study, we used RNA-seq analysis of BMSCs to identify and characterize 
gene transcripts whose splicing patterns were altered by LPS treatment. 
2.2 Results 
To investigate LPS-induced transcriptomic changes in BMSCs due to alternative 
splicing, RNA-seq analysis was conducted on BMSCs before and after LPS treatment, in 
triplicate. A strand-directed single-end RNA-seq protocol (75 bp reads) was used with the 
SOLiD 5500xl instrument. 
The total analysis resulted in 326 million reads, with each of the six samples 
ranging from 43 to 59 million reads. After removing the reads with low sequencing quality 
(see Methods) and filtering reads mapped to ribosomal RNAs and repeats, the remaining 
reads were mapped to the standard mouse reference genome (mm9). The total number of 
mappable reads in each sample ranged from 29 to 36 million, with an average mapping 
percentage of 59%. Among the mappable reads in each sample, 3.8 to 5.0 million are 
mapped to protein coding exons, and 2.8 to 4.0 million are mapped to splice junctions. 
Detailed mapping statistics for the six samples are listed in Table 2.1 Statistics of the RNA 
sequencing experiment 
. 
2.2.1 LPS-Induced Alternative Splicing 
We applied a MISO (Mixture of Isoform) algorithm [97] to identify alternative 
splicing events elicited by LPS treatment. Based on a Bayesian inference framework, 
MISO is a probabilistic framework that quantitates the expression levels of alternatively 
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spliced genes from RNA-Seq data, and identifies differentially regulated exons across 
samples. MISO computes Percent Spliced In (PSI, or Ψ) values for each alternative 
splicing event, representing the fraction of a gene’s mRNA that includes the exon. For each 
event, MISO also calculates a Bayesian Factor (BF) that quantifies the likelihood of the 
changes. For instance, [BF]=5 indicates it is five times more likely that a specific 
alternative splicing event occurred than did not occur.  
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Table 2.1 Statistics of the RNA sequencing experiment 
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Overall, we identified 197 exons whose splicing patterns differed between control 
and LPS-treated BMSCs (Bayesian factor [BF]>5 and |ΔΨ|>0.05). This number represents 
2.32% of all 8,475 events whose inclusion percentages could be reliably measured from the 
RNA-seq data; these genes generally had higher expression levels to generate enough read 
depth for splicing analysis. For genes with lower expression levels, our RNA-seq 
experiment did not have enough read depth for such analysis. The 197 LPS-induced 
alternatively spliced events included 82 cassette exons, 28 alternative donor site events 
(5’-ss), 45 alternative acceptor site events (3’-ss), and 42 intron retention events. Figure 2.1 
demonstrates the magnitude (X-axis) and significance (Y-axis) of LPS-induced splicing 
pattern changes on all the alternatively exons that could be reliably identified by MISO 
under both untreated and LPS-treated conditions (Figure 2.1). Among these 197 events 
(red dots in Figure 2.1), 117 showed positive ∆Ψ values, indicating that the percentage of 
transcripts containing the specific exon increased in the LPS-treated samples compared to 
control samples. Similarly, 80 events showed negative ∆Ψ values, indicating a decrease in 
the percentage of transcripts containing specific exons. For each of the four types of 
splicing events (cassette exons, alternative 5’-donor sites, alternative 3’-acceptor sites, and 
intron retention), we show one Sashimi plot for the exons with the largest LPS-induced 
changes (either increases or decreases) in percentage of inclusion in the gene product 
(Figure 2.2). The Sashimi plot demonstrates the RNA-seq read densities along exons and 
junctions, in the context of the structure of the gene’s isoforms. In addition, the distribution 
and the confidence intervals of the estimated Ψ under both conditions (LPS vs. untreated) 
are also included. 
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Figure 2.1 LPS-induced alternative splicing events. 
Scatter plot of all the AS events identified in MISO. The X-axis represents ∆Ψ, and the 
Y-axis represents log(BF). The shape of the dots indicates the type of the events. 
Specifically, circle indicates cassette exon events; star indicates intron retention events; 
triangle indicates alternative 5’ splice site events; and diamond indicates alternative 3’ 
splice site events. Alternatively spliced events with BF≥5 are colored in red. 
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Figure 2.2 Sashimi plots of four types of AS events.  
Sashimi plots of four types of AS events were shown, including cassette exon, intron 
retention, alternative 5’ and 3’ splice site. The red plots represent the LPS treated condition, 
and the blue ones represent controls. The X-axes indicate genomic locations, and the 
Y-axes indicate transcription intensity. In each plot, a “sashimi-like” region indicates a 
heavily transcribed region, in this case, exonic region. The blank regions between exonic 
regions indicate intronic regions. The “bridges” crossing exons indicate junction reads. 
The numbers of junction reads are shown on the “bridges”. The exonic structure of each 
AS event is shown below each Sashimi plot. On the right it displays the estimated Ψ (red 
line) value and the full posterior distribution (black bars). 
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To validate whether the alternative splicing events were induced by LPS treatment, 
we performed RNA-seq on BMSCs derived from MyD88-/- animals before and after LPS 
treatment. MyD88 is a key signaling molecule responsible for LPS response [98]. Among 
the 197 LPS-induced alternative splicing events in wild-type BMSCs, 189 did not occur 
following LPS treatment of MyD88-/- BMSCs (Figure 2.3). This observation indicates that 
a large majority of BMSC splicing changes were a direct consequence of LPS induction, 
and such effects were negated in cells whose LPS response is compromised. It should be 
noted that in addition to MyD88 pathways, LPS also functions through TRIF pathways 
[99]; the functions of TRIF pathway is intact in the MyD88-/- cells. This partially explains 
why some LPS-induced splicing effects remained in MyD88-deficient animals. 
 
Figure 2.3 LPS-induced splicing changes in wild-type BMSC were repressed in MyD88-/- 
cells.  
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The X-axis and Y-axis represents ∆PSI in wild type and MyD88 knock out animals 
respectively. Blue diamond represents LPS induced AS events in wild type only, and red 
square represents LPS induced AS events in both wild type and MyD88 knock-out cells. 
Among the 197 LPS-induced alternative splicing events, 103 were located in the 
coding regions of transcripts, and 94 were either in the 5’- or 3’- untranslated regions 
(UTRs). Among the 103 alternatively spliced coding events, 65 were composed of 
multiples of three nucleotides, leading to the inclusion or exclusion of specific amino-acid 
residues in the final protein products. These events could potentially generate multiple 
viable protein products having the same translation frame. Thirty-eight of the 103 coding 
exons contained either a premature stop codon, and/or a shift in their translation frames. 
Such events trigger either nonsense-mediated decay (NMD) mechanisms [100], or a 
translated protein having a complete different amino acid sequence downstream of the 
alternatively spliced exon. 
 
 
Figure 2.4 Distribution of AS genes in different cellular locations. 
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  1   1 
Transmembrane 
Receptor 
  3   3 
Kinase 2 9    11 
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Nuclear Receptor 
1     1 
Peptidase 1 3   2 6 
Phosphatase   1  1 2 
Transcription Regulator 17 2   1 20 
Transporter  6 1   7 
Other 30 35 12 6 34 117 
Total 64 67 18 6 42 197 
Table 2.2 Functions and cellular locations of AS genes 
 
We then systematically examined the localization and functions of the gene 
products possessing alternatively spliced exons (Figure 2.4 and Table 2.2). Among them, 
64 were nuclear proteins, including 17 transcription regulators, 13 enzymes, 2 kinases, 1 
peptidase, and 1 ligand-dependent nuclear receptor. The 67 cytoplasmic alternatively 
spliced gene products included 12 enzymes, 9 kinases, 6 transporters, 3 peptidases, and 2 
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translation regulators. In addition, we also observed six potentially secreted proteins and 
18 plasma membrane-spanning proteins. A detailed list of the genes in each category is 
provided in Table S-1. These results strongly suggest that LPS induces splicing changes in 
highly diverse proteins having a variety of cellular functions. 
To understand the biological functions of genes whose splicing patterns were 
altered by LPS treatment, we conducted functional annotation analysis using the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 [101]. Three 
functional terms in the SP_PIR (Swiss-Prot and Protein Information Resources) category 
showed significant enrichment in our gene list. Among the 161 genes that could be mapped 
to DAVID gene annotations, 97 categorized as phosphoproteins (p-value=7.2x10-12, 
FDR=6.6x10-10). In addition, 26 genes contained zinc finger domain proteins (p-value= 
3.6x10-5, FDR=2.2x10-3) whose functions range from DNA or RNA binding to 
protein-protein interactions and membrane association [102]. Furthermore, 35 genes were 
involved in protein acetylation (p-value=1.3 x10-3, FDR=3.2x10-2). Together, these 
results suggest that LPS treatment has major effects on the splicing patterns of signaling 
proteins. 
Both gene expression levels and splicing patterns may be altered by BMSC 
responses to LPS treatment. While differential gene expression may lead to changes in the 
abundance of the entire gene product, alternative spicing modifies the structural 
composition of a specific protein. To evaluate to what extent the two mechanisms interact, 
we examined the number of genes present in both differentially expressed and alternatively 
spliced gene sets. We utilized edgeR [32] to identify genes differentially expressed 
between LPS-treated and control samples. In total, 416 differentially expressed genes were 
identified using a false discovery rate  0.05. Surprisingly, only one gene, Plscr2 
(Phospholipid Scramblase 2) was both differentially expressed and alternatively spliced. 
The expression level of Plscr2 increased 1.77-fold in LPS-induced samples with 
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FDR=0.01, while the percentage of inclusion of one cassette exon in the 3’-untranslated 
region (3’-UTR) increased by 0.16. 
2.2.2 Protein Domains are Differentially Spliced 
Alternatively spliced exons residing in known protein domains are more likely to 
disrupt protein function. Therefore, we systematically searched the overlap between 
LPS-induced AS events for known protein family domains documented in the pfam 
database [103]. Among 65 alternatively spliced exons that did not disrupt codon frame, 
seven overlapped with known protein domains (Table 2.3). In addition, seven other known 
domains that overlapped flanking exons had functions ranging from RNA and protein 
binding, enzymatic activities, methyltransferase activity, phosphopantetheinyl transferase 
activity, RNA editing, and microRNA processing. 
 
Gene Symbol AS Type Pfam Domain Domain Description 
Ttc13 cassete exon TPR_11 TPR repeat 
Rabep1 cassete exon Rabaptin Rabaptin 
Camk1d cassete exon Pkinase Protein kinase domain 
Nr1h2 
alternative 5' 
splice site 
Hormone_recep 
Ligand-binding domain of 
nuclear hormone receptor 
Adarb1 
alternative 5' 
splice site 
A_deamin 
Adenosine-deaminase 
(editase) domain 
Scoc 
alternative 3' 
splice site 
DUF2205 
Predicted coiled-coil 
protein 
Ppip5k2 
alternative 3' 
splice site 
His_Phos_2 
Histidine phosphatase 
superfamily (branch 2) 
Table 2.3 Alternatively spliced genes containing known protein domains 
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2.2.3 AS in Protein Domains may Affect Protein Interactions 
To examine whether alternatively spliced protein domains modulate 
protein-protein interactions, we searched for their binding partners based on two criteria: (1) 
at least one experimental study supporting direct interaction between the partner protein 
and the alternatively spliced protein in a known protein-protein interaction network [104, 
105]; and (2) at least one structural study in the Protein Data Bank (PDB) supporting direct 
interaction between a domain in the binding partner and the domain modified by 
alternative splicing. For the first criterion, we merged two datasets of experimentally 
validated direct interactions [104, 105] and compiled a library of 9,795 protein-coding 
genes with 80,518 experimentally validated interactions. For the second criterion, we 
derived the domain interactions in PDB from iPfam [103] and then searched for proteins 
containing these domains in Pfam [103]. In total, 3,573 interactions with structural 
evidence were found between 13 alternatively spliced coding transcripts and 3103 binding 
partners. By joining two interaction tables, we identified eight interactions having both 
experimental and structural evidence. As shown in Figure 2.5, these eight interactions 
involved three genes with altered splicing domains, Rabep1 (Rab GTPase-binding effector 
protein 1), Camk1d (Calcium/Calmodulin-Dependent Protein Kinase 1D), and Nr1h2 
(nuclear receptor subfamily 1, group H, member 2). The alternatively spliced exons in 
these genes overlapped with known protein domains, including rabaptin, pkinase, and 
ligand-binding domain of nuclear hormone receptor. 
 
The differences in the percentage of inclusion for these three events ranged from 14% 
to 31%. The potential protein partners included Rabep1, Gga1 (Golgi-associated, gamma 
adaptin ear containing, ARF-binding protein 1), Gga2 (Golgi-associated, gamma adaptin 
ear containing, ARF binding protein 2), Gga3 (Golgi-associated, gamma adaptin ear 
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containing, ARF binding protein 3), Camkk1 (calcium/calmodulin-dependent protein 
kinase kinase 1, alpha), Nr0b2 (nuclear receptor subfamily 0, group B, member 2), Rxra 
(retinoid X receptor, alpha), and Rxrb (retinoid X receptor, beta). LPS-induced splicing 
changes could significantly impact these proteins’ interactions with their partners. Among 
these putative protein interaction partners, only one protein, Nr0b2 (nuclear receptor 
subfamily 0, group B, member 2), was not expressed. 
 
 
Figure 2.5 PPI with both structural and experimental evidences.  
Ten AS gene products involved in protein-protein interactions. Gene symbols are displayed 
in white regions, and corresponding protein domains are displayed with gray background. 
Blue line indicates a gene/protein contains a domain, and a red line indicates an interaction 
between protein domains. 
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2.2.4 Intrinsic Disorder and MoRF in AS Regions 
It was previously reported that alternatively spliced regions are enriched with 
unfolded protein regions (intrinsic disorder) [106]. To examine these features within 
LPS-induced alternatively spliced regions (cassette exons, alternative 5’/3’ exons and 
retained introns), we performed disorder prediction on the protein sequences of these 
regions using VSL2B [107], a bioinformatics algorithm for predicting intrinsically 
disordered regions based on the biophysical properties of amino acids. Among the 
alternative regions of 65 protein sequences translated from LPS-induced alternative 
splicing events, 34 (52.3%) were predicted to be totally disordered, 21 (32.3%) partially 
disordered, and only 10 (15.3%) totally structured (Figure 2.6). These percentages are 
consistent with previous reports that alternatively spliced exons tend to locate in 
intrinsically disordered regions [108]. 
 
Figure 2.6 Predicted disorder of AS gene products. 
(A) The distribution of 65 non-frameshifting protein coding AS genes in three categories, 
including totally disordered, partially disordered and structured. (B) The MoRF containing 
and non-containing events among partially disordered AS genes. The list of MoRF 
containing genes is shown on the right. C) The same distribution and gene list as panel B 
but it is for totally disordered AS genes. 
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gene_symbol gene_description 
Arl13b ADP-ribosylation factor-like 13B 
Senp7 SUMO1/sentrin specific peptidase 7 
Tbc1d31 TBC1 domain family, member 31 
Depdc1a DEP domain containing 1 
Arhgef11 Rho guanine nucleotide exchange factor (GEF) 11 
Aif1l allograft inflammatory factor 1-like 
Abi1 abl-interactor 1 
Usp45 ubiquitin specific peptidase 45 
Ybx3 Y box binding protein 3 
Cpeb4 cytoplasmic polyadenylation element binding protein 
4 
Rabep1 rabaptin, RAB GTPase binding effector protein 1 
Ncor1 nuclear receptor corepressor 1 
Ube2q2 ubiquitin-conjugating enzyme E2Q family member 2 
Ctnnd1 catenin (cadherin-associated protein), delta 1 
Plec plectin 
Cdc42bpa CDC42 binding protein kinase alpha (DMPK-like) 
Ambra1 autophagy/beclin-1 regulator 1 
Ehbp1l1 EH domain binding protein 1-like 1 
Zfp346 zinc finger protein 346 
Nolc1 nucleolar and coiled-body phosphoprotein 1 
Rrbp1 ribosome binding protein 1 
Miip migration and invasion inhibitory protein 
Table 2.4 Alternatively spliced genes containing Molecular Recognition Features (MoRF) 
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A molecular recognition feature (MoRF) is a region in an RNA that undergoes a 
disorder-order transformation while bound by another protein. We predicted MoRF regions 
within the alternative regions using the software tool MoRF2 [106]. As a result, among the 
55 alternatively spliced exons in the partial or totally disordered regions, 22 contained 
regions predicted to be MoRFs (Figure 2.6, Table 2.4); these regions could thus be 
regarded as potential protein-protein interaction sites. 
2.2.5 PTM within Differentially Spliced Regions 
We next annotated post-translational modification (PTM) sites in regions affected 
by LPS-induced alternative splicing. We searched known PTM sites deposited in UniProt, 
and we also predicted novel ones using ModPred [109]. Three alternatively spliced exons 
containing known PTM (phorphorylation) sites localized to three genes, Abi1 
(abl-interactor 1), Depdc1a (DEP Domain-Containing 1), and Ybx3 (Y box-binding 
protein 3). In addition, 13 PTMs were predicted to occur in 29 alternatively spliced regions, 
including proteolytic cleavage, phosphorylation, amidation, hydroxylation, carboxylation, 
ADP-ribosylation, O-linked glycosylation, acetylation, GPI anchor amidation, 
palmitoylation, pyrrolidone carboxylic acid, methylation and ubiquitination (Figure 2.7). 
Proteolytic cleavage sites were the most common PTM sites, appearing in 14 alternative 
regions. It is possible that LPS affects the signaling activities of these proteins by inclusion 
or exclusion of the PTM sites in the final protein product (i.e., whether or not it is cleaved). 
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Figure 2.7 Predicted PTM sites in AS regions. 
Column displays different types of PTM sites, and row displays the event types and 
LPS-induced AS genes. The numbers in the shadowed grids on the crossing of gene A and 
PTM type B shows how many type B PTM sites fall in the AS region of gene A. The total 
number of PTM sites in each gene is displayed on the right, and the total number of PTM 
sites in each type is displayed on the top. 
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2.2.6 Characterization of Potential Splicing Regulators 
We defined 7 regulatory regions for each cassette exon event (Figure 2.8), among 
which Region 1 and 7 are 150nt constitute exon segments, Region 2, 3, 5 and 4 are 300nt 
intronic segments, and Region 4 is the whole cassette exon. We used FIMO [110] to search 
for CISBP-RNA [111] motifs within the regulatory regions of both up-regulated and 
down-regulated cassette exon events. With p-value cutoff of 1E-4 and FDR cutoff of 0.1, 
we identified 29 RBP motifs in the up-regulated events, and 23 in the down-regulated 
events. BRUNOL5, BRUNOL4 and RBM38 are the most frequently observed RBPs. Their 
motifs concentrate in Region 2 and 3 for up-regulated events, and in Region 5 for 
down-regulated events. These three proteins are all known as RNA-splicing related. Motifs 
of several other RNA-splicing related proteins, including SRSF2, HNRNPL, HNRNPLL, 
HNRNPH2 and PCBP2, are observed in both up-regulated and down-regulated cassette 
exon regulatory regions. Some RBPs (SRSF9, RBM5, PCBP3, PCBP1, ZCRB1, NCL, 
FUSIP1, PABPN1, TARDBP and NOVA2) are found exclusively in up-regulated cassette 
exon events, and some (KHDRBS3, BRUNOL6, G3BP2, FXR1, SRSF4, SNRNPA, 
SNRPB2) are found exclusively in down-regulated events. 
2.3 Discussion 
Lipopolysaccharide (LPS, endotoxin) is a complex associated with the outer 
membrane of Gram-negative bacteria, capable of triggering a series of cellular responses in 
many cell types. One promising advance is to use LPS as a pre-conditioning agent to 
improve BMSC therapeutic efficacy for repairing ischemic, injured tissues [86, 112]. For 
such application, because LPS is a potent stimulant for the host immune system, BMSCs 
should be washed using PBS to completely remove any residual endotoxin before 
administration. We reported previously that BMSCs treated with LPS produced more 
angiogenic factors VEGF, IGF-1 and HGF [113, 114] which can spur the formation of new 
blood vessels in ischemic tissue and survival and differentiation of implanted BMSCs. By 
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contrast, with the growing incidence of sepsis, in which free LPS can bind to and activate 
Toll-like receptor 4 on many cell types, the roles of LPS on endogenous BMSCs and other 
cell types are worth detailed investigation. 
 
 
Figure 2.8 RNA binding protein (RBP) motifs in regulatory regions of differentially 
spliced events. 
RBP names and their occurrences are listed adjacent to corresponding regulatory regions. 
 
Microarray studies have reported that expression levels of hundreds of genes can be 
altered after LPS treatment in different tissues. In recent years, high-throughput RNA 
sequencing technology has provided a more accurate and comprehensive measurement of 
RNA transcript levels and their isoforms than historic array-based methods. This 
technological advance has enabled measuring not only gene expression level alterations 
amongst different conditions, but also complicated splicing pattern changes in response to 
specific cellular perturbations. In this study, we systematically identified alternative 
splicing changes in mouse bone marrow-derived mesenchymal stem cells (BMSCs) in 
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response to LPS treatment, using RNA-seq technology. We further implemented a series of 
bioinformatics tools to evaluate the biological functions of alternatively spliced exons and 
their host genes. 
We observed strong enrichment in three functional categories amongst the gene 
products whose splicing patterns were altered by LPS treatment, phosphoproteins, zinc 
finger proteins, and proteins subject to acetylation. Most of these proteins were signaling 
proteins, and the subtle differences in their splicing isoforms could affect their function. 
Among 161 gene products containing AS exons, 97 belonged to phosphoprotein 
families, five of which contained documented phosphorylation sites in their AS regions 
found in the UniProt database. These proteins included Kansl2 (KAT8 regulatory NSL 
complex subunit 2), Depdc1a (DEP domain-containing 1), Abi1 (abl-interactor 1), Ybx3 
(Y box-binding protein 3), and UBl4a (Slc10a3-Ubl4 readthrough). The functions of these 
proteins strongly associate with the functions of BMSCs. For instance, Abi1 contains one 
cassette of exons whose percentage of inclusion increased by 14% after LPS induction 
(ΔΨ=0.14), with one phosphorylation site in the AS region documented in the UniProt 
database. Widely expressed with highest levels in bone marrow, spleen, brain, testes, and 
embryonic brain, Abi1 may negatively regulate cell growth and transformation by 
interacting with the nonreceptor tyrosine kinases ABL1 and/or ABL2, thus regulating 
EGF-induced Erk pathway activation and EGFR signaling. In addition to these five 
proteins, eight other AS regions were predicted to have phosphorylation sites, based on 
their amino acid contents. These proteins included Usp45 (ubiquitin-specific peptidase 45), 
Mark3 (MAP/microtubule affinity-regulating kinase 3), Ncor1 (nuclear receptor 
corepressor 1), Ctnnd1 (cadherin-associated protein, beta 1), Ambra1 (autophagy/beclin-1 
regulator 1), Ddx6 (DEAD (Asp-Glu-Ala-Asp) box helicase 6), Ehbp1l1 (EH domain 
binding protein 1-like 1), and Akt1s1 (AKT1 substrate 1). Overall, LPS may affect the 
42 
functions of these proteins by including/excluding specific domains amenable to 
phosphorylation. 
Among the proteins containing LPS-induced alternative splicing events, 25 
contained multiple types of zinc finger domains, including PHD (Plant Homeo Domain), 
RING (Really Interesting New Gene), and C2H2-type zinc-finger domains. Four proteins, 
Phf7 (PHD finger protein 7), Phf20 (PHD finger protein 20), Phf20l1 (PHD finger protein 
20-like 1), and Phrf1 (PHD and ring finger domains 1), contained PHD-type zinc finger 
domains known to recognize trimethylated histone lysines (thus possibly influencing 
chromatin structure). Four other proteins, Rnf14 (ring finger protein 14), Rad18 (RAD18 
homolog), Trim28 (tripartite motif-containing 28), and Trim2 (tripartite motif-containing 
2), all contain RING-type zinc fingers, known ligases for ubiquitination enzymes and their 
substrates. It is well documented that both PHD and RING-type domains are usually 
involved in protein-protein binding [115, 116], and such binding could possibly be 
disrupted by splicing variations. 
Overall, the LPS-induced AS genes could be classified into several categories 
(Figure 2.9), including kinases, zinc-finger proteins, transcription, RNA-binding, 
cytoskeleton, and protein acetylation. Many of these proteins were also phosphoproteins, 
which play significant roles in cell signaling. Analysis of the relationship between splicing 
and protein structure has suggested that AS exons play major roles in controlling 
protein-protein interactions (PPIs) through disrupting either known protein interaction 
domains or molecular recognition sites, which typically locate in intrinsically disordered 
regions. Our analysis suggests that LPS-induced alternative splicing could affect PPIs 
through both mechanisms. In particular, protein interaction domains of three proteins with 
known PPI partners were disrupted by LPS-induced splicing alterations (Figure 2.5). 
Interestingly, all three interactive domains could self-interact (forming domain-domain 
interactions with themselves), and one of these domains facilitates homodimerization of 
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Rabep1 (RAB GTPase binding effector protein 1). Expressed in embryonic tissues and 
most types of stem cells, Rabep1 showed abundant expression in BMSCs (about 30 
RPKM). Homo-dimerization of this protein is involved in early endosome fusion [117], an 
event directly related to the paracrine effects of BMSCs, where small vesicles are released 
when multivesicular endosomes fuse with the plasma membrane [118, 119]. In addition, 
Rabep1 also moderates intracellular transportation between lysosomes and the Golgi 
apparatus [120], and between the Golgi apparatus and endoplasmic reticulum [121]. LPS 
treatment also increased the inclusion of the interaction domain by 14%, which could 
increase either homodimerization or heterodimerization with other interaction partners. 
 
Figure 2.9 Predicted interaction network among LPS-induced AS genes. 
Red nodes indicate genes producing phosphoproteins, and gray nodes indicate genes not 
involved in protein phosphorylation. Genes associated with terms other than 
phosphoproteins are clustered in corresponding shadowed areas. These terms include 
acetylation, cytoskeleton, transcription, zinc-finger, RNA-binding and kinase. 
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We further evaluated how differences in splicing patterns in transcriptional 
regulators affected their regulatory activity by assessing gene expression changes of their 
downstream target genes. NFYA (nuclear transcriptional factor Y) contains an alternative 
acceptor site whose splicing pattern in BMSCs is altered by LPS treatment; the overall 
percentage of inclusion of the alternative acceptor site decreased by 31% (Sashimi plot for 
NFYA shown in Figure 2.10). Moreover, the expression of five downstream target genes of 
NFYA were enriched for genes found differentially expressed (p-value≤0.01) by LPS 
treatment (FDR≤0.05), including COL11A1 (collagen, type XI, alpha 1), COL5A3 
(collagen, type V, alpha 3), FGFR2 (Fibroblast Growth Factor Receptor 2), PGK1 
(phosphoglycerate kinase 1) and RGS4 (regulator of G-protein signaling 4). It was 
previously reported that NFYA activates transcription levels of COL11A1 and FGFR2 
[122]; these two genes were both downregulated by LPS, suggesting inhibition of NFYA 
function by the removal of 18nt (or 6 amino acids) after LPS treatment, thus impacting 
NFYA downstream effectors. 
 
 
Figure 2.10 Sashimi plot of NFYA. 
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2.4 Methods 
2.4.1 Preparation of Mouse BMSCs 
A single-step stem cell purification method was employed as previously described 
[123]. Briefly, BMSCs were collected from the bilateral femurs and tibias of sacrificed 
mice by removing the epiphyses and flushing the shaft with complete media, Iscove's 
Modified Dulbecco's Medium (IMDM; Life Technologies) and 10% fetal bovine serum 
(Life Technologies), using a syringe with a 26G needle. Cells were disaggregated by 
vigorous pipetting and passed through a 30-µm nylon mesh to remove any remaining 
clumps of tissue. Cells were then centrifuged for 5 min at 500 g at 24°C. The cell pellet was 
then resuspended and cultured in 75 cm2 culture flasks in complete media at 37°C with 5% 
CO2. Since BMSCs preferentially attach to polystyrene [124], after 48 h, floating 
non-adherent cells were discarded. Fresh complete media was added and replaced every 
three or four days thereafter. When the cells reached 90% confluence, MSC cultures were 
recovered by the addition of a solution of 0.25% trypsin-EDTA (Invitrogen) and passaged. 
Cell passage was restricted to passages 6–10 for the experiments. To purify BMSCs, the 
cells were subject to fluorescence-activated cell sorting (FACS) analysis, with collection of 
cells positive for Sca-1 and CD44 [124], but negative for the hematopoietic stem cell and 
macrophage marker CD45 [88]. 
2.4.2 RNA Sample Preparation and RNA-seq Assay 
BMSCs were plated at 1×105 cells/well/ml for 24 h and further treated with LPS 
(200ng/ml) for another 24 h, and total RNA was extracted before and after LPS treatment, 
following a standard protocol [88]. Experiments were conducted in triplicate. 
Standard methods were used for RNA-seq library construction, EZBead 
preparation, and Next-Gen sequencing, based on the Life Technologies SOLiD 5500xl 
system. Briefly, 2 μg of total RNA per sample was used for library preparation. The rRNA 
was first depleted using the standard protocol of RiboMinus Eukaryote Kit for RNA-Seq 
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(Ambion), and rRNA-depleted RNA was concentrated using a PureLink RNA Micro Kit 
(Invitrogen) with 1 volume of lysis buffer and 2.5 volumes of 100% ethanol. After rRNA 
depletion, a whole transcriptome library was prepared and barcoded per sample using the 
standard protocol of SOLiD Total RNA-seq Kit (Life Technologies). Each barcoded library 
was quantified by quantitative polymerase chain reaction (qPCR) using SOLiD Library 
Taqman qPCR Module (Life Technologies) and pooled in equal molarity. EZBead 
preparation, bead library amplification, and bead enrichment were then conducted using 
the Life Technologies EZ Bead E80 System. Finally sequencing by ligation was performed 
using a standard single-read, 5′-3′ strand-specific sequencing procedure (75nt-read) on 
SOLiD 5500xl. 
2.4.3 Bioinformatics Analysis for RNA-seq Data 
RNA-seq data analysis included the following steps: quality assessment, sequence 
alignment, and alternative splicing analysis. The RNA-seq data can be accessed through 
the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with accession number 
GSE64568). 
2.4.4 Data Processing and Quality Assessment 
We used SOLiD Instrument Control Software and SOLiD Experiment Tracking 
System software for read quality recalibration. Each sequence read was scanned for 
low-quality regions, and if a 5-base sliding window had an average quality score less than 
20, the read was truncated at that position. Any read < 35 bases was discarded. Our 
experience suggests that this strategy effectively eliminates low-quality reads, while 
retaining high-quality regions [125-127]. 
2.4.5 Sequence Alignment 
We used BFAST (http://bfast.sourceforge.net) [27] as our primary alignment 
algorithm due to its high sensitivity for aligning reads on loci containing small insertions 
and deletions, as compared to the reference genome (mm9). We then used a TopHat-like 
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strategy [30] to align the sequencing reads containing cross-splicing junctions using 
NGSUtils (http://ngsutils.org/) [125]. After aligning the reads to a filtering index including 
repeats, ribosome RNA, and other sequences that were not of interest, we conducted a 
sequence alignment at three levels: genome, known junctions (University of California 
Santa Cruz Genome Browser), and novel junctions (based on the enriched regions 
identified in the genomic alignment). We restricted our analysis to uniquely aligned 
sequences with no more than two mismatches. 
2.4.6 Alternative Splicing Analysis 
We used MISO (mixture of isoforms) [97] to identify alternatively spliced exons 
whose splicing patterns were altered after LPS treatment. We first used Samtools (v0.1.19) 
to merge six RNA-seq samples into two BAM files according to their biological conditions, 
i.e., control vs. LPS-treated samples. We then estimated Percent Spliced In (PSI or Ψ), 
which indicates the proportion of RNA isoforms containing the alternatively spliced exon 
(inclusive isoforms) among all isoforms (inclusive plus exclusive isoforms). We also 
computed a Bayes factor (BF) to describe the likelihood of an AS event between the 
LPS-treated and control conditions. A BF of 5 means that an AS event is 5 times more 
likely to be differentially spliced than not. Both Ψ and BF values were computed by the 
software package MISO [97]. The difference between Ψ s across the two conditions was 
defined as ΔΨ. We required each AS event to have a BF>5 and |ΔΨ|>0.05 to be considered 
differentially spliced. 
2.4.7 Ontological Annotations 
The functions and cellular locations of AS genes were annotated by the pathway 
analysis tool Ingenuity Pathway Analysis (IPA), and the functional and biochemical 
properties of these genes were further annotated based on SwissProt and PIR keywords 
with DAVID v6.7 [101]. 
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2.4.8 Protein Domains Overlapping AS regions 
Protein domain information was predicted based on the RNA nucleotide sequences 
of the alternatively spliced exon, and 30-base flanking sequencings of both upstream and 
downstream exons. These RNA sequences were then translated into peptides, based on 
open reading frames (ORFs) documented by Ensembl and Refseq, which were then input 
into Pfam [103] for identification of protein domains overlapping AS regions. 
2.4.9 Identification of Protein Interactions 
We also examined whether alternatively spliced exons overlapped with potential 
protein-protein interaction domains. Based on the protein domains identified in or 
overlapping AS regions, we retrieved their binding partner domains with iPfam [103], 
which documents domain-domain interactions in the Protein Data Bank (PDB). We further 
used Pfam to search for genes encoding partner domains (i.e., potential protein interaction 
partners). The identified protein interaction partners were verified by two protein-protein 
interaction databases derived from high-throughput experiments. 
2.4.10 Other Characterizations 
Protein disorder was predicted with VSL2B [107], a highly regarded protein 
disorder prediction tool, especially for long regions of disorder [128]. We required the 
peptides flanking the AS regions to be at least 9 amino acids long for accurate prediction. 
Potential binding sites were predicted with MoRF2, a software tool that predicts 
protein-binding sites that undergo a disorder-order transformation while binding another 
protein molecule [129]. Known post-translational modification (PTM) sites were derived 
from UniProt, and novel PTM sites were predicted by ModPred [109]. The upstream gene 
regulator NFYA (Nuclear transcription Factor Y subunit Alpha) [130] was predicted by 
Ingenuity Pathway Analysis (IPA), based on gene expression data and known regulatory 
gene interactions. 
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Chapter 3. Developmentally Regulated Alternative Splicing 
3.1 Background 
Liver is a vital organ only found in vertebrates [131], and it is involved in many 
crucial physiological functions, including protein synthesis, detoxification and production 
of many chemicals necessary for digestion. Liver constitutes 5% of the bodyweight at birth 
but 2% in adult [132]. During organogenesis, liver originates from both the foregut 
endoderm and septum transversum mesenchyme, and many morphological and 
physiological changes take place in liver from embryo to fetus. Liver is the organ where 
most of drug metabolism processes take place. Drugs are transformed into more 
water-soluble forms for the ease of excretion after exerting their desired functions. Such 
processes include phase I and phase II metabolic reactions. Phase I involves structural 
alteration on drug molecules, including oxidation, reduction and hydrolysis. Phase II 
involves addition of functional groups, including acetylation, methylation, glucuronidation, 
sulfation, conjugation with amino acids and glutathione. It is known that many of these 
drug metabolism processes change over the lifespan of human because of the expression 
change of certain genes [133-135]. These genes include cytochrome P450s (CYPs), 
flavin-containing monooxygenases (FMO), monoamine oxidases (MAO), alcohol 
dehydrogenases (ADH), molybdenum hydroxylases, NADPH-cytochrome P450 
reductases (FAD), aldo-ketoreductases, esterases, N-acetyltransferases (NAT), 
methyltransferases, UDP glucuronosyltransferases (UGT), sulfotransferases (SULT) and 
cytosolic glutathione S-transferases (GST) [135]. Although a lot of studies profiled the 
developmental expression change of the genes that are associated with drug metabolism in 
liver, the role of alternative splicing during the development and drug metabolism in liver 
is still poorly understood. 
Alternative splicing (AS) is a regulated process during RNA transcription that 
alters the composition of exons within the mRNAs, and thus enables the production of a 
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variety of protein isoforms from one gene. AS is a common phenomenon in eukaryotes, 
and virtually 95% of multi-exonic genes go through AS [136]. Besides contributing to the 
diversity of RNA and proteins, AS also participate in the modulation of cell differentiation 
[40], developmental pathways [137], drug response [138] and other physiological 
processes [139-142] by activating in a temporal- and spatial-specific manner. Studies have 
shown that abnormalities of AS is associated with various diseases [143-145]. As the next 
generation RNA sequencing (RNA-seq) technology gets more economic and accurate, it 
has become a primary tool for studying AS. Several software tools are developed for 
studying AS. These software tools falls in two major categories, 1) whole transcript 
builders, including Cufflinks [40] and Scripture [41], which rebuild and quantifies whole 
mRNA transcripts, and 2) splicing event quantifiers, including MISO [97] and MATS 
[146], which quantifies only the alternative region and adjacent exons. In splicing event 
quantifiers, four major types of AS events are defined, i.e. cassette exon or skipped exon 
(SE), intron retention or retained intron (RI), alternative 5’ splice site (A5SS) and 
alternative 3’ splice site (A3SS). The count of RNA-seq reads within alternative region and 
spanning across splicing junctions are used to estimate a percentage-spliced in (PSI or Ψ) 
value. What’s more, MISO utilizes the count of reads within adjacent exons (constitutive 
reads) to improve the accuracy of estimated Ψ. The Ψ value of an AS event represents the 
percentage of mRNAs containing the alternative regions among all mRNAs. Both MISO 
and MATS provided solutions for identifying significant Ψ changes of an AS event across 
two time points during liver development, MATS uses a multivariate uniform distribution 
and put within-group variance into consideration. 
In this study, we introduced a Bootstrap based method that utilizes the information 
of both constitutive reads and within-group variance. We applied this method on RNA-seq 
data of human liver in three developmental stages to identify developmentally regulated 
AS events. 
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3.2 Results 
To investigate the AS changes during liver development, RNA-seq analysis was 
conducted on fresh frozen liver samples across fetal, pediatric and adult stages, with 10 
samples in each stage. A strand-directed single-end RNA-seq protocol (75 nt reads) was 
implemented with SOLiD instrument. The sequencing reads were mapped to the standard 
human genome (hg19), and the analysis resulted in 300 million mappable reads, with each 
of the 30 samples ranging from 3.3M to 17.9M reads. Among the mappable reads in each 
sample, about 0.5 to 2.8 million are mapped to protein coding exons, and about 0.2 to 1.6 
million are mapped to splice junctions. 
3.2.1 Developmentally Regulated Alternative Splicing Events in Liver 
We utilized MISO (Mixture of Isoform) algorithm [97] to estimate the probability 
distribution of Percentage Spliced In (PSI or Ψ) value for each AS event in each liver 
sample. Ψ is defined as the fraction of the mRNA isoforms that include the alternative 
region. In total 72,922 AS events were analyzed, including 42,485 SE events, 7,197 RI 
events, 9,035 A5SS events and 14,205 A3SS events. A Bootstrap approach (see Methods) 
was then applied to compare the mean of Ψ values across two groups, i.e., Pediatric group 
(Ped) vs Fetal group (Fet), or Adult group (Adu) vs Pediatric group. In each comparison, 
the Bootstrap approach calculates a P-value and a False Discovery Rate (FDR) for each 
event. 
Overall, we identified 477 exons that are differentially spliced during the 
development from fetuses to childhood, which represents 3.52% of all 13,550 measureable 
AS events, which are covered by no less than 20 reads by MISO’s default. On the other 
hand, we identified only 49 differentially spliced exons during the childhood to adult 
development, which represents 0.99% of 4,915 measurable AS events by MISO’s default. 
The obvious difference between the percentages of differentially spliced exons reasonably 
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reveals the drastic changes in transcriptome during early years of a human’s life (Table 
3.1). 
Figure 3.1 demonstrates the magnitude (X-axis) and significance (Y-axis) of liver 
developmental splicing pattern changes on all AS events that could be reliably identified 
by MISO during two developmental periods, i.e. fetus to childhood and childhood to adult. 
Among the 477 AS events differentially spliced during the fetus to childhood development, 
194 showed positive ∆Ψ values, indicating that the percentage of transcripts containing the 
specific exon increased in this process. Similarly, 283 showed negative ∆Ψ values, 
indicating decreases in the percentage of transcripts containing specific exons. On the other 
hand, 49 AS events were differentially spliced during the development from childhood to 
adult, 23 of which showed positive ∆Ψ, and 26 showed negative ∆Ψ. Twenty-one AS 
events changed their splicing patterns from fetus to childhood, and continued changing 
from childhood to adult. The contrast between the numbers of splicing changes in earlier 
and later developmental periods indicates the physiology of liver changes prominently 
during the development from fetus to childhood, while it generally reaches its mature state 
after the beginning of childhood. 
 
 SE RI A5SS A3SS 
Pediatric vs Fetal 303 76 36 62 
Adult vs Pediatric 14 20 11 4 
Table 3.1 Number of differentially spliced events 
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Figure 3.1 Volcano plot of AS events 
(A) Comparison between pediatric stage (Ped) and fetal (Fet) stage. (B) Comparison 
between adult (Adu) stage and pediatric stage. The x-axes denote mean ∆Ψ, the y-axes 
denote –log10(FDR). Each dot represents an AS event, and the red dots represent AS 
events with |∆Ψ|≥0.1and FDR≤0.05. 
 
Figure 3.2 displays a classic SE event that is differentially spliced during one 
development period but is not during the other. The alternative region in this event covers 
the total length of the fn3 domain in fibronectin 1 (FN1), a gene involved in cell adhesion 
and migration processes in embryogenesis [147-151]. The splicing of this gene is known 
as developmentally regulated [152, 153]. Its Ψ values consistently dropped (∆Ψ=-0.12, 
FDR≈0) during the fetus to childhood development, and the Ψ values remain low in the 
adult stage (Figure 3.2A). To create a straightforward visualization of the RNA-seq data, 
we merged all samples in each developmental stage and generated the Sashimi plots 
(Figure 3.2B) [97] for each stage. In the fetal stage, 131 and 94 reads are mapped to the 
junctions supporting the inclusive transcript, and 183 reads are mapped to the junction 
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supporting the exclusive transcript. But in the pediatric stage, the number of inclusive 
junction reads drops to 29 and 22, while the number of exclusive junction reads raised to 
298. This leads to a conclusion that the relative dosage of the fn3 domain declined during 
the fetus to childhood development, which is consistent with the observation of reduced 
Ψ in Figure 3.1A. In the adult stage, both inclusive and exclusive junction reads reduced 
due to lower sequencing depth, but the change is not as dramatic as the previous 
developmental period and is insignificant statistically. 
To understand the biological functions of genes whose splicing patterns are 
developmentally regulated in liver, we implemented functional annotation analysis using 
the IPA [154] (Figure 3.3A). In the fetus to childhood development, 477 AS events were 
mapped to 474 genes. Among these genes, 36 are transcription regulators, 22 are kinases, 
19 are transporters, 18 are peptidases, 10 are translation regulators, 7 are transmembrane 
receptors and 121 are other enzymes. Among the 49 AS genes that are differentially 
spliced during the childhood to adult development, 4 are transcription regulators, 4 are 
transporters, 1 is peptidase, 1 is translation regulator and 18 are other enzymes. We also 
implemented an analysis on the cellular locations where these genes exert their 
biophysical functions (Figure 3.3B). Comparing with the earlier development period 
(fetus to childhood), the percentages of differentially expressed genes in the later period 
(childhood to adult) are higher in cytoplasm (55% vs 44%) and nucleus (31% vs 25%), 
but lower in extracellular space (8% vs 10%) and plasma membrane (2% vs 10%). 
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Figure 3.2 An alternative splicing event in fibronectin 1 
(A) Ψ distributions of an AS event. The x-axis displays the names of samples. The y-axis 
denotes the probability distribution of Ψ. The mean of each probability distribution is 
marked as a red dot. (B) Sashimi plot of the same AS event. The sashimi-like color blocks 
denote expression intensity distributions of RNA-seq reads on genomic coordinates. The 
curves connecting color blocks show the numbers of exon-exon junction reads. The 
genomic structure of the AS event is displayed at the bottom, with black boxes as exons 
and straight lines as introns. The upper structure shows the transcript including the 
alternative region, and the lower one shows the transcript without the alternative region. 
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Figure 3.3 Functions and locations of AS events 
(A) Cellular locations of differentially spliced events. (B) Function of differentially 
spliced events. 
 
3.2.2 Transporters Associated with Diseases and Drug Metabolism 
Transporter genes play an important role in liver physiology and drug metabolism 
[155-157]. During the fetus to childhood development, 19 splicing pattern changes took 
place in 16 transporter genes, among which 8 locate in cytoplasm, 5 locate on plasma 
membrane, 1 in extracellular space and 1 in nucleus (Table 3.2). ABCB6 is a porphyrin 
transporter, and it belongs to a protein family (ATP-binding cassette) known to be 
associated with drug resistances [158]. AP2M1 is a transporting vesicle coat component, 
which is involved in cargo selection and vesicle formation, but can also be hijacked by 
HPV for viral assembly [159]. Similarly, ARFGAP1, a protein required in vesicle and 
target compartment fusion, can also be hijacked by HPV to create a phosphatidylinositol 
4-phosphate enriched microenvironment [160]. SEC14L2 is a lipid transporter and is 
reported to enhance vitamin E mediated inhibition of lipid peroxidation and thus promote 
HCV replication [161]. SLC37A4 transports glucose-6-phosphate into the lumen of 
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endoplasmic reticulum and inorganic phosphate to the opposite direction. It is reported to 
be associated with glycogen storage disease type Ib [162, 163]. SLC13A5 is a 
sodium-dependent citrate transporter that locates on plasma membrane. The intake of 
citrate facilitates synthesis of fatty acids and cholesterol. Its transcription can be 
stimulated by the drug rifampicin and induce lipid accumulation in hepatocytes [164]. 
SLC38A4 is a sodium-dependent amino acid transporter, and a recent genome-wide 
association study identifies it as risk loci for alcoholic hepatitis [165].  
One gene AP1G1 is differentially spliced during the development from childhood 
to adult. This gene is an important component of clathrin-coated vesicles that transport 
ligand-receptor complexes from plasma membrane or trans-Golgi network to lysosomes. 
Mutations in this gene may induce multiple abnormalities during early development 
[166]. 
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Comparison 
Cellular 
Location 
Gene 
Symbol 
Gene Name 
Ped vs Fet 
Cytoplasm 
ABCB6 ATP binding cassette subfamily B 
member 6 (Langereis blood group) 
AP2M1 Adaptor related protein complex 2 
mu 1 subunit 
ARFGAP1 ADP ribosylation factor GTPase 
activating protein 1 
SEC14L2 SEC14-like lipid binding 2 
SLC25A16 
Solute carrier family 25 
(mitochondrial carrier), member 16 
SLC37A4 Solute carrier family 37 
(glucose-6-phosphate transporter), 
member 4 
STAU1 Staufen double-stranded RNA 
binding protein 1 
USO1 USO1 vesicle transport factor 
Plasma 
Membrane 
ATP11C ATPase, class VI, type 11C 
SLC13A5 Solute carrier family 13 
(sodium-dependent citrate 
transporter),  member 5 
SLC38A4 Solute carrier family 38 member 4 
SLC39A7 Solute carrier family 39 (zinc 
transporter), member 7 
TFRC Transferrin receptor 
Extracellular 
Space 
APOC4 Apolipoprotein C-IV 
Nucleus XPO7 Exportin 7 
Adu vs Ped Cytoplasm AP1G1 
Adaptor related protein complex 1 
gamma 1 subunit 
Table 3.2 Cellular location of transporter proteins 
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3.2.3 Cytochrome P450s 
Cytochromes P450 proteins are a group of monooxygenases that catalyze a 
variety of reactions and play important roles in drug metabolism [167-169], and can be 
potential targets for personal drug treatments [170, 171]. We have found CYP2E1 and 
CYP3A5 differentially spliced during the fetus to childhood development, and CYP3A5 
differentially spliced during the childhood to adult development. CYP3A5 is involved in 
the metabolism of several drugs, including irinotecan (CPT-11) [172], paclitaxel [173], 
cyclosporine [174, 175], tacrolimus [174, 176] and statins [177]. Two AS events 
containing premature stop codons change their splicing patterns in CYP3A5, and the 
dosage of the alternative region increases during the fetus to childhood development 
(∆Ψ1=0.32, ∆Ψ2=0.25) and decreases during the childhood to adult development 
(∆Ψ1=-0.17, ∆Ψ2=-0.19). The premature stop codons in these transcripts will result in 
truncated P450 domain in translated proteins, and thus change the percentage of 
functional P450 domains, which may affect drug response. CYP2E1 is known for its 
association with oxidative stress and drug toxicity [178, 179]. It significantly contributes 
to the formation of a toxin N-acetyl-p-benzoquinone imine (NAPQI), and is the major 
cause of liver necrosis during acetaminophen overdose [180]. Two SE events changed 
their splicing pattern during the fetus to childhood development (∆Ψ1=0.11, ∆Ψ2=0.17). 
Both of the alternative exons are components of the P450 domain, but the length of 
neither exon can be evenly divided by 3, which means exclusion of these exons will 
induce frame shift and result in non-functional protein isoforms. 
3.2.4 Potential Disease-causing Genes 
Insertion and deletion of highly conservative and structured regions in proteins 
may change its function and behavior [181-183], and may cause diseases [184]. To 
further identify AS events with higher biological importance, ExonImpact [185] to 
calculate functional impact scores (FIS) for each AS region based on its PhyloP scores, 
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secondary structure, accessible surface area (ASA), disorderness, protein domain 
coverage and post translational modification (PTM) sites. With FIS cutoff 0.82 [185], an 
A3SS event and an SE event in PGS1 and MYL6 are identified as events with higher 
functional impact in fetus to childhood development and childhood to adult development, 
respectively. Both AS events are highly structured in the alternative regions with average 
structured probability scores 0.82 and 0.85, and average disorder probability both as 0. 
PGS1 is a gene that functions in the cardioipin and glycerrophospholipid biosynthesis 
pathways. The A3SS region locates in the protein coding region, and down regulated 25.0% 
from fetus to childhood. MYL6 is a gene in the myosin family and functions as molecular 
motors. The alternative exon in MYL6 encodes a part of the EF-hand 6, a protein domain 
that interacts with Ca2+ ions [186]. The SE region in this gene down regulated 14.8% 
from childhood to adult. 
3.2.5 PPIs are Developmentally Regulated through Alternative Splicing 
To examine whether developmentally regulated alternative splicing events 
modulate protein-protein interactions (PPI), we searched for interactions between the 
differentially spliced protein domains and their binding partners based on two criteria: (1) 
at least one yeast two-hybrid study [104, 187, 188] supports the direct interaction 
between the pair of interacting proteins and (2) at least one structural study in the Protein 
Data Bank (PDB) supporting direct interaction between the same pair of proteins (See 
Methods). 
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Figure 3.4 Protein-protein interactions that may be disrupted by splicing change 
The orange nodes indicate differentially spliced genes during development, and the blue 
nodes indicate binding partners that interacts with the alternatively spliced protein domains 
of the genes in the previous category. The numbers and the width of the edges indicate the 
number of interacting domains in the partner protein. 
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For the developmental stages from fetus to childhood, we identified 32 PPIs, 
including 15 genes of which the splicing is developmentally regulated and 26 other 
binding partner proteins, as well as 6 self-interactions. For the childhood to adult 
development, we identified 11 PPIs, involving 3 genes that contains developmentally 
regulated AS events and 9 binding partner proteins, and 2 self-interactions (Figure 3.4). 
The interaction between HLA-A (major histocompatibility complex, class I, A) and 
KIR3DL2 (killer cell immunoglobulin like receptor, three Ig domains and long 
cytoplasmic tail 2) is a part of the natural killer cell mediated cytotoxity pathway (KEGG 
ID: map04650). This indicates this pathway may be affected by the developmental 
regulation of HLA-A’s splicing. 
3.3 Discussion 
Liver is an important organ where most drug metabolism take place. Each step in 
drug metabolism could potentially be affected by differences in gene variation, 
expression and RNA splicing. While gene variations in somatic cells mostly stay 
unchanged during the lifespan of human, gene expression and RNA splicing changes over 
time. In this study we analyzed the RNA-seq result of fetus, pediatric and adult stages, 
and identified 477 and 49 AS events during the fetus to childhood development and 
childhood to adult development respectively. The overt discrepancy in the number of 
differentially spliced AS events in these two developmental periods implies much fewer 
tramscriptome activity changes in the development after childhood comparing to that 
before childhood. We found the splicing of drug metabolism genes, including 
transcriptors, cytochrome P450s, and two potential disease causing genes (PGS1 and 
MYL6) are developmentally regulated in liver. This implies that AS is one of the 
mechanisms that cells employ to regulate drug metabolism and other biophysical 
functions during development. We also found 32 and 11 protein binding domains 
disrupted by developmentally regulated AS during the fetus to childhood and childhood 
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to adult development, respectively. One among these PPIs can be mapped to a known 
natural killer cell mediated cytotoxity pathway in KEGG, this demonstrates that 
developmentally regulated AS events can exert their biophysical functions through 
regulating PPIs in cellular pathways. 
 
 
Figure 3.5 Differentially spliced genes that are essential to liver functions during fetus to 
childhood development 
Each data points represents an AS event, and the gene name is labeled next to data points. 
The x-axis is the logarithm of gene fold change, while the y-axis is ∆Ψ, the change of AS. 
 
While AS is an important factor that regulates liver functions, gene expression 
could also be a regulator from another dimension. To investigate the co-occurrence of 
developmentally regulated AS and gene expression, we visualized the ∆Ψ and fold 
change scatter plot for functionally important AS genes that are differentially spliced 
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during the fetus to child development (Figure 3.5). For transporter genes, the ∆Ψ range 
from -0.25 to 0.35, and the log2-fold-change of gene expression range from -3.5 to 6.4, 
which demonstrate evenly scattered pattern on both AS and gene expression dimensions. 
The ∆Ψ of cytochrome P450s range from 0.11 to 0.25, which indicates an increase of the 
alternative region in childhood comparing to fetus. The log2-fold-change of gene 
expression in the same developmental period range from 3.90 to 8.13, showing that 
CYP3A5 and CYP2E1 are both up regulated in childhood comparing with fetal stage. 
The disease associated gene PGS1 has a ∆Ψ of -0.24, indicating the percentage of the 
mRNA transcripts containing the alternative region down regulated 24% during the fetus 
to childhood development. Its log2-fold-change of gene expression is -0.3, which is not 
as a dramatic change as the cytochrome P450 genes and some of the transporters. 
Interestingly, the three main categories of genes, transporters, cytochrome P450s and 
predicted disease associated genes, can be clearly separated according to their ∆Ψ and 
log2-fold-change values, except APOC4, an outlier of the transporter category. This 
distinct difference among gene categories may be induced by shared regulatory 
mechanisms within categories, or shared evolutionary pressure among genes with similar 
functions. 
To investigate which RNA binding proteins (RBP) may have contributed to 
developmentally regulate AS, we implemented an RBP motif analysis on 303 SE events 
that are differentially spliced during fetus to childhood development. Seven regulatory 
regions were defined for each SE event (Figure 3.6). Region 1 and 7 were defined as the 
150 nucleotides long sequence in the exon starting from the splicing site, region 2, 3, 5 
and 6 were defined as 300 nucleotides long sequence in the intron starting from the 
splicing site, and region 4 was the full length of the alternative exon. We retrieved the 
genomic sequence of these 7 region from each SE event, and searched for RBP motifs 
against the RBP motifs from the CISBP-RNA database [189] with FIMO [110]. We found 
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6 RBPs contributing to the upregulation of SE events. Among these RBPs, HNRNPC, 
PABPC1 and SART3 are known as AS regulators. The motif “ATTTTTG” is a potential 
intronic splicing enhancer (ISE), “AGAAAAA” and “AAAAAAA” are potential exonic 
splicing enhancers (ESE) (Figure 3.6A). On the other hand, all 6 RBPs contributing to the 
downregulation of SE events are known as AS regulators. Motifs “TTTTTTC”, 
“GGGAGGC”, “GGGAGGA”, “TGTGTGT”, “GTGTGTG” and “GGGTGTG” are 
potential intronic splicing silencers (ISS), and “GAAGGAA” is a potential exonic 
splicing silencer (ESS) (Figure 3.6A). 
To identify whether an RBP is associated with the up-regulation or 
down-regulation of a cassette exon during development, we implemented a principal 
component analysis on the percentage of regulated cassette exons among four categories 
of cassette exon events, including the up-regulated or down-regulated during the fetus to 
childhood development and the fetus to adulthood development (Ped vs Fet Up, Ped vs 
Fet Down, Adu vs Fet Up and Adu vs Fet Down). Figure 3.6B demonstrates these RBPs 
clearly separated into two groups. In the figure, each dot represents an RBP. The group on 
the left (colored orange) represents the RBPs associated with down regulated cassette 
exons during development, while the group on the right (colored cyan) represents the 
RBPs associated with up regulated cassette exons. It is important to clarify that an RBP’s 
association of up or down regulation does not lead to the interpretation of an enhancing 
or repressing function, because it may also be achieved by the inhibition or activation of a 
repressing RBP. 
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Figure 3.6 RBP and RBP binding motifs 
(A) Regulatory motifs of SE events. For each RBP row, the values are RBP name, number 
of motif matches, p-value and motif sequence. The green tables in the upper half of the 
figure show potential splicing enhancer motifs, and the orange tables in the lower half 
show potential splicing silencers motifs. (B) RBPs associated with up-regulated and 
down-regulated cassette exons are separated in principle component analysis. 
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3.4 Methods 
3.4.1 Bootstrap Approach for Differential Alternative Splicing Detection 
The MISO Analysis (MISO Run) component calculates sample-wise Ψ 
probability distributions for each AS event, and these distributions are distinct from one 
sample to another. This renders it impractical to apply classical statistical tests (e.g. 
Student T-test or Friedman test), which assumes a uniformed type of distribution across 
all samples, to detect differentially spliced events.  
The MISO [97] algorithm has a built-in component - MISO Comparison that 
compares the Ψ distribution of a pair of samples and calculates a Bayes Factor (BF) to 
describe the likelihood of splicing change. To implement group-wise comparisons on 
multiple samples with MISO, users have to merge all samples in each group and then 
apply MISO Comparison on the merged Binary Sequence Alignment/Map (BAM) files. 
This method overlooks within group variance and the difference of the Ψ probability 
distribution across samples. On the other hand, MATS [146] is capable to implement 
group-wise comparison without sample merging, however it uses only junction reads to 
evaluate Ψ, which misses valuable information in reads mapped to alternative regions and 
constitutive exons. To combine the advantages of MISO and MATS, we developed a 
Bootstrap approach to estimate the significance of AS change. 
The Bootstrap approach consists of two steps. The first step is to calculate the 
weighted mean on Ψ values randomly sampled from the probability distributions from 
each group (Fetal, Pediatric or Adult), then calculate the difference between mean Ψ 
values (∆Ψ) across two groups. Let the number of samples in two comparing groups be m 
and n, and let i be the current round of iteration and e be the number of the current AS 
event, then we can derive ∆Ψ for event e in iteration i with the following equation: 
∆𝛹𝑒𝑖 =∑𝑊𝑒𝑗𝛹𝑒𝑗𝑖
𝑚
𝑗=1
−∑𝑊𝑒𝑘𝛹𝑒𝑘𝑖
𝑛
𝑘=1
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W denotes the weight of each Ψ value, and it is calculated with the following 
equation: 
𝑊𝑒𝑠 = 1 − 𝐶𝑒𝑠 
Ces is the width of the 95% confidence interval of the Ψ probability distribution of 
event e in sample s. 
The second step is to iterate the first step for a certain amount of times (10,000 
times in this work) and calculate the p-value based on the alternative hypothesis that the 
mean of ∆Ψ is not 0: 
𝑝 =
𝑁𝑇𝑎𝑖𝑙
𝑁𝐴𝑙𝑙
 
Assuming most of the iterations generated ∆Ψ larger than 0, then NTail is the 
number of iterations that generated ∆Ψ less than 0, and vice versa. NAll is the total 
number of iterations. False discovery rates (FDR) are then calculated based on p-values 
with the Benjamini-Hochberg approach [190]. AS events with |∆Ψ|≥0.1 and FDR≤0.05 
are considered as differentially spliced. 
3.4.2 Identification of PPI Affected by Differential Splicing 
We examined protein-protein interactions (PPI) potentially affected by differential 
splicing with both structural and experimental evidences. We firstly identified Pfam [191] 
domains within or overlapped with alternative regions, then mapped them to binding 
partner domains with iPfam [103], which documents domain-domain interactions found 
in Protein Data Bank (PDB) [37]. These PPIs are then verified with a non-redundant PPI 
dataset (172,911 protein pairs) derived from three yeast two-hybrid screening datasets 
[104, 187, 188]. 
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Chapter 4. Novel Alternative Splicing Events in Transcriptome 
4.1 Background 
Alternative splicing is an important level of gene regulation that greatly 
contributes to proteome diversity [192]. It enables one gene to produce multiple isoforms 
that can have different biological functions. In humans, more than 90% of genes encode 
multiple protein isoforms [183], and many diseases are caused by the dysregulation of 
splicing patterns [193]. Traditionally, EST (Expressed Sequence Tags) databases and 
microarray technologies have been utilized to study splicing regulation [194-197]. In 
recent years, high-throughput RNA sequencing (RNA-seq) technology has revolutionized 
functional genomics by offering the most comprehensive and accurate measurements of 
RNAs. In addition to previously known splicing events, RNA-seq technology can be used 
to identify novel splicing events.  
Many bioinformatics tools have been developed to derive splicing patterns from 
RNA-seq data. For instance, dozens of strategies have been designed for aligning 
RNA-seq reads. Using various strategies, such tools, including TopHat [30], MMES 
[198], SpliceMap [199], SplitSeek [200], G-Mo-R-Se [201], GSNAP [202] and SAW 
[203], enable alignment of short sequencing reads over splice junction sites even across 
large intronic regions. Based on such splicing-sensitive alignments, follow-up algorithms, 
such as Cufflinks [204] and Scripture [205] have been developed to reconstruct transcript 
isoforms using a genome-guided approach. Although the idea of reconstructing the whole 
transcriptome is intriguing, a quantitative estimate of the expression levels of each 
isoform is difficult, particularly for transcripts expressed at low levels and/or when more 
than a few isoforms exist. In addition, isoform-based approaches increase the complexity 
of studying splicing regulation when many isoforms are present in the sample. 
Event-based approaches, however, only focus on the inclusion and exclusion of 
individual splicing events, regardless of membership in different isoforms. This greatly 
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reduces the computational complexity, and offers a direct path for studying splicing 
regulation. Based on the sequencing reads supporting inclusion and exclusion events, 
MISO (mixture of isoforms) [42] is designed to estimate the percentage of inclusion for 
every previously documented alternative-splicing event in a sample. It further offers a 
probabilistic framework for detecting differentially regulated exons, and provides 
functional insights into pre-mRNA processing.  
One requirement for implementing MISO is to provide a pre-defined alternative 
event annotation. Such an annotation heavily relies on previous knowledge, and is not 
complete or even available for many species. For instance, in the official MISO release, 
alternative splicing annotation library [42] is only available for human, mouse, and 
Drosophila genomes, and does not allow event-based analysis on datasets from other 
species. In addition, even for the species whose alternative splicing has been heavily 
investigated, identifying novel splicing events can be important. Therefore, having a tool 
for detecting novel splicing events directly from RNA-seq data is desirable.  
In this study, we developed a tool, Alt Event Finder, for generating de novo 
annotation for alternative splicing events from a map of transcripts and isoforms 
reconstructed from RNA-seq experiments. In conjunction with upstream alignment and 
isoform reconstruction tools, we demonstrated that Alt Event Finder has the ability to 
identify novel cassette exon events that are not documented in the established databases. 
We evaluated the performance of this strategy with different combinations of alignment 
and transcript reconstruction algorithms, using a human dataset where alternative splicing 
events have been extensively investigated. We further implemented this tool on an 
RNA-seq dataset from rat genome, for which alternative-splicing annotation is not 
available. 
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4.2 Results 
4.2.1 Workflow 
As shown in Figure 4.1A, the input to Alt Event Finder is a mixture of RNA 
isoforms identified from transcriptome reconstruction tools, such as Cufflinks [204] or 
Scripture [205]. The output is a list of alternative splicing events directly derived from 
isoform annotation. Alt Event Finder includes two major steps. First, based on a GTF or 
BED file for isoform annotation, the unions of the exon regions are split into the smallest 
units that do not overlap with each other in the genome space, or minimum 
non-overlapping exon units. This design is similar to the PSR (probe selection regions) 
definition for Affymetrix exon arrays [206], and can reflect the complexity of the exon 
structures where alternatively spliced exons from the same gene may overlap (i.e. 
alternative donor or acceptor sites). Second, individual transcript isoforms (identified 
from transcriptome reconstruction tools such as Cufflinks and Scripture) will be projected 
to the non-overlapping exon units (Figure 4.1B). The number of isoforms containing each 
unit is recorded. Special strings of such numeric patterns will be used for deriving 
different types of splicing events. For instance, for a gene with two isoforms, a string of 
[2-0-1-0-2] indicates the presence of a cassette exon. Although this report focuses on 
cassette exons, such simple design allows extension to other types of events easily. 
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Figure 4.1 Workflow of the alternative splicing event identification pipeline 
(A) RNA-seq-derived transcriptome data was aligned using a customized RNA-seq 
pipeline based on known splicing junctions or Tophat. Cufflinks or Scripture was used for 
isoform annotation. Based on the data-derived transcript annotation, Alt Event Finder was 
applied to identify the novel alternative events. (B) Strategies of Alt Event Finder for de 
novo event detection. 
 
4.2.2 Alternative Splicing Event Annotations from Human Liver Data 
To test the performance of our strategy, we implemented Alt Event Finder on a 
RNA-seq dataset derived from human primary hepatocytes; the RNA-seq experiment was 
conducted using the SOLiD 5500xl system (Life Technologies). The dataset consists of 7 
pairs of samples derived from 7 individuals. Each pair includes a drug exposed sample 
and a control sample. To test the performance of Alt Event Finder on data with various 
sequencing depths, in addition to the 14 RNA-seq samples, we created 7 patient-specific 
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datasets by merging the exposed and control samples from the same individual; and 1 
hepatocyte-specific dataset by merging all the 14 samples together.  
We used BFAST [207] as the primary aligner of short reads, due to its higher 
sensitivity on color-space data [208]. The alignment was conducted on both genomic 
DNA sequences and a junction library including all the combinations of known junction 
boundaries (within a 100 kb span) annotated in the UCSC Gene database. The total 
number of mappable reads in each sample ranged from 6.6 million to 19.5 million. We 
then used Cufflinks [204] to reconstruct transcript isoforms. From that, we applied Alt 
Event Finder. The number of identified alternative splicing events increased as a function 
of depth of coverage (Figure 4.2A); events ranged from 433 to 1,049 in individual 
samples, from 761 to 1,298 for patient-specific datasets (combining control and treated 
data), and was 1,771 for all the samples combined.  
 
 
 
 
 
 
 
 
74 
 
Figure 4.2 Performance assessment for the Alt Event Finder 
(A) The total number of identified events increases with sequencing depth. Each dot 
corresponds to a sample; the color and the shape of the sample denote its biological 
condition; the regression line is displayed in dashed line with an R-squared value of 0.9383; 
(B) Performance for the Alt Event Finder pairing with a customized alignment pipeline and 
Cufflinks. The X-axis (rate of known events) is defined by the number of overlapping 
events divided by the number of data-driven events, and Y-axis (recall) is defined as the 
number of overlapping events divided by the number of events in the official MISO 
annotation library; (C) The rate of known events does not change with sequencing depth; 
(D) The recall rate of the Alt Event Finder increase linearly with the logarithmic 
transformation of the total mappable reads. The regression line is displayed in dashed line 
with an R-squared value of 0.9684. 
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To evaluate the performance of the proposed strategy, we compared our 
data-derived events with known alternative splicing events documented in the MISO 
release (based on UCSC hg19 assembly) [42]. For each sample, we calculated a rate of 
known events (RKE), which measures the percentage of identified events that were in the 
known splicing events annotation, and a recall value, which was calculated as the 
percentage of known splicing events that were recovered by our strategy. As shown in 
Figure 4.2B, the rate of known events varies from 0.4 to 0.57. This indicates that a 
significant portion of splicing events we detected was not documented in the current 
database, although junction reads were found in support of their existence. The recall 
values, however, are low, ranging from 0.004 to 0.025. This is not surprising since the 
known event annotation aims at completeness, and therefore documents events from 
many tissues with a variety of biological conditions; most of these events should not be 
present in one tissue under one or two biological conditions. We further evaluated the 
relationship between sequence depth and rate of known events (Figure 4.2C) and recall 
values (Figure 4.2D). Rate of known events do not show apparent changes, suggesting 
that the genes expressed at lower levels contain a similar percentage of novel events as 
the more abundant transcripts, but they require greater sequencing depth to identify. The 
recall, however, increases almost linearly with logarithmic transformation of the total 
number of mappable reads. These results (Figure 4.2C and D) indicate that many more 
events will be identified with deeper sequenced samples, while the percentage of novel 
events doesn’t change. Therefore, more novel events will be identified from deeper 
sequenced data.  
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Figure 4.3 Screenshot of one of the novel cassette exon events 
The diagram demonstrates reads supporting a cassette exon event that was not previously 
documented. This gene locates on the reverse strand. The genomic loci of the cassette exon, 
the 5’ and 3’ constitutive exon are chr1: 93073138-93073284, chr1: 93089733-93089891, 
and chr1: 93070864-93070959, respectively. (A) Sequencing reads supporting the junction 
of the 5' and 3' constitutive exons, which indicates exon exclusion; (B) Sequencing reads 
supporting the junction of the cassette exon and the 3' constitutive exon; (C) Sequencing 
reads supporting the transcription of the cassette exon; (D) Sequencing reads supporting 
the junction of the 5' constitutive exon and the cassette exon; (E) UCSC gene annotation 
track; (F) Alternative splicing annotation track; (G) Human EST track; H) The cassette 
exon in UCSC gene annotations. No previous evidence of this cassette exon event was 
shown in the gene annotations, alternative splicing event annotations or the EST records. 
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Figure 4.3 is the screen shot of one of the novel cassette exons (chr1: 
93073138-93073284) not documented in either the official MISO annotation library 
(based on UCSC hg19 assembly) [42] or the Alt Event track (Figure 4.3F) in the UCSC 
Genome Browser (GRCh37/hg19, Feb. 2009) [209]. As shown in the figure, 40 reads are 
identified around this exon (Figure 4.3ABCD), of which 37 (Figure 4.3BCD) support 
inclusion events (exonic reads on the alternative exon, and junction reads connecting the 
upstream or downstream exon with the alternative exon), and 3 (Figure 4.3A) support 
exclusion events (reads connecting upstream and downstream exons directly), 
respectively. Importantly, the presence of 28 exclusive junction reads provides a strong 
evidence for the presence of this novel event. 
 
Figure 4.4 Performance with adjusted known event annotation 
The rate of known events and recall values were calculated only based on the events that 
have at least 10 junction reads supporting the inclusive event and 1 junction read 
supporting the exclusive event. 
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Due to the tissue specific nature of gene expression and alternative splicing, using 
all the known events in the human genome cannot fairly evaluate the sensitivity of the 
proposed approach. This is either due to the absence of certain isoforms in a specific 
tissue, hepatocytes in this case, or because the overall gene expression levels are too low 
to be detected given a specific sequencing coverage. We therefore removed the events 
either with low expression levels, or with extremely unbalanced inclusion/exclusion ratio, 
from the overall alt event library. For the latter, it is possible that the RNA-seq data can 
only detect the isoforms with inclusion or exclusion events, but not both. To fairly 
evaluate the performance, we derived exon inclusion and exclusion ratios using MISO, 
based on all the annotated splicing events. We further filtered the annotated events 
containing no less than 10 reads supporting inclusion and 1 read supporting exclusion. 
After applying this filtering, for the hepatocyte-specific sample (merging reads from all 
the 14 samples), 83.4% of the 39,232 total annotated cassette exon events were removed. 
The adjusted recall rate is shown in Figure 4.4. Clearly, for individual samples, the recall 
remains low, ranging from 0.9% to 3.6%. This number increased for patient-specific 
samples (merging control and drug treatment for one individual), ranges from 2.6% to 
5.0%, and 12.4% for all the 14 samples combined. This low recall rate may be due to the 
stringent threshold of Cufflinks, which aims at maximizing specificity.  
 
79 
 
Figure 4.5 The number of identified events differs with different combinations of 
alignment and transcript reconstruction algorithms 
Each dot describes a sample. X and Y axes denotes sequencing depth and the total number 
of identified events. Samples were color-coded based on their combinations of upstream 
algorithms. 
 
4.2.3 Selection of Alignment and Transcriptome Reconstruction Tools 
We further evaluated how the performance of the Alt Event Finder is influenced 
by the alignment and transcriptome reconstruction tools. For the alignment tool, in 
addition to our customized RNA-seq pipeline which focus on known splicing junctions, 
we also tested TopHat [30], one of the most widely used RNA-seq alignment software. 
For the transcriptome reconstruction tool, in addition to Cufflinks [204], which aims at 
maximizing specificity, we have also tested Scripture [205], a computational algorithm 
aiming at higher sensitivity.  
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The total number of events identified based on 4 different strategies (Customized 
RNA-seq pipeline and Cufflinks, Customized RNA-seq pipeline and Scripture, Tophat 
and Cufflinks, and Tophat and Scripture) varies significantly (Figure 4.5). At low 
sequencing coverage, the customized RNA-seq pipeline (using BFAST and annotated 
exon boundaries) consistently identified more events. When the sequencing depth is 
higher than 100 million reads, however, our AS identification pipeline offers significantly 
more events when Tophat is partnering with Scripture (Figure 4.5). When comparing two 
transcriptome reconstruction tools, Scripture offers higher number of events regardless of 
the sequencing depth and sequencing alignment algorithm (Figure 4.5). Among all the 
four strategies, the combination of Tophat and Scripture at high sequencing coverage 
identified highest number of events. 
4.2.4 Identify Alternative Splicing Events in the Rat Genome 
We applied Alt Event Finder to study the alcohol-induced alternative splicing 
changes in liver tissue, using alcohol-preferring rats as a model system. Seven female rats 
were heavily exposed to alcohol for 10 weeks followed by 2 weeks without alcohol, and 
another 7 were not subjected to alcohol exposure (controls). An RNA-seq experiment was 
conducted on the liver tissues. After sequence alignment using TopHat, 123,017,701 and 
92,389,972 total reads were mapped in the 7 control and 7 alcohol-exposed animals, 
respectively. Scripture was used for transcript reconstruction. Alt Event Finder identified 
505 candidate events with a mixture of multiple isoforms in the combined sample of all 
14 rats. With a MISO isoform differential expression test, we found 75 were alternatively 
spliced at Bayesian Factor (BF) [42] larger than 2; this number implies that it is twice as 
likely for the events to be alternatively spliced than not. A more stringent cutoff derived 
55 events with BF>5.  
Figure 4.6 shows the Sashimi plots [42] for three events with apparent 
alcohol-induced splicing changes in genes highly expressed in liver tissues, LOC691397 
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(similar to PI-3-kinase-related kinase SMG-1), Glycerol kinase, and CD47 (Figure 4.6A). 
For LOC691397, 40 junction-reads support exon inclusion in the control samples, and 17 
support exclusion. In the alcohol exposed samples, however, these numbers changed to 8 
and 15, respectively. This pattern indicates that chronic alcohol exposure induces higher 
relative expression levels of the isoforms without the cassette exon, with a BF value 
15.37. Similarly, CD47 showed lower inclusion ratio after alcohol exposure (Figure 4.6C), 
while alcohol drinking induces exon inclusion for the glycerol kinase (Figure 4.6B). 
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Figure 4.6 Sashimi plot for three novel events that are alternatively spliced in rat liver with 
chronic alcohol exposure. 
The RNA-seq read densities supporting inclusion and exclusion events are shown in the 
figure. The estimated percentage of inclusion for the alternative events and their estimated 
confidence intervals are also demonstrated. The Sashimi plot is produced by the MISO 
package. 
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4.3 Discussion 
In this study, we developed a tool, Alt Event Finder, which generates splicing 
event annotations from RNA-seq data. Most event-based analysis, such as MISO [42], 
cannot work without a library of known event annotations. Therefore they cannot be 
implemented on a genome for which annotation is unavailable, such as the rat genome. 
Even for a genome for which alternative splicing has been extensively studied, such as 
human or mouse, lack of a de novo event finding tool limits the power of studying events 
that are not previously documented. Alt Event Finder bridges the gap between 
event-based analysis and isoform-based transcriptome reconstruction algorithms, such as 
Cufflinks and Scripture. It’s an important addition to the current AS analysis toolset. 
Our algorithm extracts “minimum non-overlapping exon units” (Figure 4.1B) 
from RNA-seq-derived transcript isoform annotation based on Cufflinks or Scripture, and 
further identifies potential alternative events. This strategy greatly increases the flexibility 
of our methods. Although the current study focuses on cassette exon, it can be easily 
extended for other types splicing events, such as intron retention, alternative 5’ donor, 
alternative 3’ acceptor, and so on. This is important because certain types of events can be 
more prevalent in specific tissue types. For instance, cassette exons are dominant in brain 
tissues, while alternative 5’ donor and 3’ acceptor events are more abundant in liver 
tissues [210]. 
Alt Event Finder relies on upstream alignment and isoform reconstruction tools. 
We have evaluated how different tool combinations affect the ability to discover novel 
splicing events. We found that a customized alignment pipeline based on known exon 
boundaries perform better in low sequencing coverage (<100 Million reads), while 
TopHat did better for high sequencing coverage. This is because TopHat derives exon 
structures mainly based on the accumulation of RNA sequencing reads. Since it does not 
rely on existing exon annotations, at lower coverage, the data may not have adequate 
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power to properly identify low expressed exons. For higher coverage, however, TopHat 
will not only have enough power to precisely map the boundaries of known exons, but 
also be more suitable for identifying novel exons. We have also found that we can 
generally identify more AS events using Scripture as isoform reconstruction tool, 
compared to using Cufflinks, because Scripture aims at maximizing sensitivity, while 
Cufflinks aims at specificity. Overall, we recommend using the mapping algorithm based 
on known exon annotation and Scripture combination at a low sequencing depth, and the 
TopHat and Scripture strategy with high sequencing coverage. 
To find out the cause of the low recall rate, we investigated the AS events that 
were identified with the official MISO library but not found in our annotations. One of 
the major causes of such events is lack of junction reads between the cassette exon and 
constitutive exons, which makes the inclusive isoform not detectable by Cufflinks and 
Scripture, but still quantifiable by MISO since reads are covering the cassette exon. 
Another cause is additional alternative spliced 3’ and 5’ sites on a cassette exon event, 
which make an event in our annotation different from the official MISO annotation. 
Since Alt Event Finder is a data-driven approach, its power highly depends on the 
sequencing depth. When the sequencing depth is low, a lot of junction read will be missed, 
and a lot of low expressed exons could be “disconnected”; this will significantly decrease 
the power of the transcriptome reconstruction algorithm for rebuilding the isoforms from 
RNA-seq data, therefore affect the performance of Alt Event Finder. Therefore, when 
possible, increasing the sequencing depth can significantly elevate the power of novel 
event identification. 
When deep sequencing data is not available, at the de novo event identification 
step, we recommend pooling sequencing reads from all the samples. This will enable 
identification of the events that lowly expressed in individual samples. It will also enable 
us to identify the events that have complete inclusion in one condition, but exclusion in 
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another. These events cannot be identified within individual samples, but the 
inclusion/exclusion switches are enormously interesting. 
4.4 Methods 
4.4.1 Dataset 
RNA-seq dataset. We used two RNA-seq datasets for de novo alternative splicing 
event identification, human hepatocytes and rat liver cells. In the human study, primary 
hepatocytes were isolated from seven individual subjects, and treated with Rifampin. 
Total RNA from both control and treated samples were extracted. RNA-seq experiments 
were conducted using the SOLiD 5500xl system with the standard protocol. In the rat 
study, RNA-seq experiments were conducted on liver tissues from 7 non-drinking 
alcohol-preferring rats, and 7 alcohol-preferring rats that were heavily exposed to alcohol 
for 10 weeks followed by 2 weeks without alcohol. The experiment was conducted on the 
SOLiD 4 system with the standard protocol. 
Known splicing event annotation. The known alternative splicing event 
annotation for human genome was retrieved from the official MISO library (based on 
UCSC hg19 assembly). The annotation file was generated based on transcript annotation 
using an EST database; a splicing event was considered alternative if it was supported by 
multiple ESTs. 
4.4.2 RNA-seq Alignment 
We used two RNA-seq alignment pipelines, TopHat [30] and a customized 
strategy using BFAST [207] as primary aligner and known splicing sites documented in 
UCSC Known Gene database [211]. TopHat v1.4.0 was used with standard parameter 
settings on color space data. The customized pipeline uses BFAST [207] as a primary 
aligner due to its computability with small insertions/deletions, and reported higher 
sensitivity on color space data [208]. The overall alignment of our customized RNA-seq 
pipeline includes two levels, alignment on genomic DNA sequences, and alignment on a 
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junction library based on all possible exon combinations within a 100,000-bp span, based 
on documented exon boundaries. This is different from TopHat strategy, which uses 
sequencing reads enrichment and splicing sequence features (GU…AG) for exon 
boundary detection. 
4.4.3 Other Algorithms for Splicing Analysis 
Based on the alignment output from TopHat or the customized pipeline, Cufflinks 
v1.2.1 [204] and Scripture [205] were used for isoform reconstruction. fastMISO 
(Mixture of Isoforms) [42] was used to calculate the percentage of inclusion for 
annotated and novel alternative splicing events. Standard parameter settings were used 
for all the three programs.  
4.4.4 De novo Alternative Splicing Event Identification 
As shown in Figure 4.1A, Alt Event Finder uses transcript isoform annotation 
from Cufflinks (GTF format) or Scripture (BED format) as input. The output is the 
data-derived alternative event annotation in GFF3 format, which can be used as MISO 
input. From the isoform annotation, the Alt Event Finder extracts “minimum 
non-overlapping exon regions” as expression units (Figure 4.1B), counts the number of 
isoforms that include each expression unit, and further derives appropriate AS events 
based on the string of counts (Figure 4.1B). In this study, we focus on cassette exons. 
4.4.5 Performance Assessment 
The ability of Alt Event Finder was evaluated by comparing with the splicing 
event annotation in the MISO library. Events from two annotations are considered 
consistent only if the genomic loci of the alternative exon (cassette exon) and their 5’ 
upstream and 3’ downstream exons are identical. This ensures the most conservative 
evaluation. The performance of Alt Event Finder is assessed by using three measurements, 
the total number of identified events, and the rate of known events and the recall of the 
overall finding. The rate of known events is defined by the percentage of known events 
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within data-driven ones, and recall is defined as the percentage of data-driven events 
within known ones. 
  
88 
Chapter 5. Novel Alternative Splicing Events in Proteome 
5.1 Background 
Human cells benefit from elaborate mechanisms to modify proteins, creating 
many protein variants (isoforms), both to increase the diversity of functions and to 
regulate the activities of proteins. A protein isoform is any of several different forms of 
the same protein. Different forms of a protein may be produced from related genes such 
as single-nucleotide polymorphisms (SNPs) or may arise from the same gene by 
alternative splicing or post-translational modifications (PTM). Alternative splicing and 
SNPs expands the number of messenger RNAs to about 88,000 mRNA variants during 
transcription of these genes. About 8% of these protein isoforms are generated from 
mRNA transcripts affected by alternative splicing or SNPs, whereas over 90% of protein 
isoforms are created through post-translational modifications (PTMs) after the mRNA is 
translated into a protein [212]. Recent studies have shown that the identification, analysis 
and characterization of these individual protein isoforms (Alternative Splicing, SNPs and 
PTMs) could improve understanding of diseases improve disease diagnosis or 
interventions [213-222]. 
Recent advances in clinical proteomics technology, particularly liquid 
chromatography-coupled tandem mass spectrometry (LC-MS/MS), have enabled 
biomedical researchers to characterize thousands of proteins in parallel in biological 
samples[223]. Identifying disease-related protein isoforms using tandem mass 
spectrometry, therefore, can provide hope for improving both the sensitivity and the 
specificity of candidate disease biomarkers, because proteomics identification, instead of 
quantification, of the same set of protein isoforms is often sufficient to distinguish 
between disease samples and controls. 
However, identifying protein isoforms using current MS proteomics search 
databases and software tools has been challenging, primarily because of the smaller size 
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of known or common alternatively spliced protein isoforms relative to several orders of 
magnitude larger size of MS search databases, which makes exhaustive novel peptide 
identification computationally inefficient for routine proteomics studies. Up to 80% of all 
MS spectra peaks in a typical proteomics experiment may remain uncharacterized when 
searched against a standard MS database with little protein isoform information. Such 
standard MS search databases include: the IPI database [224], the NCBI-nr database, and 
the UniProt knowledge base [225]. These databases integrate more than a dozen public 
protein and DNA sequence databases into a non-redundant list of both known and 
predicted protein sequences, with only publicly known splice variant transcripts 
represented. MS search software such as SEQUEST [226], Mascot [227], X!Tandem 
[228], and OMSSA [229]. may further allow customized identification of limited types of 
PTM-derived peptides and proteins. However, these protein sequence databases do not 
contain information about alternatively spliced transcripts or theoretically possible 
“mis-spliced” protein isoforms; nor do they contain peptide variants arising from SNPs 
that result in amino acid changes. Therefore, they are ill-suited for comprehensive protein 
isoform identification purposes. 
Although there are several publicly available alternative splicing mRNA transcript 
databases and SNP databases including ASTD [230], EID [231, 232], ASPicDB [233], 
ECgene [234], MutDB [235, 236], and dbSNP [237], none of these databases can be 
readily used for identification of novel peptides derived from uncharacterized protein 
isoforms. Since predictions of gene splicing patterns in all the methods are based on 
alignments of transcript data (mostly expressed sequence tags, ESTs) to a genomic 
sequence, some limitations exist in all these methods mostly due to the sequence errors 
frequently occurring in ESTs and to the repetitive structure of the genome sequence. 
Moreover, all the databases mentioned contain a rather small set of alternatively spliced 
peptides because they are either manually curated or literature-based data sets, as well as 
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poor annotation of splice events, which are inadequate for the identification of 
alternatively spliced protein isoforms. To explore the huge solution space of all possible 
alternatively spliced combination of exons and potentially coding introns, one must 
generate virtual peptides exhaustively so that uncharacterized MS spectra can be searched 
against them. In addition, the database of virtual peptides should be expanded to 
accommodate the amino acid alterations introduced by each SNP. 
In this paper, we describe the development of a Peptideomics Database of Protein 
Isoforms (PEPPI), which consists of systematically generated virtual peptides that cover 
alternative splicing events and known SNP variations, for identifying protein isoforms in 
large-scale proteomics results. In the PEPPI database, we introduce a peptidomics 
approach to integrating genome, transcriptome, proteome and SNP information for 
human proteomics studies. The database contains a comprehensive set of peptides 
derived from all known annotated human genes in the Genome Reference Consortium 
Human genome build 37 by generating alternative splicing events and incorporating 
non-synonymous SNPs. It is the first comprehensive database that can be used to 
characterize novel protein isoforms derived from alternative splicing and SNP variations 
in MS spectra. The database has a web user interface that allows its users to query a 
gene/protein and compare all its above-mentioned types of protein isoforms and 
associated virtual peptides online.  
5.2 Results 
5.2.1 Database Content 
Drawn from Ensembl’s genomic data [238], the PEPPI database contains a 
comprehensive set of peptides derived from all known human protein-coding genes and 
was constructed by generating both annotated and hypothetical alternative splicing events 
and incorporating non-synonymous SNPs. In addition to representing an in-frame peptide 
for each exonic region (EXON_KB) of human proteins, four types of PEPPI splice 
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junctions are also captured for all possible combinations of each coding sequence of gene: 
annotated exon-exon junctions (E_E_KB type), hypothetical exon-exon junctions 
(E_E_TH type), hypothetical exon-intron junctions (E_I_TH type), and hypothetical 
intron-exon junctions (I_E_TH type). An exonic region or a splice junction is defined as a 
peptide region. For each peptide region, we also include hypothetical peptides translated 
with each known non-synonymous SNP. By cataloguing each peptide configurations in 
the PEPPI database, users can study alternative splicing events such as exon skipping, 
alternative donor site, alternative accepter site, and intron retention at the proteome level. 
They can also batch-download the peptide annotation and sequences in FASTA format for 
MS data searching. The current PEPPI database includes human data only. As of April 
2010, it is comprised of 7,848,236 PEPPI peptide entries derived from 23,491 
protein-coding genes and 66,384 proteins, incorporating 150,054 non-synonymous SNPs 
(Table 1). 
A peptide-protein mapping is also captured for comparing the MS search results 
derived with the PEPPI and conventional protein sequence databases. In total 613,591 
peptides are mapped to 66,384 IPI [224] proteins (Table 1). 
5.2.2 General Online Features 
In Figure 5.1, we show the user interfaces of the web-based online version of the 
PEPPI database. It allows searching by Ensembl Gene ID, gene symbol, UniProt ID, IPI 
AC, peptide sequence, PEPPI Peptide Region ID and PEPPI Peptide ID.  With the 
cross-links users can easily link to Ensembl [238], IPI [224], UniProt [239], HAPPI [240] 
and HPD [241] and get access to much more detailed information about genes, proteins, 
protein-protein interactions and human pathways. The peptide annotations and sequences 
are freely available for batch-download in FASTA format on the download page. 
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Figure 5.1 Web Interface Structure 
(A) Search Home: main search page allowing five types of query string: Ensembl gene ID, 
IPI protein accession number, peptide sequence, PEPPI region ID and peptide ID. (B) Gene 
View: search result page visualizing peptide regions within a gene. (C) Region View: 
search result page displaying peptides within a peptide region. (D) Peptide View: PEPPI 
peptide information page. (E) Protein View: search result page of PEPPI peptides mapped 
to an IPI protein. (F) Sequence Search: search result page of PEPPI peptides mapped to a 
query peptide sequence. 
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Figure 5.2 Gene View 
(A) Gene scale. It shows the user the chromosome coordinates and strand of the gene. With 
the gene scale, users can read the approximate position of the peptide regions. (B) Peptide 
regions. It shows the user which five types of peptide regions within current given gene 
that the peptide belong to. The coloring of the peptide regions indicates the ORF (Red: 0, 
Green: 1, Blue: 2). The solid bars indicate exons, and the blank bars indicate introns. The 
curve between two exons means the exons are spliced with each other. 
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Figure 5.3 Region View 
(A) The different colors of the cDNA and peptide sequences indicate two different exons, 
or an exon and an intron. The amino acid letter colored in red overlaps with the splice site. 
(B) Green and light cyan backgrounds are used to indicate SNP in cDNA and peptide 
sequences. (C) By clicking on a SNP in sequence, users can see the details of the SNP. A 
link to the dbSNP database is provided. 
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Figure 5.4 Peptide View 
(A) The cDNA and peptide sequences that the current PEPPI peptide is mapped to. Same 
color theme is used in the region view. By clicking on SNP in sequence, users can access 
detailed information of the SNP. (B) In the protein mapping list, the view displays all the 
proteins mapped to the current PEPPI peptide. The peptide sequence is highlighted from 
within the protein sequence. 
 
5.2.3 Case Study 1: Browsing PEPPI Peptides and Relating Information 
For users who would like to overview all the peptide regions and peptides within 
a gene of interest, we provide the standard gene search procedure. In this case study we 
show how to browse the PEPPI peptide regions, PEPPI peptides and related information 
within gene PRH1. Users will start from the Search Home (Figure 5.1A), go through the 
Gene View (Figure 5.1B), Region View (Figure 5.1C), and finally navigate to the Peptide 
View (Figure 5.1D). 
By searching with gene PRH1 in the standard query box provided at the PEPPI 
database home page, users can retrieve all peptide regions corresponding to this gene 
(Figure 5.2). In the Gene View, the PEPPI database visualizes all the peptide regions that 
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can be mapped to this gene. The “Location” section shows this gene is located on 
chromosome 12, from 11,033,560 bp to 11,036,883 bp. Links to Ensembl are provided on 
the gene ID and location. A scale of chromosome coordinate is provided on the top and 
bottom of the visualization. The arrow on the chromosome coordinate scale shows this 
gene is located on the reverse strand, so the 5’ end of the gene should be the right end. 
Peptide regions are displayed in five categories, including EXON_KB, E_E_KB, E_I_TH, 
I_E_TH and E_E_TH. The color of the region indicates the protein translation open 
reading frame (ORF) of the corresponding cDNA. By clicking on the peptide region 
REG005324254, the browser will be re-directed to the Region View. 
The Region View (Figure 5.3) displays detailed information of the peptide region 
and the peptide sequences within this region. In the “Peptide Region Overview” section, 
the exon coordinate is the chromosome coordinate of the source exon, and the segment 
coordinate is the coordinate of the flanking sequence beside the splice site. The peptide 
without SNP is displayed on the top of the “cDNA/Peptide Sequence” section, and the 
peptides with SNPs are displayed below. In the sequences, black and blue are used to 
color different exons/introns. An amino acid residue overlapping a splice site is colored in 
red. SNPs are highlighted by green and light cyan. By clicking on the highlighted SNPs, 
the SNP ID will be shown along with the nucleotide change and amino acid change. A 
link to the corresponding page in dbSNP is also provided. By clicking on a PEPPI peptide 
ID, e.g., “PEP007847820”, the browser will be navigated to the Peptide View. 
In the Peptide View (Figure 5.4), detailed information of the peptide region and a 
peptide-protein mapping is shown in the “Peptide Region Overview” section. The cDNA 
and peptide sequence is displayed in the same pattern as the Region View. The “Protein 
Mapping” section lists the proteins mapped to the current peptide. The result shows that 
IPI00847261 is the only protein mapped to the peptide PEP007847820. The annotation 
on IPI states that IPI00847261 is one of the protein products of PRH1. Since the peptide 
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PEP007847820 contains a mutant non-synonymous SNP allele, we can infer that the 
mapped protein IPI00847261 is not the wild-type. 
5.2.4 Case Study 2: Identifying Genomic Origins of AS Events 
For users, especially MS proteomics scientists, who want to start the query from a 
peptide sequence or a protein, we provided a peptide sequence search function (Figure 
5.1F) and the Protein View (Figure 5.1E). In this case study we demonstrate that the 
PEPPI database can help identify the genomic origins of peptides detected from MS data, 
and can help characterize the alternative splicing events related to these peptides. 
The MS peptides can be derived from Healthy Human Individual's Integrated 
Plasma Proteome Database (HIP-2) [242] by inputting its protein ID. For this example, 
by entering “IPI00023636” as the query, a mapping table with several MS peptides 
identified by the MS data analysis program will be returned (Figure 5.5A). To identify the 
genomic region that encodes a specific peptide sequence, we can search the peptide 
sequence on the PEPPI database’s search home. 
As shown in Figure 5.5B and C, peptide 1 is mapped to “PEP000841715”, which 
is an E_E_KB peptide, and peptide 2 is mapped to “PEP000841692” which is an 
EXON_KB peptide. This indicates peptide 1 is coded by an exon-exon junction, and 
peptide 2 is coded by a single exon.  
To study the related alternative splicing events, we then compared the number of 
proteins which can be mapped to these peptides. By clicking on the peptide ID, we can 
get access to the proteins mapped to each peptide. We found 4 proteins mapped to peptide 
1, and 5 proteins mapped to peptide 2. Interestingly, only one protein (IPI00745806) was 
differentially mapped. By looking up the protein information in IPI, we found that the 
proteins involved are five different alternatively spliced isoforms of MP2K7_HUMAN, 
and IPI00745806 is the third isoform. Therefore, it is likely that only a specific 
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alternative splicing event that takes place is annotated and can be mapped onto the 
protein sequence IPI00745806. 
 
 
Figure 5.5 Identifying The Genomic Origin of MS Detected Peptides and The Relating 
Alternative Splicing Event 
(A) The HIP-2 search result page of protein IPI00023636, displaying the evidence peptides 
detected in MS experiments. (B) The PEPPI sequence search result page of peptide 1, 
indicating the query peptide is produced from an exon-exon combination region. The 
corresponding PEPPI peptide can be mapped to 4 proteins. (C) The sequence search result 
page of peptide 2, indicating the peptide comes from an exon, and can be mapped to 5 
proteins. (D) The search result of the wild-type MP2K7_HUMAN, showing the regions 
mapped by the peptides. Peptide 1 crosses the splice site of two exons (PEP000841690 and 
PEP000841692). Peptide 2 is produced from a single exon, PEP000841692. (E) The search 
result of the 3rd isoform of MP2K7_HUMAN, the protein that is mapped to the peptide 2 
but not mapped to peptide 1. That is because the insertion of a cassette exon 
(PEP000841691) changed the sequence of the protein. 
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To verify our suspicion on the existence of the alternative splicing event, we 
compared the protein-peptide mapping of the wild-type and the third isoform of 
MP2K7_HUMAN. In the wild-type MP2K7_HUMAN (Figure 5.5D), “PEP000841715” 
contains the splice junction of two exons (PEP000841690 and PEP000841692), and 
peptide 1 just crosses the splice site. Nevertheless, in the MP2K7_HUMAN isoform 3 
(Figure 5.5E), we found a unique cassette exon (PEP000841691) spliced between the two 
exons, which hampered the coding of sub-sequence mappable to peptide 1. Meanwhile, 
peptide 2 is only mapped to a single exon (PEP000841692), which exists in all five 
proteins and unaffected by any splice events. Thus we have confirmed the suspicion that 
a cassette exon event caused the protein mapping difference between two MS peptides, 
and have shown the PEPPI database’s ability to help infer alternative splicing events from 
peptides detected from MS experiments. 
5.2.5 Case Study 3: Identifying New Peptide Isoforms for Human 
Human fetal liver can evolve into a major site of embryonic hematopoiesis; 
therefore, protein profiling may help researchers understand how the interaction between 
hepatic and hematopoietic systems and the migration of the hematopoietic system during 
mammalian development take place. We collected four human fetal liver cytoplasm 
proteome data sets from the human fetal liver project (http://hlpic.hupo.org.cn /dblep). 
SDS-PAGE with different cross-linking percentages 15%, 10%, and 7.5% was used for 
protein separation to obtain a full representation of proteins ranging from 5 kDa to more 
than 300 kDa. After these gels were stained with Colloidal Coomassie Blue R250 and the 
gel lanes were manually excised from loading position to the bottom of the gel, the 
extracted peptide mixtures were loaded onto nanoscale LC-ESI-Q-TOF MS or 
micro-LC-ion trap MS systems for protein identification [243]. 
In order to show that the PEPPI database can be used to identify additional novel 
peptide isoforms than the traditional protein database, we downloaded the protein 
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database IPI and created three datasets using the PEPPI database: 1) annotated exonic 
peptides and exon-exon combinations without SNP (PEPPI_KB), 2) all PEPPI peptides 
without SNP (PEPPI_without_SNP), and 3) all PEPPI peptides including peptides with 
SNP (PEPPI_with_SNP). PEPPI_KB consists of peptides of both the EXON_KB and 
E_E_KB region types without additional SNP permutations; PEPPI_without_SNP 
consists of peptides of the EXON_KB, E_E_KB, E_I_TH, I_E_TH, and E_E_TH region 
types without additional SNP permutations; PEPPI_with_SNP consists of peptides of all 
types, with or without SNPs, in the PEPPI database. We also created four corresponding 
inverse sequence datasets to evaluate the false discovery rate with a target-decoy search 
strategy [244]. The four peak list files of human fetal liver from LC-ESI-Q-TOF MS or 
micro-LC-ion trap MS raw files were searched by OMSSA[229] against the four 
databases and their four inverse databases in order to compare the results among them.  
OMSSA reports hits ranked by E-value. An E-value for a hit is a score that is the 
expected number of random hits from a search library to a given spectrum, such that the 
random hits have an equal or better score than the hit. For example, a hit with an E-value 
of 1.0 implies that one hit with a score equal to or better than the hit being scored would 
be expected at random from a sequence library search [229]. The search results with 
OMSSA can vary substantially with differing search parameters, sequence libraries, and 
samples [244]. Therefore, we adopted the MS/MS false discovery rate (FDR) instead of 
E-value as scoring criterion for evaluating the four databases, and this method is based on 
commonly used scoring methodologies and the target-decoy search strategy [244]. All 
other OMSSA search parameters [229] for the four databases are the same. To increase 
identification accuracy, only peptides/proteins with at least two hits of different samples 
was recognized as true peptides/proteins.  
A comparison of search results against four MS databases, i.e., IPI, PEPPI_KB, 
PEPPI_without_SNP, and PEPPI_with_SNP, is shown in Table 2. Results are shown only 
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at a commonly used 1% MS/MS FDR for each database. Compared to the traditional IPI 
database, the elapsed time for PEPPI_KB decreased although the dataset size increased 
by two and a half times. And with the increase of sizes, the elapsed time increases 
significantly linearly from PEPPI_KB to PEPPI_without_SNP to PEPPI_with_SNP 
(Intercept=8.17021, slope=0.04738 , and adjusted R2=0.9975). 
 
 
Figure 5.6 Overlap of Peptides/Genes Identified by Four Search Databases. 
(A) Peptides identified from two or more samples. (B) Proteins identified from two or more 
samples. 
 
Under the criteria of MS/MS FDR 0.01, the target MS/MS hits markedly 
increases with the increase of database size, and target peptide hits, target protein hits, 
and target PEPPI hits all increase while the corresponding FDRs remained approximate. 
The overlap of genes identified by each database is shown graphically by Venn diagram 
in Figure 5.6. The results show that the PEPPI database can be used to identify more 
peptides/proteins under the same false positive rate than the traditional IPI database. 
From the four human fetal liver MS data sets, we identified 63 peptides which 
mapped to 74 PEPPI peptides and 9 SNP events using PEPPI_with_SNP (See Table S-2). 
Among the 74 PEPPI peptides, 55 EXON_KB type peptides were also annotated 
previously in IPI, and 19 peptides were novel peptides uniquely identified with the PEPPI 
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database (13 E_E_KB type peptides, 2 E_E_TH type peptides, 1 I_E_TH type peptide, 
and 3 E_I_TH type peptides) 
The peptide hit matrix shows the number of PEPPI peptides mapped to the 
peptides detected from the samples, and the number of samples (N) in which the peptide 
is detected (See Table S-3). 
5.3 Discussion 
We created a comprehensive PEPPI database of both annotated and hypothetical 
peptides representing human protein isoforms for MS analysis. The PEPPI database made 
it possible for high-throughput identification of gene variations, exon expression, and 
alternative splicing events at the proteome level. We also constructed a web-server for 
searching and visualizing the peptides. With the user-friendly interface and powerful 
search functions, users can easily study the alternative splicing events and gene variations 
related to any gene, protein, or peptide sequence of interest. 
A comparison between the PEPPI database and conventional MS methods is 
shown in Table 3. An MS approach with the PEPPI database uses the same samples, 
equipments and analysis software as a conventional MS approach. To use the PEPPI 
database, users just need to set the PEPPI database or a subset of the PEPPI database as 
the user defined sequence database in the MS search software. With the PEPPI database, 
users can gain information on the expression of exons, alternative splicing events, SNPs, 
and protein existence from the proteome, while the conventional MS approach can only 
derive the protein existence information. Users can opt to use different subsets of the 
PEPPI database for different study purposes. The computational cost of adopting the 
PEPPI database approach over a conventional approach is kept low, due to the use of 
computing cycles without human intervention. 
Since the database incorporated a large number of hypothetical peptides, it is 
possible that the search result contains false positives due to the noise. To solve this 
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problem, we will design an optimized routine for MS data analysis. For example, users 
may analyze several samples at one time, and only keep the peptides detected in more 
than one sample. On the other hand, a recently published article [245] reported tissue 
dependent splicing patterns, which make it possible to generate tissue specific PEPPI 
peptides and reduce the chance of incorporating false positives. 
5.4 Methods 
5.4.1 Genome Data Source 
The PEPPI peptides were generated from the human genome. The source genome 
data was downloaded from Ensembl Version 55 [238] with BioMart. As shown in Figure 
5.7A, four tables, including Un-Translated Region (UTR), Gene Sequence, Gene-Protein 
Mapping and Gene Structure, were pulled from the Ensembl Homo sapiens Genes 
Dataset. The UTR table describes the coordinates of all the transcript UTRs. The Gene 
Sequence table contains chromosome coordinates and sequences in FASTA format. The 
Gene Structure table contains the exon annotation information, including Exon ID, Gene 
ID, Transcript ID, as well as the genome coordinate and translation phase of the exons. 
The SNP table was derived from the Ensembl Homo sapiens Variation Dataset, and 
contains the SNP’s chromosome coordinate and nucleotide shift. The PEPPI database 
incorporated 44,285 genes and 16,489,577 SNPs. 
5.4.2 Data Pre-Processing 
A data pre-processing procedure (Figure 5.7B) was implemented to remove 
non-coding genes and SNPs which are not in exonic regions.  
Firstly we imported all the source tables into a SQLite3 database with the 
SQLite3 command-line interface, and then we used SQL statements to remove 
non-coding genes. The Gene-Protein Mapping was utilized as a filter, and genes not 
mapped to proteins were considered as non-coding genes. The Coding Gene Sequence 
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and Coding Gene Structure table was derived after filtering, and 21,351 protein-coding 
genes were captured.  
 
Figure 5.7 Data Generation Process. 
The whole data generation process was divided into three steps: (A) deriving the genome 
data from Ensembl; (B) pre-processing of the data to select protein-coding genes and SNPs 
within coding exons; and (C) generation of peptide regions and PEPPI peptides. The result 
datasets are colored in red. 
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Then we compiled a C program with the SQLite3 library to extract the annotated 
transcription information from the Coding Gene Structure table, and produced two tables. 
The Exon Knowledgebase table describes all the protein-coding exons, and the Exon 
Comb Knowledgebase table describes all the exon-exon combinations found in the 
annotated transcripts. Then the SNP table was searched against the Exon Knowledgebase 
table, and 390,539 SNPs within the annotated coding exons were retrieved for peptide 
generation. 
5.4.3 Peptide Region Generation 
We compiled a pipeline program with C and the SQLite3 library to generate 
peptide regions (Figure 5.7C). The program first generated the wild-type cDNA 
sequences of the peptide region, and then translated the cDNA sequences into peptides. 
The derived peptides were estimated by the program according to a set of protocols, and 
un-qualified peptides and the corresponding region were discarded. Different cDNA 
generation procedures and peptide estimation protocols were implemented on different 
types of peptide regions. 
For the EXON_KB type, the chromosome coordinate of the exons were derived 
directly from the Exon Knowledgebase table, and the whole length of the exon cDNA 
sequence was captured from the gene sequence. Then the exon’s cDNA sequences were 
translated into peptides according to the annotated ORF. In the peptide estimation process, 
if a stop codon existed anywhere except the end of the peptide, the corresponding region 
was considered invalid and was discarded. 
Similar to the EXON_KB type, the chromosome coordinates of the two exons in 
the E_E_KB type were derived directly from the Exon Comb Knowledgebase table. Then 
the derived cDNA sequences were translated into peptides according to the annotated 
ORF of the exon on the 5’ end. The same peptide estimation protocol used with the 
EXON_KB type was applied to the E_E_KB type. 
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For the E_I_TH and I_E_TH type, the program derived the chromosome 
coordinates of exons from the Exon Knowledgebase table and spliced them with the 
adjacent introns. The cDNA flanking sequence on both side of the splice site was limited 
to 120 nucleotides. If the exon/intron is shorter than 120 nucleotides, the program will 
pull out the actual sequence. This limit was set according to the longest peptide in the 
HIP-2 database [242], which had a length of 80 amino acids and corresponded to 240 
nucleotides in the cDNA sequence. This represents the length of the longest peptide that 
can be identified from an MS experiment. In this way we made sure that any MS 
identified peptide that crosses the splice site can be captured by the PEPPI database. In 
the peptide estimation process, a stop codon is tolerated in the intron of E_I_TH, but not 
tolerated anywhere expect the 3’ end in I_E_TH. 
When producing the E_E_TH type of peptide regions, all possible exon-exon 
combinations were generated and searched against the Exon Comb table. Any 
combinations that cannot be found in the Exon Comb table were captured as an E_E_TH 
type candidate. Then each E_E_TH type cDNA was translated in all 3 ORFs, and if a stop 
codon was found in the 5’ end exon, the peptide was discarded. Note if more than one 
E_E_TH peptide derived from the 3 ORFs were considered valid, then a peptide region 
was created for each ORF. 
5.4.4 PEPPI Peptide Generation 
After the generation of peptide region, PEPPI peptides were produced by inserting 
non-synonymous SNPs into the wild-type peptide of the corresponding region (Figure 
5.7C). All the non-synonymous SNPs within a peptide region were first captured in a list, 
and then inserted into the wild-type cDNA according to their chromosome coordinates. 
Each cDNA sequence with SNP was then translated into peptides. The peptides were then 
estimated according to the peptide estimation protocol of its own region type, and invalid 
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ones were discarded. During peptide generation, a table of Peptide-SNP Mappings was 
also generated. The wild type peptides were also deposited in the PEPPI Peptide table.  
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5.4.5 Online PEPPI Server Design 
The online version of PEPPI database is a typical 3-tier web application, with a 
MySQL database at the backend database service layer, Apache/PHP server scripts to the 
middleware application web server layer, and CSS driven web pages presented on the 
browser. The Javascript library uuCanvas is used to render the real-time data 
visualizations in the gene view and the protein view.  
The result tables derived from the data generation step were imported into the 
MySQL database (Figure 5.8). The chromosome coordinate information was deposited in 
the Peptide Region table, and the sequence information was deposited in the PEPPI 
Peptide table. The ID mapping tables for genes and proteins enable users to query the 
database with different IDs.  
  
110 
Chapter 6. Long Non-coding RNAs in Transcriptome 
6.1 Background 
Alcohol is the third leading cause of preventable death in the United States  
[246]. Alcohol misuse negatively affects the quality of life for millions of Americans, and 
has profound sociological and economic impacts. The neurobiological basis underlying 
alcohol dependence is not fully understood, but extensive evidence indicates that genetic 
factors play key roles in influencing the risk of alcohol dependence [247-254]. Over the 
past decades, several specific genes have been implicated in the risk of alcoholism [249, 
255-265]. In addition, recent studies suggest that epigenetic processes play a critical role 
in affecting the risks of alcohol dependence [266-268]. 
Deep sequencing data from the Encyclopedia of DNA Elements Consortium 
(ENCODE) suggests that over 90% of the human genome can be transcribed, and 
non-protein-coding RNAs (ncRNA) exceed the number of protein-coding genes [67]. The 
recent discovery of over 200 ncRNAs significantly enriches the portfolio of potential 
genetic factors [269]. Rather than being transcriptional noise, many ncRNAs serve as 
master regulators that affect expression levels of dozens or even hundreds of target genes 
[270, 271]. These regulatory RNAs integrate signals from both genetic and environmental 
factors, and therefore can play major roles in controlling alcohol preference. Most notably, 
a strong association of epigenetic marks with long non-coding RNAs (lncRNAs, >200 
nucleotides) in humans and mice was recently described [272]. Many lncRNAs contain 
conserved elements and show spatiotemporally restricted expression patterns, implying 
that they are functional and regulated [273]. These lncRNAs are reported to regulate 
dosage compensation, imprinting, and development by establishing chromatin domains in 
an allele- and cell-type specific manner [274-276]. It is also reported that lncRNAs are 
involved in post-transcriptional regulations [277]. 
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It is now possible to identify novel lncRNAs from the high-throughput 
sequencing data. Guttman et al [34] found that genes being transcribed by RNA 
polymerase II (Pol II) are marked by trimethylation of lysine 4 of histone 3 (H3K4me3) 
in the promoters and trimethylation of lysine 36 of histone 3 (H3K36me3) along the 
transcribed regions. They defined such structure as “K4-K36 domains” and identified 
more than 1600 previously unknown K4-K36 domains from mouse by CHIP-sequencing; 
these transcription active regions represent either protein coding genes or lncRNAs. 
In the current study, we designed an RNA-sequencing experiment and a computer 
approach to identify and characterize novel lncRNAs that are actively transcribed and 
correlated with alcohol preference in rat. We conducted a scan on the transcriptional 
intensities within the rat orthologous regions of the mouse K4-K36 domains published by 
Guttman et al [58], and focused on “intergenic” lncRNAs, i.e., lncRNAs residing outside 
all known protein-coding genes. We identified 420 novel lncRNAs, among which 37 
were differentially expressed between P (alcohol preferring) and NP (alcohol 
non-preferring) rats. Our pathway analysis on the differentially expressed lncRNAs 
demonstrated that many of them had shown significant association with neural functions. 
Our method is also applicable to other diseases and species. 
6.2 Results 
In order to understand the role of lncRNA in alcohol preference, we conducted 
RNA sequencing and bioinformatics analysis on P (alcohol preferring) and NP (alcohol 
non-preferring) rat strains. Our analysis includes four major steps: (i) deriving the rat 
orthologous regions of the K4-K36 domains in mouse; (ii) acquiring the transcriptome 
from the hippocampus of P and NP rats by means of next-generation sequencing; (iii) 
identifying potential regulatory lncRNAs associated with alcohol consumption, based on 
the RNA sequencing and epigenetic marker information; and (iv) inferring the functions 
of lncRNAs differentially expressed in P and NP rat strains (Figure 6.1). 
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Figure 6.1 The Workflow of LncRNA Annotation. 
The dashed boxes indicate extern data source, and solid boxes indicate results generated in 
our analysis. The numbers at the right of the boxes are the number of putative lncRNAs 
after each step of filtering. The filtering begins from 1673 K4-K36 domain in mouse and 
ends up with 420 putative lncRNA regions in rat. 
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6.2.1 Rat Genomic Regions Orthologous to Mouse K4-K36 Domains 
Guttman et al [58] reported 1673 K4-K36 domains in the mouse genome that may 
include lncRNAs. To identify rat lncRNAs, we mapped these K4-K36 domains to the rat 
genome with UCSC LiftOver [278]; 1542 putative lncRNA regions were identified. 
We discarded or truncated the rat orthologous domains to eliminate overlaps with 
(i) known protein-coding genes in rat, or (ii) orthologous regions of known 
protein-coding genes in mouse and human. We focused on the remaining 1319 putative 
lncRNA regions, in which all the known protein coding sequences were excluded. 
6.2.2 Hippocampus Rranscriptomes of P and NP Rats 
To examine the transcription activity of these regions in alcohol-preference, we 
implemented an RNA sequencing experiment on P and NP rats. P and NP rats  [279] are 
a pair of model animals developed for alcohol dependence research, traits other than 
alcohol preference were strictly controlled. Total RNA was extracted from the 
hippocampus of 8 non-inbred P and 8 NP rats, poly-adenylated RNA was selected and 
reverse transcribed. The resulting cDNA was sequenced using the Illumina Genome 
Analyzer IIe, with the strand of the RNA transcripts restrained. RNA from each 
individual rat was sequenced in one Illumina lane that produced 2.8 to 12.8 million 
mappable reads. 
6.2.3 Potential Regulatory lncRNA Regions in P and NP Rats 
Among the regions that were transcribed, we assumed that the strand preference 
for each transcript should be consistent across all the samples, and discarded those that 
were not. With this filtering, 516 and 426 transcripts were derived from the putative rat 
lncRNA regions from P and NP rats, respectively (Figure 6.2A). By uniting these two sets 
of transcripts and removing duplicates, we derived 532 putative lncRNA transcripts with 
strand specificity. 
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Figure 6.2 Features of identified lncRNAs. 
(A) Strand preference. The horizontal and vertical axes denote transcription activity on 
forward and reverse strand, respectively. The circles denotes the lncRNA candidates not 
showing significant strand preference, while the blue and red dots denotes the lncRNA 
candidates that are transcribed on the forward and reverse strand, respectively. (B) 
Distribution of the ratio between lncRNA gene length and exonic region length. 
 
We used a computational algorithm to annotate exons in the putative lncRNA 
regions based on the transcriptional intensity. Within each exon, we required at least 8 
reads, with a maximum distance between two reads of 25 nucleotides. By discarding the 
putative lncRNA regions of which the total exonic lengths were less than 200 nucleotides, 
the candidate pool was reduced to 452 putative lncRNA regions. 
We aligned the exonic sequences of putative lncRNAs and known proteins with 
BlastX [280, 281], and then eliminated a small portion (≈7%) of putative lncRNAs that 
included exons showing protein-coding capacity (Methods). Eventually, we derived 420 
novel lncRNAs with significant transcriptional activity and no significant potential to 
code for proteins. 
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Novel 
lncRNA 
Known 
lncRNA 
Protein-coding 
genes 
Number of regions 420 99 13892 
Length of longest transcript (nt) 72075 83437 17599 
Length of shortest transcript (nt) 200 374 105 
Mean of all transcript lengths (nt) 4053 4947 2131 
Median of all transcript lengths (nt) 1939 3240 1767 
Maximum exon number 244 48 106 
Minimum exon number 1 1 1 
Mean of exon number 14 5 9 
Median of exon number 8 4 7 
Length of longest exon (bp) 10454 83437 11972 
Length of shortest exon (bp) 32 20 3 
Mean exon length (bp) 283 913 244 
Median of exon length (bp) 208 150 132 
Maximum expression intensity (rpkm) 1104.17 N/A 2905.00 
Minimum expression intensity (rpkm) 0 N/A 0 
Mean expression intensity (rpkm) 3.73 N/A 15.44 
Median of expression intensity (rpkm) 0.94 N/A 2.26 
Table 6.1 Statistics of Predicted LncRNA, Known LncRNA and Protein-coding Genes 
Novel lncRNA indicates the lncRNAs identified by our pipeline; known lncRNAs 
include known lncRNAs in both mouse and rat; protein-coding genes refers to rat 
protein-coding genes only. 
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Figure 6.3 Volcano plot of differential expression in P and NP samples. 
The black dots denote the lncRNAs that are not differentially expressed. Red and blue 
dots denote lncRNAs that are significantly higher expressed in P and NP rats, 
respectively. 
  
These novel lncRNAs are equally distributed along different chromosomes, with 
43 and 9 on chr1 and chr12, respectively, which are the longest and shortest 
chromosomes of rat. The transcript lengths of novel lncRNAs fell between 200 and 
72,075 nucleotides, and the ratio of lncRNA transcripts and lncRNA genes ranges from 1 
to 165 (Figure 6.2B), which are similar to known lncRNAs (Table 6.1). The mean 
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transcriptional intensity of novel lncRNAs is 3.7 RPKM, while the average RPKM of 
protein-coding genes is 15.44. 
 
6.2.4 lncRNA Functions and Associations with Alcohol Preference 
Among 420 lncRNAs identified in P or NP rat hippocampus, 37 were 
differentially expressed at a false discovery rate of 0.1 in our Friedman test (Figure 6.3). 
Among the differentially expressed lncRNAs, expression levels of 26 are higher in P rats, 
while 11 are higher in NP rats. This trend is significantly different from protein-coding 
genes (p≤0.001), where expression levels of 1401 and 2009 genes were high in P and NP 
rats respectively (Table 6.2). This is consistent with the observations that most known 
lncRNAs exert their functions by repressing the expression of protein-coding genes. 
 
 Up-regulated Down-regulated 
lncRNA 26 11 
Protein coding gene 1401 2009 
P-value=0.0006 (Chi-square) 
Table 6.2 Chi-square Test of LncRNA Negative Regulation on Protein-coding Genes 
Up-regulated indicates the lncRNA or gene is up-regulated in P rats vs NP rats; 
conversely, down-regulated indicates the lncRNA or gene is down-regulated in P rats vs 
NP rats. 
 
We used a generalized linear model to characterize the correlations between the 
transcription levels of lncRNAs and genes. Among the 2873 genes significantly 
correlating (FDR<0.2, p-value<0.005) with the differentially expressed lncRNAs, 120 are 
correlated with more than 3 lncRNAs. Several of lncRNA correlating genes are known as 
associated with alcohol dependence, including ALDH1A1, ALDH9A1, GABRA2, 
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CHRM2, PDYN and CNR1. We conducted a pathway analysis on these 120 genes with 
Ingenuity Pathway Analysis (IPA) and found that physiological function most frequently 
associated to lncRNAs is nervous system development and functions.  
Among all the differentially expressed lncRNAs, 22 correlate with more than 30 genes 
each. 15 of these lncRNAs correlate with genes enriched in nervous system development 
and function, 8 with neurological diseases, and 6 with behaviors. Moreover, 10 of the 22 
lncRNAs are associated to genetic disorder, which may reveal the hereditary nature of 
alcoholism.  
 
 
Figure 6.4 Potential cis-regulation of lncRNA. 
The pie-chart demonstrates the percentage of transcription factors, miRNA and other 
genes in lncRNA neighbors and in all genes. The proportion of transcription factors and 
miRNAs in lncRNA neighbors is significantly higher (p=2.2×10-16) than that in all 
genes. 
 
Among genes proximal to lncRNAs differentially expressed between P and NP, 
9.2% are annotated as transcription factors, and 6.6% as miRNA; for genes not proximal 
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to differentially expressed lncRNAs, however, this proportion dropped to 6.2% and 1.5% 
for transcription factors and miRNAs. This difference is significant with χ2 p-value 
2.2×10-16, suggesting that many of the novel lncRNAs may be associated with 
neighboring transcription factors and miRNAs, and work in a cis-acting manner. 
6.3 Discussion 
We report an RNA-seq experiment on the hippocampus of P and NP rats, and a 
bioinformatics strategy to identify lncRNAs from the RNA-seq information and 
characterize their roles in alcohol preference. Our strategy includes four components, 
orthologous lncRNA region mapping from mouse to rat, RNA-seq on P and NP rats, 
lncRNA annotation and pathway characterization. We identified 420 lncRNAs, 37 of 
which are differentially expressed across P and NP rats. By applying a generalized linear 
model to differentially expressed lncRNAs and protein-coding genes, we derived 3699 
significantly correlated lncRNA-gene pairs involving 2873 genes. We created a set of 
significantly correlated genes for each lncRNA, and inferred their functional roles by 
pathway analysis. The result revealed that 15 are significantly correlated with nervous 
system development and function. Our statistical analysis also revealed that the 
proportion of TF and miRNA are significantly higher among the lncRNA neighboring 
genes than other genes, implying a cis-acting mechanism (Figure 6.4). 
Evidence was found supporting the existence and potential regulation functions of 
the differentially expressed lncRNAs. Region1384_rev is significantly correlated with 
824 genes, of which 61 are significantly associated with nervous system development and 
function; it is located in the promoter (179 nt upstream of transcription start site) of a 
protein-coding gene CHD2, whose product alters gene expression by modification of 
chromatin structures [282]. Given the observations that many lncRNAs locating in the 
promoter of protein-coding genes possess regulation functions on the corresponding 
genes, the location of region1384_rev suggests a tremendous possibility of a regulatory 
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role upon CHD2, and thus regulating a large group of genes by chromatin modification. 
Moreover, we observed several rat ESTs and orthologous non-coding genes of mouse and 
human within this region, verifying the existence of this lncRNA. (Figure 6.5) 
 
 
Figure 6.5 Observations supporting the existence of lncRNA. 
A dark grid indicates that evidence was found for the corresponding lncRNA, while a 
white grid indicates no such evidence was found. Rat ncGene stands for rat non-coding 
genes; Ortho-ncGene stands for orthologous non-coding genes; N-scan and SGP stands 
for N-scan and SGP gene prediction, respectively; EST stands for expressed sequence 
tags. The lncRNAs are sorted by the number of evidences found. 
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Evidence was also found in support of the existence of other differentially 
expressed lncRNAs and their potential functions on gene regulation and signal 
transduction. Four lncRNAs (region0877_for, region1066_for, region0112_for, and 
region0138_for) were identified sequentially adjacent to zinc-finger proteins, which were 
generally found as a component of transcription factors; besides, region0867_for was 
identified neighboring a gene coding transcription factor, and region0283_rev was found 
near a gene coding a DNA binding protein; these observations indicates that lncRNA may 
regulate the expression of transcription factor genes. Moreover, two lncRNAs 
(region0314_for and region0007_for) were identified adjacent to genes coding G-protein 
regulation proteins (Rho GTPase activating protein 5 and Rho guanine nucleotide 
exchange factor), which implies that lncRNAs may also play roles in cell signaling. 
Region1374_rev was found next to a small-nuclear RNA that is involved in snRNA 
modifications, and region0430.1_for was next to an RNA motif binding protein; this 
indicates that lncRNAs may also be involved in RNA regulations. 
The “K4-K36” domain only represents a transcription active region that may be a 
gene, it is unable to differentiate an intronic lncRNA from a novel exon. Therefore our 
strategy focused on intergenic ncRNAs only, we may have missed the lncRNAs located 
in intronic regions and untranslated regions. In addition, we required the expression of all 
candidate lncRNAs be higher on one of the two strands to eliminate noises and error in 
sequencing data. Because of this criterion, we may also have missed the lncRNAs that are 
transcribed on an antisense strand of a non-coding gene. Nevertheless, once we have new 
transcriptome data with deeper sequencing and longer reads, we will be able to identify 
more lncRNAs from intragenic regions. 
In the future, we plan to conduct RT-PCR experiments to validate the 
transcriptional activity of the lncRNAs which are likely to be associated to gene 
regulations in alcohol preference. We also plan to sequence more brain regions of rats at 
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different drinking levels, thus to characterize the tissue related functions of lncRNA and 
their association with different drinking scores. 
6.4 Methods 
6.4.1 Eliminating Protein-coding Regions 
The annotation library of rat genes and orthologous regions in human and mouse 
were downloaded from UCSC table browser. To remove non-coding genes from the 
library, the genes that cannot be mapped to UniProt accessions were eliminated. Then the 
putative lncRNA regions were superimposed to the protein-coding genes and classified 
into three categories according to the overlap length, 1) non-overlapping, 2) complete 
overlapping and 3) partial overlapping. The putative lncRNA regions not overlapping 
with protein-coding regions were retained for next step, while the complete overlapping 
regions were discarded. For partially overlapped regions, we truncated the overlap and 
shortened the lncRNA regions, if transcriptional activity were detected outside the 
overlap. 
6.4.2 Determining Transcriptional Strand Preference 
To determine the transcriptional strand preference within the putative lncRNA 
regions, we firstly calculated two transcription intensities in RPKM for each lncRNA 
region in each sample, one is for forward strand and the other is for reverse strand. Then 
we conducted a Friedman test to compare the transcriptional intensities on different 
strands. A putative lncRNA region with p-value<0.01 was defined as significantly strand 
biased and the higher expressed strand were defined as the sense strand, while the 
insignificant regions were eliminated. Both the RPKM calculation and Friedman test 
were implemented with Partek® Genomics Suite® software, version 6.6 Copyright ©; 
2016 Partek Inc., St. Louis, MO, USA. 
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6.4.3 Refining Exon Structures 
To reduce computational time, we eliminated all the RNA-seq reads outside the 
putative lncRNA regions and on the antisense strand. Then SAMtools was used to pileup 
all the reads. A list of expressed chunks was generated based on the pileup file. If the 
distance between two chunks was less than 25 basepairs, they were merged into one 
chunk. If the number of reads covered by a chunk was less than 8, this chunk was 
discarded. The derived chunks were defined as putative exons and mapped to the lncRNA 
regions. A refflat file was generated for each lncRNA regions, annotating their 
coordinates and putative exon structures. 
6.4.4 Detecting Protein-coding Potential 
The sequences of the putative exons were extracted and aligned against SwissProt 
with BlastX. In the cases that several alignments were generated for one exon sequence, 
we only retained the one with the highest alignment score. Then we calculated the 
average log10(E-value) of all exons for each lncRNA to evaluate their protein-coding 
potential. LncRNA regions with an average log10(E-value) < -3 were discarded; the rest 
regions were defined as non-coding potential regions. 
6.4.5 Deriving Significantly Correlated LncRNA-gene Pairs 
It is reasonable to assume that number of sequence tags identified in each lncRNA 
region follows a Poisson distribution; we therefore used a generalized linear model to 
infer the relationship between the expression intensity of lncRNAs and protein-coding 
genes. 
𝑌𝑖𝑘~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜇𝑖𝑗𝑘) 
log 𝜇𝑖𝑗𝑘 = 𝑁𝑖𝑘 + 𝛼 + 𝛽1𝑠𝑘 + 𝛽2𝑔𝑗𝑘 + 𝛽3𝑏𝑘 
In this model, i, j, and k are the indices of lncRNA, gene and animal. Yik is the 
number of RNA-seq read counts in the region of lncRNA i in animal k; μijk is the 
expected value of Yik; Nik is a constant value that serves as a normalization factor to 
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balance sample and lncRNA specific variation. Here, Nij=log(Ki)+log(Mk), where Ki is 
the length of exon model of lncRNA i and Mk is the total number of mappable reads for 
sample k. sk is the strain of animal k (P or NP); gik is the transcription intensity (RPKM) 
of gene i in animal k; bk is the batch effect of the experiment (Run1 or Run2). The 
significance of β2 was used to evaluate the correlation between lncRNA i and gene j.  
To simplify the model and derive the most trustworthy results, we assumed that 
there is no interaction between strain and gene transcription intensity. To rule out the 
cases that the interaction may exist, we used another generalized linear model to identify 
these cases. 
𝑌𝑖𝑘~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜇𝑖𝑗𝑘) 
log 𝜇𝑖𝑗𝑘 = 𝑁𝑖𝑘 + 𝛼 + 𝛽1𝑠𝑘 + 𝛽2𝑔𝑗𝑘 + 𝛽3𝑏𝑘 + 𝛽4𝑠𝑘𝑔𝑗𝑘 
If the coefficient of strain-gene interaction term β4 was significant (p≤0.05), then 
the corresponding lncRNA-gene pair was discarded.  
To increase the reproducibility of the results, we required that all lncRNAs and 
genes should have transcriptional intensities more than 0.5 RPKM in at least 8 samples.  
All lncRNA-gene pairs involving ineligible lncRNA or genes were discarded. 
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Chapter 7. Conclusions and Discussions 
7.1 Research Summary and Contributions 
About 150 years after the first observation of nucleic acids, the advance of 
high-throughput sequencing technologies has unleashed numerous possibilities in genetic 
and genomic research. This dissertation demonstrated 5 use cases in transcriptome 
research facilitated by mRNA sequencing and protein mass spectrometry.  
Chapter 2, 3 and 4 covered identification methods for both known and novel 
alternative splicing (AS) events, and made functional insights on these AS events that can 
be utilized in hypothesis generation for wet-lab research. In Chapter 2, we identified and 
characterized stimulant induced AS events. In Chapter 3, we improved the AS event 
identification technique and applied it for identifying AS events that are regulated across 
three human development stages (fetal, pediatric and adult). In the two chapters above, 
we implemented functional analysis on AS events from several aspects, including gene 
function, disruption on protein structure and interaction, as well as RNA-binding proteins 
(RBP) and genomic regions that may be involved in AS regulation. In Chapter 4, we 
developed a method for identifying novel AS events from RNA-seq results. We validated 
the novel AS events by visualizing their Sashimi plots [97]. 
In Chapter 5, we extended our investigation on AS to the proteome level. We 
established a peptide sequence database PEPPI [62] for exons and exon junctions. This 
database enables researchers to identify splicing junctions from MS/MS results. 
In Chapter 6, we developed a set of methodologies to identify long non-coding 
RNAs (lncRNAs) from RNA-seq data. Most lncRNAs share the same transcription 
mechanism with mRNAs and has poly-A tails, which enables them to present in mRNA 
sequencing data derived with poly-A selection. However, many analyses only focused on 
mRNAs and overlooked lncRNAs, rendering this precious information into a forgotten 
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treasure. Therefore we developed these methods and turned mRNA sequencing data into 
a gold mine of lncRNA information. 
7.2 Future Research Directions 
7.2.1 Biochemical Validation on Discovered Splicing Events and lncRNA 
In this dissertation, we discovered and characterized differentially regulated 
alternative splicing events and lncRNAs that are associated to biological functions, and 
validated them with prior knowledge published in publications and databases. However, 
we haven’t got the time and resource to implement biochemical validations on these 
discoveries. The presence of these alternative splicing events and lncRNA can be 
validated by PCR and Sanger sequencing experiments. The protein-protein interactions 
may be validated with yeast two-hybrid approach or chip-based analysis. The RBP-RNA 
interactions may be validated with CLIP sequencing. Novel lncRNAs may be knocked 
off or knocked down to examine their biological functions. 
7.2.2 Better Sequencing Technology Enables Better Results 
All RNA-seq data utilized in this dissertation are single-ended, with the longest 
read length of 75nt. By the year of 2017, Illumina provides paired-end sequencing 
solutions with 100~150nt on each end at affordable prices. Most of exons are less than 
200bp in length [283]. Therefore most of the paired-end reads will be covering at least 
one splice junction. Employing the latest sequencing technology will enormously 
improve the number and accuracy of identifiable AS events. It will allow researchers to 
accurately deduct the genomic structure of lncRNAs. 
On the other hand, emerging long read length sequencing technologies may 
become rather helpful for alternative splicing and lncRNA research. The Oxford 
Nanopore sequencing technology is capable of achieving the median read length around 
1200bp [284, 285]. Pacific Biosciences sequencing technology can achieve an even 
longer median read length of 30,000bp [22, 286]. These sequencing technologies will 
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provide informative long length reads covering multiple splicing junctions and even the 
whole length transcript. With such information, alternative splicing research will not be 
limited to individual splicing events. Instead, the sequence and the expression intensity of 
different RNA isoforms can both be derived accurately. 
7.2.3 DNA Variations Affect AS 
The regulation of AS depends on the facilitation of AS related RNA-binding 
proteins (RBP). Change of the sequence in binding regions (ESE, ESS, ISE, ISS) on RNA 
may affect the binding affinity between the RNA molecule and RBP. While the exon 
sequence is generally available from RNA-seq data, the intron sequences are mostly 
unavailable. DNA sequencing allows users to identify variations in introns, and thus 
systematically associate variations in AS regulatory regions and change of AS. 
7.2.4 Prioritization of AS Events 
In this dissertation we characterized AS from several aspects, including gene 
function, PTM sites, effect on protein structure and interactions. Such information can 
also be collected for disease causing insertion/deletion variations. The effect of 
insertion/deletion variations (indels) is similar to AS at the protein level. Therefore we 
may use the genomic and protein structural information of disease causing indels as a 
training set for prioritizing AS events that may be associated with disease. 
7.2.5 Algorithm for AS Event Validation 
MISO [42] and rMATS [43] provided solutions for quantifying the percentage of 
splicing isoforms (PSI or Ψ) as well as the significance of AS change across two biological 
conditions. However, we observed many “significantly changed AS events” showing 
unrealistic base coverages in Sashimi-plots [42]. Such unrealistic base coverages are 
generally induced by the variability and limitations of the RNA-seq technology. In this 
dissertation, we manually reviewed the Sashimi-plot for each AS event to make sure it is 
biologically valid. This will become a bottleneck if we need to automate AS identification 
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and characterization. In the future, we may utilize machine learning methods in image 
analysis to automate this scanning process on the base coverages of AS events. 
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Supplementary Materials 
Table S-1 The function and localization of alternatively spliced genes 
AS Type 
Gene 
Symbol 
Gene Description 
Gene 
Location 
Gene 
Type 
∆Ψ 
cassete 
exon 
Mgrn1 
mahogunin ring finger 1, E3 
ubiquitin protein ligase 
Cytoplasm 
enzym
e 
-0.25 
cassete 
exon 
Smox spermine oxidase Cytoplasm 
enzym
e 
0.37 
cassete 
exon 
Rhot1 
ras homolog family member 
T1 
Cytoplasm 
enzym
e 
-0.15 
cassete 
exon 
Magi3 
membrane associated 
guanylate kinase, WW and 
PDZ domain containing 3 
Cytoplasm kinase -0.42 
cassete 
exon 
Pank2 pantothenate kinase 2 Cytoplasm kinase -0.21 
cassete 
exon 
Mark3 
MAP/microtubule 
affinity-regulating kinase 3 
Cytoplasm kinase -0.22 
cassete 
exon 
Camk1d 
calcium/calmodulin-depende
nt protein kinase ID 
Cytoplasm kinase -0.31 
cassete 
exon 
Cdc42bp
a 
CDC42 binding protein 
kinase alpha (DMPK-like) 
Cytoplasm kinase -0.12 
cassete 
exon 
Plscr2 phospholipid scramblase 2 Cytoplasm other 0.16 
cassete 
exon 
Fopnl FGFR1OP N-terminal like Cytoplasm other 0.11 
cassete Cyb561a cytochrome b561 family, Cytoplasm other 0.37 
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exon 3 member A3 
cassete 
exon 
Mpv17 
MpV17 mitochondrial inner 
membrane protein 
Cytoplasm other 0.23 
cassete 
exon 
Tbc1d31 
TBC1 domain family, 
member 31 
Cytoplasm other 0.22 
cassete 
exon 
Picalm 
phosphatidylinositol binding 
clathrin assembly protein 
Cytoplasm other -0.06 
cassete 
exon 
Numbl 
numb homolog 
(Drosophila)-like 
Cytoplasm other -0.39 
cassete 
exon 
Arhgef11 
Rho guanine nucleotide 
exchange factor (GEF) 11 
Cytoplasm other 0.29 
cassete 
exon 
Abi1 abl-interactor 1 Cytoplasm other 0.14 
cassete 
exon 
Spc25 
SPC25, NDC80 kinetochore 
complex component 
Cytoplasm other 0.15 
cassete 
exon 
Fhl1 
four and a half LIM domains 
1 
Cytoplasm other -0.05 
cassete 
exon 
Mob4 
MOB family member 4, 
phocein 
Cytoplasm other 0.25 
cassete 
exon 
Spag9 sperm associated antigen 9 Cytoplasm other 0.2 
cassete 
exon 
Mphosph
9 
M-phase phosphoprotein 9 Cytoplasm other -0.36 
cassete 
exon 
Plec plectin Cytoplasm other 0.05 
cassete Xpnpep3 X-prolyl aminopeptidase Cytoplasm peptid 0.27 
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exon (aminopeptidase P) 3, 
putative 
ase 
cassete 
exon 
Blmh bleomycin hydrolase Cytoplasm 
peptid
ase 
0.25 
cassete 
exon 
Fabp5 
fatty acid binding protein 5 
(psoriasis-associated) 
Cytoplasm 
transp
orter 
0.1 
cassete 
exon 
Copg2 
coatomer protein complex, 
subunit gamma 2 
Cytoplasm 
transp
orter 
0.2 
cassete 
exon 
Rabep1 
rabaptin, RAB GTPase 
binding effector protein 1 
Cytoplasm 
transp
orter 
0.14 
cassete 
exon 
Pctp 
phosphatidylcholine transfer 
protein 
Cytoplasm 
transp
orter 
0.39 
cassete 
exon 
Arl13b 
ADP-ribosylation factor-like 
13B 
Extracellu
lar Space 
other -0.29 
cassete 
exon 
Slit2 slit homolog 2 (Drosophila) 
Extracellu
lar Space 
other 0.53 
cassete 
exon 
Baz2b 
bromodomain adjacent to 
zinc finger domain, 2B 
Extracellu
lar Space 
other -0.39 
cassete 
exon 
Suv420h
1 
suppressor of variegation 
4-20 homolog 1 (Drosophila) 
Nucleus 
enzym
e 
0.12 
cassete 
exon 
Clk4 CDC-like kinase 4 Nucleus kinase 0.18 
cassete 
exon 
Uty 
ubiquitously transcribed 
tetratricopeptide repeat gene, 
Y chromosome 
Nucleus other 0.25 
cassete Sun1 Sad1 and UNC84 domain Nucleus other -0.21 
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exon containing 1 
cassete 
exon 
Maf1 
MAF1 homolog (S. 
cerevisiae) 
Nucleus other -0.2 
cassete 
exon 
Morf4l2 mortality factor 4 like 2 Nucleus other 0.17 
cassete 
exon 
Hmgxb4 
HMG box domain containing 
4 
Nucleus other -0.22 
cassete 
exon 
Phf20 PHD finger protein 20 Nucleus other -0.13 
cassete 
exon 
Zfp120 zinc finger protein 932 Nucleus other -0.33 
cassete 
exon 
Ift122 
intraflagellar transport 122 
homolog (Chlamydomonas) 
Nucleus other 0.38 
cassete 
exon 
Phf7 PHD finger protein 7 Nucleus other -0.46 
cassete 
exon 
Ctnnd1 
catenin (cadherin-associated 
protein), delta 1 
Nucleus other -0.22 
cassete 
exon 
Rad18 
RAD18 homolog (S. 
cerevisiae) 
Nucleus other 0.23 
cassete 
exon 
Senp7 
SUMO1/sentrin specific 
peptidase 7 
Nucleus 
peptid
ase 
-0.52 
cassete 
exon 
Depdc1a DEP domain containing 1 Nucleus TR 0.16 
cassete 
exon 
Ybx3 Y box binding protein 3 Nucleus TR -0.12 
cassete Ncor1 nuclear receptor corepressor Nucleus TR -0.33 
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exon 1 
cassete 
exon 
Kansl2 
KAT8 regulatory NSL 
complex subunit 2 
Other 
enzym
e 
0.22 
cassete 
exon 
Ube2q2 
ubiquitin-conjugating 
enzyme E2Q family member 
2 
Other 
enzym
e 
0.31 
cassete 
exon 
Kansl2 
KAT8 regulatory NSL 
complex subunit 2 
Other 
enzym
e 
0.22 
cassete 
exon 
Rnf214 ring finger protein 214 Other other 0.37 
cassete 
exon 
Tmem16
1b 
transmembrane protein 161B Other other 0.19 
cassete 
exon 
Zfp740 zinc finger protein 740 Other other -0.3 
cassete 
exon 
Ubl4a Slc10a3-Ubl4 readthrough Other other -0.12 
cassete 
exon 
Asb7 
ankyrin repeat and SOCS box 
containing 7 
Other other 0.36 
cassete 
exon 
Lins lines homolog (Drosophila) Other other 0.24 
cassete 
exon 
Ttc13 
tetratricopeptide repeat 
domain 13 
Other other -0.21 
cassete 
exon 
Slx4ip SLX4 interacting protein Other other -0.3 
cassete 
exon 
Ppp4r1l-
ps 
protein phosphatase 4, 
regulatory subunit 1-like, 
Other other -0.41 
134 
pseudogene 
cassete 
exon 
Smim8 
small integral membrane 
protein 8 
Other other 0.27 
cassete 
exon 
Zmym4 zinc finger, MYM-type 4 Other other 0.47 
cassete 
exon 
Smim8 
small integral membrane 
protein 8 
Other other 0.27 
cassete 
exon 
Svil supervillin Other other 0.22 
cassete 
exon 
Adprm 
ADP-ribose/CDP-alcohol 
diphosphatase, 
manganese-dependent 
Other other 0.34 
cassete 
exon 
Tbc1d9b 
TBC1 domain family, 
member 9B (with GRAM 
domain) 
Other other -0.4 
cassete 
exon 
Pwwp2a 
PWWP domain containing 
2A 
Other other 0.53 
cassete 
exon 
Adprm 
ADP-ribose/CDP-alcohol 
diphosphatase, 
manganese-dependent 
Other other 0.34 
cassete 
exon 
Smim8 
small integral membrane 
protein 8 
Other other 0.27 
cassete 
exon 
2810474
O19Rik 
KIAA1551 Other other 0.28 
cassete 
exon 
Usp45 
ubiquitin specific peptidase 
45 
Other 
peptid
ase 
-0.41 
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cassete 
exon 
Prepl prolyl endopeptidase-like Other 
peptid
ase 
0.14 
cassete 
exon 
Rnf14 ring finger protein 14 Other TR -0.19 
cassete 
exon 
Tmem11 transmembrane protein 11 PM GPCR 0.16 
cassete 
exon 
Ttll7 
tubulin tyrosine ligase-like 
family, member 7 
PM other 0.38 
cassete 
exon 
Aif1l 
allograft inflammatory factor 
1-like 
PM other 0.32 
cassete 
exon 
Aif1l 
allograft inflammatory factor 
1-like 
PM other 0.32 
cassete 
exon 
Dnajc5 
DnaJ (Hsp40) homolog, 
subfamily C, member 5 
PM other -0.18 
cassete 
exon 
Cpeb4 
cytoplasmic polyadenylation 
element binding protein 4 
PM other 0.52 
cassete 
exon 
Tpm1 tropomyosin 1, alpha PM other -0.05 
cassete 
exon 
Jmjd6 jumonji domain containing 6 PM TMR 0.14 
A3SS Eci2 enoyl-CoA delta isomerase 2 Cytoplasm 
enzym
e 
0.16 
A3SS Cyp4f16 
cytochrome P450, family 4, 
subfamily f, polypeptide 16 
Cytoplasm 
enzym
e 
-0.49 
A3SS Rabggtb 
Rab 
geranylgeranyltransferase, 
Cytoplasm 
enzym
e 
0.09 
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beta subunit 
A3SS Akt1 
v-akt murine thymoma viral 
oncogene homolog 1 
Cytoplasm kinase 0.29 
A3SS Ppip5k2 
diphosphoinositol 
pentakisphosphate kinase 2 
Cytoplasm kinase 0.26 
A3SS Cdv3 CDV3 homolog (mouse) Cytoplasm other 0.05 
A3SS Dock9 dedicator of cytokinesis 9 Cytoplasm other 0.48 
A3SS Akt1s1 
AKT1 substrate 1 
(proline-rich) 
Cytoplasm other 0.08 
A3SS Scoc short coiled-coil protein Cytoplasm other -0.23 
A3SS Becn1 beclin 1, autophagy related Cytoplasm other -0.1 
A3SS Blmh bleomycin hydrolase Cytoplasm 
peptid
ase 
0.25 
A3SS Rrbp1 ribosome binding protein 1 Cytoplasm 
transp
orter 
-0.26 
A3SS Arfgap1 
ADP-ribosylation factor 
GTPase activating protein 1 
Cytoplasm 
transp
orter 
-0.4 
A3SS Sparc 
secreted protein, acidic, 
cysteine-rich (osteonectin) 
Extracellu
lar Space 
other 0.1 
A3SS Bod1l 
biorientation of 
chromosomes in cell division 
1-like 1 
Extracellu
lar Space 
other 0.34 
A3SS Mettl3 methyltransferase like 3 Nucleus 
enzym
e 
0.45 
A3SS Tyms thymidylate synthetase Nucleus 
enzym
e 
0.09 
137 
A3SS Mcm9 
minichromosome 
maintenance complex 
component 9 
Nucleus 
enzym
e 
-0.46 
A3SS Rev1 
REV1, polymerase (DNA 
directed) 
Nucleus 
enzym
e 
-0.22 
A3SS Zfp346 zinc finger protein 346 Nucleus other 0.39 
A3SS Chchd1 
coiled-coil-helix-coiled-coil-
helix domain containing 1 
Nucleus other -0.12 
A3SS Fra10ac1 
fragile site, folic acid type, 
rare, fra(10)(q23.3) or 
fra(10)(q24.2) candidate 1 
Nucleus other 0.43 
A3SS Srrt 
serrate RNA effector 
molecule homolog 
(Arabidopsis) 
Nucleus other 0.22 
A3SS Ivns1abp 
influenza virus NS1A binding 
protein 
Nucleus other 0.07 
A3SS Hnrnpr 
heterogeneous nuclear 
ribonucleoprotein R 
Nucleus other 0.18 
A3SS Cdc27 cell division cycle 27 Nucleus other -0.2 
A3SS Phrf1 
PHD and ring finger domains 
1 
Nucleus other -0.33 
A3SS Nolc1 
nucleolar and coiled-body 
phosphoprotein 1 
Nucleus TR 0.14 
A3SS Htatip2 
HIV-1 Tat interactive protein 
2, 30kDa 
Nucleus TR 0.4 
A3SS Rbm39 RNA binding motif protein Nucleus TR -0.21 
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39 
A3SS Hdac10 histone deacetylase 10 Nucleus TR -0.44 
A3SS Nfya 
nuclear transcription factor Y, 
alpha 
Nucleus TR -0.32 
A3SS Ankzf1 
ankyrin repeat and zinc finger 
domain containing 1 
Nucleus TR -0.42 
A3SS Fus fused in sarcoma Nucleus TR 0.21 
A3SS Sbno1 
strawberry notch homolog 1 
(Drosophila) 
Other 
enzym
e 
0.3 
A3SS 
4833420
G17Rik 
chromosome 5 open reading 
frame 34 
Other other -0.38 
A3SS Eml3 
echinoderm microtubule 
associated protein like 3 
Other other -0.42 
A3SS Phf20l1 PHD finger protein 20-like 1 Other other -0.27 
A3SS Ubl4a Slc10a3-Ubl4 readthrough Other other -0.12 
A3SS Dda1 
DET1 and DDB1 associated 
1 
Other other 0.07 
A3SS Ttpal 
tocopherol (alpha) transfer 
protein-like 
Other other 0.41 
A3SS Miip 
migration and invasion 
inhibitory protein 
Other other 0.18 
A3SS Ppp4r1 
protein phosphatase 4, 
regulatory subunit 1 
Other 
phosp
hatase 
0.23 
A3SS Ly6a 
lymphocyte antigen 6 
complex, locus A 
PM other 0.44 
A3SS Prnd prion protein 2 (dublet) PM other -0.45 
139 
A5SS Ndufs1 
NADH dehydrogenase 
(ubiquinone) Fe-S protein 1, 
75kDa (NADH-coenzyme Q 
reductase) 
Cytoplasm 
enzym
e 
-0.24 
A5SS Birc6 
baculoviral IAP repeat 
containing 6 
Cytoplasm 
enzym
e 
0.28 
A5SS Nit1 nitrilase 1 Cytoplasm 
enzym
e 
-0.33 
A5SS Map3k7 
mitogen-activated protein 
kinase kinase kinase 7 
Cytoplasm kinase -0.4 
A5SS Ehbp1l1 
EH domain binding protein 
1-like 1 
Cytoplasm other -0.05 
A5SS Cmc2 
COX assembly mitochondrial 
protein 2 homolog (S. 
cerevisiae) 
Cytoplasm other 0.1 
A5SS Spc25 
SPC25, NDC80 kinetochore 
complex component 
Cytoplasm other 0.15 
A5SS Dnajb12 
DnaJ (Hsp40) homolog, 
subfamily B, member 12 
Cytoplasm other -0.52 
A5SS Mrps33 
mitochondrial ribosomal 
protein S33 
Cytoplasm other -0.22 
A5SS Mkks 
McKusick-Kaufman 
syndrome 
Cytoplasm other -0.17 
A5SS Ddx6 
DEAD (Asp-Glu-Ala-Asp) 
box helicase 6 
Nucleus 
enzym
e 
0.14 
A5SS Fen1 flap structure-specific Nucleus enzym 0.1 
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endonuclease 1 e 
A5SS Ddx6 
DEAD (Asp-Glu-Ala-Asp) 
box helicase 6 
Nucleus 
enzym
e 
0.14 
A5SS Naa10 
N(alpha)-acetyltransferase 
10, NatA catalytic subunit 
Nucleus 
enzym
e 
0.28 
A5SS Adarb1 
adenosine deaminase, 
RNA-specific, B1 
Nucleus 
enzym
e 
0.23 
A5SS Nr1h2 
nuclear receptor subfamily 1, 
group H, member 2 
Nucleus 
ligand 
-depen
dent 
nuclea
r 
recept
or 
0.29 
A5SS Srsf7 
serine/arginine-rich splicing 
factor 7 
Nucleus other 0.19 
A5SS Srsf7 
serine/arginine-rich splicing 
factor 7 
Nucleus other 0.19 
A5SS Zfp60 zinc finger protein 60 Nucleus other -0.29 
A5SS Hira histone cell cycle regulator Nucleus TR 0.15 
A5SS Yeats2 YEATS domain containing 2 Nucleus TR -0.47 
A5SS 
Tmem23
4 
transmembrane protein 234 Other other 0.31 
A5SS Arl16 
ADP-ribosylation factor-like 
16 
Other other -0.3 
A5SS Zfp740 zinc finger protein 740 Other other -0.3 
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A5SS Efr3a 
EFR3 homolog A (S. 
cerevisiae) 
PM other -0.1 
A5SS Smek1 
SMEK homolog 1, 
suppressor of mek1 
(Dictyostelium) 
PM other 0.22 
A5SS Inpp5a 
inositol 
polyphosphate-5-phosphatas
e, 40kDa 
PM 
phosp
hatase 
0.2 
A5SS Jmjd6 jumonji domain containing 6 PM TMR 0.14 
retained 
intron 
Hspa8 heat shock 70kDa protein 8 Cytoplasm 
enzym
e 
0.12 
retained 
intron 
Trim2 tripartite motif containing 2 Cytoplasm 
enzym
e 
0.17 
retained 
intron 
Coq6 
coenzyme Q6 
monooxygenase 
Cytoplasm 
enzym
e 
0.38 
retained 
intron 
Dgkq 
diacylglycerol kinase, theta 
110kDa 
Cytoplasm kinase 0.29 
retained 
intron 
Yipf2 
Yip1 domain family, member 
2 
Cytoplasm other 0.32 
retained 
intron 
Rasa2 RAS p21 protein activator 2 Cytoplasm other 0.24 
retained 
intron 
Wipi2 
WD repeat domain, 
phosphoinositide interacting 
2 
Cytoplasm other 0.19 
retained 
intron 
Rps18 ribosomal protein S18 Cytoplasm other 0.09 
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retained 
intron 
Wdr11 WD repeat domain 11 Cytoplasm other -0.21 
retained 
intron 
Golga1 golgin A1 Cytoplasm other 0.15 
retained 
intron 
Becn1 beclin 1, autophagy related Cytoplasm other -0.1 
retained 
intron 
Lrrc45 
leucine rich repeat containing 
45 
Cytoplasm other -0.28 
retained 
intron 
Ambra1 
autophagy/beclin-1 regulator 
1 
Cytoplasm other -0.37 
retained 
intron 
Eif4a2 
eukaryotic translation 
initiation factor 4A2 
Cytoplasm TLR 0.09 
retained 
intron 
Eif4a2 
eukaryotic translation 
initiation factor 4A2 
Cytoplasm TLR 0.09 
retained 
intron 
Tmem21
4 
transmembrane protein 214 
Extracellu
lar Space 
other -0.4 
retained 
intron 
Msh3 mutS homolog 3 Nucleus 
enzym
e 
0.31 
retained 
intron 
Nle1 
notchless homolog 1 
(Drosophila) 
Nucleus 
enzym
e 
0.39 
retained 
intron 
Sirt7 sirtuin 7 Nucleus 
enzym
e 
0.27 
retained 
intron 
Nek8 NIMA-related kinase 8 Nucleus kinase -0.38 
retained 
intron 
Mis18a 
MIS18 kinetochore protein 
homolog A (S. pombe) 
Nucleus other 0.16 
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retained 
intron 
9930012
K11Rik 
chromosome 8 open reading 
frame 58 
Nucleus other 0.25 
retained 
intron 
Ncaph2 
non-SMC condensin II 
complex, subunit H2 
Nucleus other -0.08 
retained 
intron 
Lrif1 
ligand dependent nuclear 
receptor interacting factor 1 
Nucleus other 0.28 
retained 
intron 
Xab2 XPA binding protein 2 Nucleus other 0.23 
retained 
intron 
Sapcd2 
suppressor APC domain 
containing 2 
Nucleus other 0.39 
retained 
intron 
Cdan1 codanin 1 Nucleus other 0.34 
retained 
intron 
Hnrnph1 
heterogeneous nuclear 
ribonucleoprotein H1 (H) 
Nucleus other -0.06 
retained 
intron 
Gtf2a2 
general transcription factor 
IIA, 2, 12kDa 
Nucleus TR 0.28 
retained 
intron 
Hsf1 
heat shock transcription 
factor 1 
Nucleus TR -0.34 
retained 
intron 
Tfe3 
transcription factor binding to 
IGHM enhancer 3 
Nucleus TR 0.16 
retained 
intron 
Trim28 tripartite motif containing 28 Nucleus TR 0.25 
retained 
intron 
Snapc4 
small nuclear RNA activating 
complex, polypeptide 4, 
190kDa 
Nucleus TR -0.31 
retained Mroh1 maestro heat-like repeat Other other 0.2 
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intron family member 1 
retained 
intron 
Morc4 
MORC family CW-type zinc 
finger 4 
Other other -0.3 
retained 
intron 
Dus1l 
dihydrouridine synthase 
1-like (S. cerevisiae) 
Other other 0.15 
retained 
intron 
Slc7a6os 
solute carrier family 7, 
member 6 opposite strand 
Other other -0.14 
retained 
intron 
Psmd5 
proteasome (prosome, 
macropain) 26S subunit, 
non-ATPase, 5 
Other other -0.06 
retained 
intron 
Sharpin 
SHANK-associated RH 
domain interactor 
PM other 0.22 
retained 
intron 
Lmbr1l 
limb development membrane 
protein 1-like 
PM other -0.4 
retained 
intron 
Jmjd6 jumonji domain containing 6 PM TMR 0.14 
retained 
intron 
Slc39a7 
solute carrier family 39 (zinc 
transporter), member 7 
PM 
transp
orter 
-0.1 
 
TR: transcription regulator 
TMR: transmembrane receptor 
TLR: translation regulator 
GPCR: G-protein coupled receptor 
PM: plasma membrane 
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Table S-2 Peptides identified by PEPPI database 
Peptide peppi SNP Gene 
Splici
ng 
FDR Mass 
Theo 
Mass 
AGEYG
AEALER 
PEP006
194756 
rs3394
3087(A
/G) 
ENSG00
0001885
36 
E_E_
KB 
0.0032 1165.19 1164.54 
APVPTG
EVYFA
DSFDR 
PEP003
042584  
ENSG00
0001270
22 
EXO
N_K
B 
0.0073 1769.79 1769.83 
ASSVVV
SGTPIR 
PEP001
086304  
ENSG00
0001038
76 
EXO
N_K
B 
0.0100 1173.11 1171.66 
ATSFLL
ALEPEL
EAR 
PEP004
603386  
ENSG00
0001639
02 
EXO
N_K
B 
0.0031 1660.01 1658.89 
AVFPSI
VGR 
PEP006
209453 
rs1154
9244(C
/T) 
ENSG00
0001840
09 
EXO
N_K
B 
0.0031 945.881 944.543 
AVFVD
LEPTVL
DEVR 
PEP006
626718 
rs3621
5077(G
/C) 
ENSG00
0001980
33 
E_E_
KB 
0.0067 1701.74 1700.9 
AVFVN
LEPTVI
DEVR 
PEP002
507811 
rs1154
6624(G
/A) 
ENSG00
0001234
16 
E_E_
KB 
0.0066 1700.66 1699.91 
AVNTL
NEALEF
PEP000
166109  
ENSG00
0000218
E_E_
KB 
0.0088 1418.72 1418.74 
146 
AK 26 
DLLDDL
KSELTG
K 
PEP004
712877  
ENSG00
0001641
11 
EXO
N_K
B 
0.0062 1445.69 1445.76 
DPQLVP
ILIEAAR 
PEP003
888536  
ENSG00
0001473
83 
EXO
N_K
B 
0.0036 1435.05 1433.83 
EGDVLT
LLESER 
PEP007
510716  
ENSG00
0002270
97 
EXO
N_K
B 
0.0090 1359.8 1359.69 
EGDVLT
LLESER 
PEP007
749514  
ENSG00
0002339
27 
EXO
N_K
B 
0.0090 1359.8 1359.69 
ELFSNL
QEFAGP
SGK 
PEP006
264479  
ENSG00
0001854
32 
EXO
N_K
B 
0.0035 1622.75 1622.79 
ETTIQG
LDGLSE
R 
PEP003
467192  
ENSG00
0001368
72 
E_E_
KB 
0.0066 1417.67 1417.71 
FGGLLL
TEKPIV
LK 
PEP004
835823  
ENSG00
0001608
70 
EXO
N_K
B 
0.0032 1526.87 1526.94 
FLEQQD
QVLQT
K 
PEP005
639485 
rs6172
6455(A
/G) 
ENSG00
0001728
67 
EXO
N_K
B 
0.0089 1477.5 1475.76 
FPGQLN PEP001
 
ENSG00 EXO 0.0085 1131.11 1129.59 
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ADLR 260206 0001011
62 
N_K
B 
FPGQLN
ADLR 
PEP001
635184  
ENSG00
0001048
33 
EXO
N_K
B 
0.0085 1131.11 1129.59 
FPGQLN
ADLR 
PEP003
177389  
ENSG00
0001372
67 
EXO
N_K
B 
0.0085 1131.11 1129.59 
FPGQLN
ADLR 
PEP003
198554 
rs1054
331(G/
C) 
ENSG00
0001372
85 
EXO
N_K
B 
0.0085 1131.11 1129.59 
FVTVQT
ISGTGA
LR 
PEP002
709222  
ENSG00
0001251
66 
EXO
N_K
B 
0.0100 1448.73 1448.8 
GALQNI
IPASTG
AAK 
PEP001
993065 
rs1154
9348(G
/C) 
ENSG00
0001116
40 
E_E_
TH 
0.0066 1411.99 1410.78 
GLGTDE
DTIIDIIT
HR 
PEP006
091881  
ENSG00
0001970
43 
E_E_
KB 
0.0033 1767.84 1767.9 
GLSEDT
TEETLK 
PEP002
153670  
ENSG00
0001150
53 
EXO
N_K
B 
0.0025 1322.28 1321.63 
GTEDFI
VESLDA
SFR 
PEP002
703216  
ENSG00
0001247
83 
EXO
N_K
B 
0.0071 1684.73 1684.79 
148 
GTLYII
KLSADI
R 
PEP002
266542  
ENSG00
0001155
93 
I_E_
TH 
0.0046 1463.68 1461.86 
GTVTDF
PGFDER 
PEP004
712880  
ENSG00
0001641
11 
EXO
N_K
B 
0.0031 1341.46 1339.6 
IFTSIGE
DYDER 
PEP005
147259  
ENSG00
0001670
85 
EXO
N_K
B 
0.0000 1444.87 1443.65 
IITLTGP
TNAIFK 
PEP005
100585  
ENSG00
0001695
64 
EXO
N_K
B 
0.0039 1389.78 1387.81 
ILGVGP
DDPDL
VR 
PEP004
526503  
ENSG00
0001602
85 
EXO
N_K
B 
0.0014 1366.67 1364.73 
IPNPDFF
EDLEPF
R 
PEP003
042599  
ENSG00
0001270
22 
EXO
N_K
B 
0.0066 1734.8 1734.83 
IWHHTF
YNELR 
PEP000
663301  
ENSG00
0000756
24 
EXO
N_K
B 
0.0062 1514.73 1514.74 
KIPNPD
FFEDLE
PFR 
PEP003
042599  
ENSG00
0001270
22 
EXO
N_K
B 
0.0098 1862.9 1862.92 
KPEEVD
DEVFYS
PEP000
367628  
ENSG00
0000364
EXO
N_K
0.0072 1708.73 1708.8 
149 
PR 73 B 
LASDLL
EWIR 
PEP000
700443  
ENSG00
0000721
10 
E_E_
KB 
0.0062 1214.65 1214.67 
LASDLL
EWIR 
PEP002
700953  
ENSG00
0001304
02 
E_E_
KB 
0.0062 1214.65 1214.67 
LATQSN
EITIPVT
FESR 
PEP001
796472  
ENSG00
0001062
11 
EXO
N_K
B 
0.0055 1904.91 1904.99 
LAVDEE
ENADN
NTK 
PEP000
643567  
ENSG00
0000722
74 
EXO
N_K
B 
0.0050 1560.65 1560.69 
LDETDD
PDDYG
DR 
PEP000
150404  
ENSG00
0000142
16 
EXO
N_K
B 
0.0081 1524.78 1524.59 
LGANSL
LDLVVF
GR 
PEP007
587517 
rs6898
538(A/
G) 
ENSG00
0002329
61 
E_I_
TH 
0.0081 1473.02 1472.83 
LGGPEA
GLGEYL
FER 
PEP000
526191  
ENSG00
0000870
86 
EXO
N_K
B 
0.0072 1606.99 1606.8 
LLDNW
DSVTST
FSK 
PEP002
177464  
ENSG00
0001181
37 
EXO
N_K
B 
0.0100 1611.71 1611.78 
LLSGED PEP000
 
ENSG00 EXO 0.0094 1545.73 1545.73 
150 
VGQDE
GATR 
839802 0000701
82 
N_K
B 
LPLQDV
YK 
PEP001
557134  
ENSG00
0001012
10 
E_I_
TH 
0.0028 974.937 974.544 
LPLQDV
YK 
PEP001
557050  
ENSG00
0001012
10 
EXO
N_K
B 
0.0028 974.937 974.544 
LPLQDV
YK 
PEP004
163143  
ENSG00
0001565
08 
EXO
N_K
B 
0.0028 974.937 974.544 
LQEAAE
LEAVEL
PVPIR 
PEP000
044823  
ENSG00
0000049
39 
EXO
N_K
B 
0.0081 1876.24 1876.03 
LRVDPV
NFK 
PEP006
194445 
rs4151
5552(G
/A) 
ENSG00
0001885
36 
EXO
N_K
B 
0.0098 1086.58 1086.62 
LSESHP
DATEDL
QR 
PEP004
546571  
ENSG00
0001635
54 
EXO
N_K
B 
0.0081 1597.72 1596.74 
LVNVV
LGAHN
VR 
PEP006
276907  
ENSG00
0001964
15 
EXO
N_K
B 
0.0032 1291.44 1289.76 
NIEDVI
AQGIGK 
PEP006
028640  
ENSG00
0001776
00 
E_E_
KB 
0.0057 1255.63 1255.68 
151 
NILGGT
VFR 
PEP003
130712  
ENSG00
0001384
13 
EXO
N_K
B 
0.0062 977.345 975.549 
QEYDES
GPSIVH
R 
PEP000
663267  
ENSG00
0000756
24 
EXO
N_K
B 
0.0072 1515.61 1515.7 
QEYDES
GPSIVH
R 
PEP006
209424  
ENSG00
0001840
09 
EXO
N_K
B 
0.0072 1515.61 1515.7 
QEYDES
GPSIVH
R 
PEP006
500247  
ENSG00
0001882
19 
EXO
N_K
B 
0.0072 1515.61 1515.7 
QITLND
LPVGR 
PEP002
213772  
ENSG00
0001231
31 
EXO
N_K
B 
0.0046 1225.31 1224.68 
QNQIAV
DEIR 
PEP000
031946  
ENSG00
0000053
81 
EXO
N_K
B 
0.0088 1186.55 1184.62 
RLFEGN
ALLR 
PEP005
143967  
ENSG00
0001708
89 
E_E_
KB 
0.0090 1187.7 1187.68 
RLSEDY
GVLK 
PEP005
474171  
ENSG00
0001678
15 
EXO
N_K
B 
0.0072 1178.61 1178.63 
SFAAVI
QALDG
PEP000
671849  
ENSG00
0000794
E_E_
KB 
0.0025 1506.71 1506.75 
152 
EMR 59 
SLLEGE
GSSGGG
GR 
PEP006
172793  
ENSG00
0001863
95 
E_E_
KB 
0.0031 1262.46 1261.59 
SNPEDQ
ILYQTE
R 
PEP001
630051  
ENSG00
0001109
17 
EXO
N_K
B 
0.0062 1591.97 1591.75 
SNPEDQ
ILYQTE
R 
PEP001
630055  
ENSG00
0001109
17 
E_E_
KB 
0.0062 1591.97 1591.75 
SQIHDI
VLVGG
STR 
PEP001
592926  
ENSG00
0001099
71 
EXO
N_K
B 
0.0067 1480.77 1480.8 
SYELPD
GQVITI
GNER 
PEP000
664177  
ENSG00
0000756
24 
E_I_
TH 
0.0049 1789.73 1789.89 
SYELPD
GQVITI
GNER 
PEP001
946883  
ENSG00
0001077
96 
EXO
N_K
B 
0.0049 1789.73 1789.89 
TGAIVD
VPVGEE
LLGR 
PEP004
285208  
ENSG00
0001522
34 
EXO
N_K
B 
0.0072 1624.07 1623.88 
THLAPY
SDELR 
PEP002
177456  
ENSG00
0001181
37 
EXO
N_K
B 
0.0097 1300.62 1300.64 
TPAQY PEP005
 
ENSG00 EXO 0.0025 1221.54 1221.59 
153 
DASELK 624473 0001827
18 
N_K
B 
VEYHFL
SPYVSP
K 
PEP000
643542  
ENSG00
0000722
74 
EXO
N_K
B 
0.0082 1564.75 1564.79 
VGGVQ
SLGGTG
ALR 
PEP002
477459  
ENSG00
0001200
53 
EXO
N_K
B 
0.0023 1271.8 1270.7 
VLSGDL
GQLPTG
IR 
PEP001
210793  
ENSG00
0001008
89 
EXO
N_K
B 
0.0090 1424.95 1424.8 
VTQWA
EER 
PEP003
255754  
ENSG00
0001371
77 
E_E_
TH 
0.0067 1019.25 1017.49 
YLSYTL
NPDLIR 
PEP005
271414  
ENSG00
0001668
25 
EXO
N_K
B 
0.0000 1467.65 1466.78 
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Table S-3 Peptide hit matrix 
 
P
R
ID
E
1
7
8
0
 
P
R
ID
E
1
7
8
1
 
P
R
ID
E
1
7
8
3
 
P
R
ID
E
1
7
8
4
 
P
R
ID
E
1
7
8
5
 
P
R
ID
E
1
7
8
6
 
P
R
ID
E
1
8
4
8
 
P
R
ID
E
1
8
4
9
 
N 
AGEYGAEALER 1 0 0 0 0 0 0 7 2 
APVPTGEVYFADSFDR 0 0 5 2 0 2 0 0 3 
ASSVVVSGTPIR 0 2 0 0 0 0 2 0 2 
ATSFLLALEPELEAR 1 0 0 0 1 0 0 0 2 
AVFPSIVGR 0 1 0 0 0 0 2 2 3 
AVFVDLEPTVLDEVR 1 1 1 0 1 0 1 0 5 
AVFVNLEPTVIDEVR 3 4 0 0 5 0 3 0 4 
AVNTLNEALEFAK 0 0 0 4 0 0 25 0 2 
DLLDDLKSELTGK 0 0 0 2 0 0 0 4 2 
DPQLVPILIEAAR 0 1 1 0 1 0 0 0 3 
EGDVLTLLESER 0 0 0 0 1 0 0 1 2 
ELFSNLQEFAGPSGK 0 0 1 1 0 0 0 0 2 
ETTIQGLDGLSER 0 0 0 2 0 0 3 0 2 
FGGLLLTEKPIVLK 0 0 5 0 0 1 0 0 2 
FLEQQDQVLQTK 7 4 0 0 0 2 1 0 4 
FPGQLNADLR 0 1 2 1 2 0 0 0 4 
FVTVQTISGTGALR 0 0 0 0 0 1 4 0 2 
GALQNIIPASTGAAK 0 0 4 3 0 1 3 0 4 
GLGTDEDTIIDIITHR 0 0 3 3 0 0 0 0 2 
GLSEDTTEETLK 0 0 0 0 0 0 6 1 2 
GTEDFIVESLDASFR 0 0 1 1 0 0 0 0 2 
155 
GTLYIIKLSADIR 0 1 0 0 0 0 0 1 2 
GTVTDFPGFDER 1 3 0 0 0 0 0 0 2 
IFTSIGEDYDER 1 1 0 0 1 4 0 0 4 
IITLTGPTNAIFK 0 0 0 0 0 0 1 1 2 
ILGVGPDDPDLVR 0 3 0 0 1 3 0 0 3 
IPNPDFFEDLEPFR 0 0 5 2 0 0 0 0 2 
IWHHTFYNELR 0 0 0 2 0 0 3 0 2 
KIPNPDFFEDLEPFR 0 0 5 0 0 2 0 0 2 
KPEEVDDEVFYSPR 0 0 1 0 0 0 2 0 2 
LASDLLEWIR 0 0 0 1 0 0 17 0 2 
LATQSNEITIPVTFESR 0 0 0 2 0 1 0 0 2 
LAVDEEENADNNTK 0 0 4 5 0 1 0 0 3 
LDETDDPDDYGDR 0 1 0 0 0 0 1 0 2 
LGANSLLDLVVFGR 0 0 0 1 1 0 0 0 2 
LGGPEAGLGEYLFER 0 0 4 2 2 0 0 0 3 
LLDNWDSVTSTFSK 0 0 0 2 0 0 0 5 2 
LLSGEDVGQDEGATR 0 0 0 8 0 0 1 0 2 
LPLQDVYK 0 0 0 0 0 0 4 3 2 
LQEAAELEAVELPVPIR 0 0 0 4 2 0 0 0 2 
LRVDPVNFK 0 0 3 0 0 0 0 7 2 
LSESHPDATEDLQR 0 2 0 0 0 0 3 0 2 
LVNVVLGAHNVR 1 1 0 0 0 0 0 0 2 
NIEDVIAQGIGK 0 0 2 0 0 0 0 1 2 
NILGGTVFR 0 1 0 0 0 0 6 0 2 
QEYDESGPSIVHR 0 0 0 0 0 2 4 3 3 
156 
QITLNDLPVGR 0 1 0 0 1 0 0 0 2 
QNQIAVDEIR 2 2 0 0 0 0 0 0 2 
RLFEGNALLR 0 2 1 0 1 0 0 0 3 
RLSEDYGVLK 0 0 0 2 0 0 0 3 2 
SFAAVIQALDGEMR 0 0 1 1 0 0 0 0 2 
SLLEGEGSSGGGGR 9 0 0 0 0 3 0 0 2 
SNPEDQILYQTER 0 0 0 0 1 1 0 0 2 
SQIHDIVLVGGSTR 0 0 1 0 0 0 11 0 2 
SYELPDGQVITIGNER 0 0 0 2 0 2 0 0 2 
TGAIVDVPVGEELLGR 0 0 0 3 4 0 0 0 2 
THLAPYSDELR 0 0 0 2 0 0 0 5 2 
TPAQYDASELK 0 0 2 4 0 0 0 0 2 
VEYHFLSPYVSPK 0 0 4 5 0 0 0 0 2 
VGGVQSLGGTGALR 0 1 0 0 0 0 7 0 2 
VLSGDLGQLPTGIR 0 0 0 0 1 0 3 0 2 
VTQWAEER 1 1 0 0 0 0 0 0 2 
YLSYTLNPDLIR 0 4 1 0 0 2 0 0 3 
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